<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>058 Pharmacology Ini-Cet 2023 - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / PYQ / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">34</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x3f4b85=_0x2dfa;(function(_0x59c261,_0x333cd9){const _0x1b7698=_0x2dfa,_0x2ecec1=_0x59c261();while(!![]){try{const _0x9234cf=-parseInt(_0x1b7698(0x1fb))/0x1*(-parseInt(_0x1b7698(0x3af))/0x2)+-parseInt(_0x1b7698(0x2ad))/0x3*(parseInt(_0x1b7698(0x36d))/0x4)+parseInt(_0x1b7698(0x361))/0x5*(parseInt(_0x1b7698(0x2ed))/0x6)+-parseInt(_0x1b7698(0x20d))/0x7+parseInt(_0x1b7698(0x250))/0x8*(-parseInt(_0x1b7698(0x4b8))/0x9)+-parseInt(_0x1b7698(0x32b))/0xa*(parseInt(_0x1b7698(0x23e))/0xb)+parseInt(_0x1b7698(0x311))/0xc;if(_0x9234cf===_0x333cd9)break;else _0x2ecec1['push'](_0x2ecec1['shift']());}catch(_0x3ba28a){_0x2ecec1['push'](_0x2ecec1['shift']());}}}(_0x37ce,0xa3a32));const _0x1e7ce4=(function(){let _0x23a75a=!![];return function(_0x1106ef,_0x50d2f7){const _0xeb902f=_0x23a75a?function(){const _0x58d775=_0x2dfa;if(_0x50d2f7){const _0x201564=_0x50d2f7[_0x58d775(0x418)](_0x1106ef,arguments);return _0x50d2f7=null,_0x201564;}}:function(){};return _0x23a75a=![],_0xeb902f;};}()),_0x4fd904=_0x1e7ce4(this,function(){const _0xd6fc11=_0x2dfa,_0x4aa968={'amIyx':_0xd6fc11(0x4be)};return _0x4fd904['toString']()['search'](_0x4aa968['amIyx'])[_0xd6fc11(0x23f)]()[_0xd6fc11(0x297)](_0x4fd904)[_0xd6fc11(0x382)](_0x4aa968['amIyx']);});_0x4fd904();const _0x51b722=(function(){const _0xa18e04=_0x2dfa,_0x176929={'oXKth':function(_0xc55571,_0x1d17e2){return _0xc55571!==_0x1d17e2;},'GgVYh':_0xa18e04(0x31c),'XxHQB':function(_0x45ca4b,_0x329d26){return _0x45ca4b===_0x329d26;},'dCOtb':_0xa18e04(0x350)};let _0x2b551b=!![];return function(_0x45a61e,_0x436402){const _0xb74685=_0xa18e04;if(_0x176929[_0xb74685(0x296)](_0xb74685(0x350),_0x176929['dCOtb'])){const _0x28cfe3=_0x2b551b?function(){const _0x46ef68=_0xb74685;if(_0x436402){if(_0x176929[_0x46ef68(0x490)](_0x176929['GgVYh'],_0x176929['GgVYh'])){const _0x4dc40c={'CiSXd':function(_0x3a7a2c,_0x1b79af){return _0x3a7a2c<_0x1b79af;}},_0x143262=_0x4e469e[_0x46ef68(0x249)](_0x55626d[_0x46ef68(0x25a)](_0x46ef68(0x472)))||[];_0x143262[_0x46ef68(0x2da)](_0x20ff3f=>{const _0x57c0cf=_0x46ef68;_0x20ff3f[_0x57c0cf(0x498)][_0x57c0cf(0x2a6)](_0x254e9f[_0x57c0cf(0x2be)]()[_0x57c0cf(0x461)](/ /g,'-'))&&(_0x4dc40c['CiSXd'](_0x20ff3f['questionIndex'],_0x31b35e[_0x57c0cf(0x491)])&&(_0x10ab94[_0x20ff3f['questionIndex']][_0x57c0cf(0x2ff)]=!![]));});}else{const _0x168edb=_0x436402['apply'](_0x45a61e,arguments);return _0x436402=null,_0x168edb;}}}:function(){};return _0x2b551b=![],_0x28cfe3;}else _0x2abf19=_0x5019dd;};}()),_0x535ff5=_0x51b722(this,function(){const _0x32f86d=_0x2dfa,_0x59179c={'TtzpC':_0x32f86d(0x392),'gnfiP':_0x32f86d(0x243),'Klsqu':function(_0x136a58,_0x59be72){return _0x136a58(_0x59be72);},'cZOVQ':function(_0x2e2e6c,_0x154baa){return _0x2e2e6c+_0x154baa;},'MJzJt':_0x32f86d(0x401),'rVPyB':'{}.constructor(\x22return\x20this\x22)(\x20)','zsaaD':function(_0x2625c2){return _0x2625c2();},'HmvCn':_0x32f86d(0x3f3),'YKrOH':'warn','TXQKv':'error','MGWIl':_0x32f86d(0x41e),'LFpUL':_0x32f86d(0x312),'wuAcX':_0x32f86d(0x4a2),'dfMDc':function(_0xc5cbac,_0x1d55a5){return _0xc5cbac<_0x1d55a5;},'CQynj':function(_0x14b092,_0x50f7f7){return _0x14b092===_0x50f7f7;},'rQLUb':_0x32f86d(0x3c3)},_0x5a3efa=function(){const _0x4b1a48=_0x32f86d;let _0x17162f;try{_0x59179c['TtzpC']!==_0x59179c[_0x4b1a48(0x1f3)]?_0x17162f=_0x59179c['Klsqu'](Function,_0x59179c[_0x4b1a48(0x294)](_0x59179c[_0x4b1a48(0x294)](_0x59179c['MJzJt'],_0x59179c[_0x4b1a48(0x30e)]),');'))():_0x12b572['removeItem'](_0x4b1a48(0x3d0));}catch(_0x39b362){_0x17162f=window;}return _0x17162f;},_0x897fb1=_0x59179c['zsaaD'](_0x5a3efa),_0x7fbb83=_0x897fb1['console']=_0x897fb1[_0x32f86d(0x2f4)]||{},_0x4c18d7=[_0x59179c['HmvCn'],_0x59179c['YKrOH'],_0x32f86d(0x388),_0x59179c[_0x32f86d(0x424)],_0x59179c[_0x32f86d(0x432)],_0x59179c[_0x32f86d(0x22d)],_0x59179c['wuAcX']];for(let _0x43639b=0x0;_0x59179c[_0x32f86d(0x464)](_0x43639b,_0x4c18d7[_0x32f86d(0x491)]);_0x43639b++){if(_0x59179c[_0x32f86d(0x34e)](_0x32f86d(0x3c3),_0x59179c[_0x32f86d(0x29b)])){const _0x1d22db=_0x51b722[_0x32f86d(0x297)][_0x32f86d(0x45d)][_0x32f86d(0x35f)](_0x51b722),_0x3ff0b5=_0x4c18d7[_0x43639b],_0x4986f7=_0x7fbb83[_0x3ff0b5]||_0x1d22db;_0x1d22db['__proto__']=_0x51b722[_0x32f86d(0x35f)](_0x51b722),_0x1d22db[_0x32f86d(0x23f)]=_0x4986f7[_0x32f86d(0x23f)][_0x32f86d(0x35f)](_0x4986f7),_0x7fbb83[_0x3ff0b5]=_0x1d22db;}else _0x115548=0x0,_0x5474ba(),_0x59179c[_0x32f86d(0x483)](_0x2d07b7);}});_0x535ff5();function _0x2dfa(_0x3371ac,_0x25b3d9){const _0x3f7c18=_0x37ce();return _0x2dfa=function(_0x535ff5,_0x51b722){_0x535ff5=_0x535ff5-0x1e4;let _0x40b757=_0x3f7c18[_0x535ff5];return _0x40b757;},_0x2dfa(_0x3371ac,_0x25b3d9);}let questionsData=[{'text':_0x3f4b85(0x470),'choices':[{'id':0x1,'text':_0x3f4b85(0x287)},{'id':0x2,'text':_0x3f4b85(0x2e8)},{'id':0x3,'text':_0x3f4b85(0x27b)},{'id':0x4,'text':_0x3f4b85(0x3fb)}],'correct_choice_id':0x1,'solution':_0x3f4b85(0x3ee),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x499),'choices':[{'id':0x1,'text':_0x3f4b85(0x416)},{'id':0x2,'text':_0x3f4b85(0x3cb)},{'id':0x3,'text':_0x3f4b85(0x3b6)},{'id':0x4,'text':'Erlotinib'}],'correct_choice_id':0x2,'solution':_0x3f4b85(0x2ba),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Nomogram\x20used\x20for\x20vancomycin\x20dosing\x20is?','choices':[{'id':0x1,'text':_0x3f4b85(0x251)},{'id':0x2,'text':_0x3f4b85(0x450)},{'id':0x3,'text':'Rummack-mathew'},{'id':0x4,'text':'Matzke'}],'correct_choice_id':0x4,'solution':_0x3f4b85(0x24a),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x45e),'choices':[{'id':0x1,'text':_0x3f4b85(0x3c1)},{'id':0x2,'text':'It\x20can\x20cause\x20fine\x20tremors\x20in\x20the\x20therapeutic\x20range'},{'id':0x3,'text':'Approved\x20for\x20the\x20treatment\x20of\x20absent\x20seizures'},{'id':0x4,'text':_0x3f4b85(0x30c)}],'correct_choice_id':0x2,'solution':_0x3f4b85(0x4ac),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Match\x20the\x20following','choices':[{'id':0x1,'text':_0x3f4b85(0x1e4)},{'id':0x2,'text':_0x3f4b85(0x3a9)},{'id':0x3,'text':'A-4,\x20B-2,\x20C-3,\x20D-1'},{'id':0x4,'text':_0x3f4b85(0x2af)}],'correct_choice_id':0x2,'solution':_0x3f4b85(0x3c8),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x44d),'choices':[{'id':0x1,'text':_0x3f4b85(0x3eb)},{'id':0x2,'text':_0x3f4b85(0x347)},{'id':0x3,'text':'Denotes\x20safety\x20and\x20efficacy\x20in\x20an\x20individual'},{'id':0x4,'text':_0x3f4b85(0x279)}],'correct_choice_id':0x2,'solution':_0x3f4b85(0x2c3),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x405),'choices':[{'id':0x1,'text':_0x3f4b85(0x3a5)},{'id':0x2,'text':_0x3f4b85(0x254)},{'id':0x3,'text':_0x3f4b85(0x2d3)},{'id':0x4,'text':_0x3f4b85(0x303)}],'correct_choice_id':0x1,'solution':'<div\x20class=\x22page\x22\x20title=\x22Page\x201404\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>The<strong>\x20T790M\x20mutation</strong>\x20in\x20the\x20<strong>EGFR\x20gene</strong>\x20is\x20known\x20to\x20<strong>cause\x20resistance\x20to\x20first\x20and\x20second-generation\x20EGFR\x20inhibitors</strong>.\x20<strong>Osimertinib</strong>,\x20as\x20a\x20<strong>third-generation\x20EGFR\x20inhibitor</strong>,\x20is\x20effective\x20against\x20this\x20resistance,\x20hence\x20it\x20is\x20often\x20<strong>used\x20for\x20patients\x20with\x20the\x20T790M\x20mutation</strong>\x20<strong>after</strong>\x20<strong>they\x27ve\x20progressed</strong>\x20on\x20first\x20or\x20second-generation\x20EGFR\x20inhibitors.</p>\x0a<p>The\x20question\x20seems\x20to\x20be\x20asking\x20specifically\x20for\x20the\x20mutation\x20that\x20osimertinib\x20is\x20particularly\x20known\x20for\x20being\x20used\x20against,\x20and\x20that\x20would\x20be\x20the\x20T790M\x20mutation.</p>\x0a<p>Osimertinib&nbsp;is\x20a\x20kinase\x20inhibitor\x20that\x20is\x20approved\x20for&nbsp;</p>\x0a<ul>\x0a<li>Patients\x20with\x20<strong>metastatic\x20non\x20small\x20cell\x20lung\x20carcinoma</strong>(NSCLC)&nbsp;that\x20has\x20progressed\x20<strong>after\x20prior\x20EGFR\x20TKI\x20treatment\x20and\x20is\x20positive\x20for\x20the\x20EGFR\x20T790M\x20mutation</strong>.</li>\x0a<li>First-line\x20treatment\x20of\x20patients\x20with\x20<strong>metastatic\x20NSCLC</strong>\x20and\x20<strong>adjuvant\x20therapy</strong>\x20after\x20<strong>resection\x20of\x20NSCLC\x20with\x20EGFR\x20exon\x2019\x20deletions\x20or\x20exon\x2021\x20L858R\x20mutations</strong></li>\x0a</ul>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201404\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>So,\x20osimertinib\x20is\x20used\x20both\x20for\x20the\x20L858R\x20mutation\x20and\x20T790M\x20mutation\x20in\x20different\x20settings.\x20But\x20T790M\x20mutation\x20is\x20often\x20highlighted\x20because\x20of\x20its\x20association\x20with\x20resistance\x20to\x20first\x20and\x20second-generation\x20EGFR\x20inhibitors,\x20and\x20because\x20osimertinib\x20can\x20overcome\x20this\x20resistance.</p>\x0a<p>Osimertinib\x20is\x20<strong>administered\x20orally\x20</strong>and&nbsp;is\x20a\x20<strong>substrate\x20of\x20CYP3A</strong>.\x20The\x20drug\x20is\x20primarily\x20eliminated\x20in\x20the\x20feces\x20and\x20to\x20a\x20lesser\x20extent\x20in\x20the\x20urine.\x20Concurrent\x20administration\x20of\x20inducers\x20of\x20CYP3A4\x20may\x20necessitate\x20an\x20increase\x20in\x20the\x20dose.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201405\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>The<strong>&nbsp;adverse\x20effects</strong>\x20after\x20osimertinib\x20treatment\x20are&nbsp;<strong>leukopenia</strong>,&nbsp;<strong>diarrhea</strong>,\x20skin\x20rash,\x20<strong>interstitial\x20lung\x20disease</strong>,\x20<strong>QTc\x20prolongation</strong>,\x20and\x20left\x20ventricular\x20dysfunction.</p>\x0a<p>&nbsp;</p>\x0a<p>&nbsp;</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20patient\x20was\x20started\x20on\x20a\x20drug\x20for\x20mood\x20disorder\x20and\x20he\x20developed\x20priapism.\x20The\x20causative\x20drug\x20is:','choices':[{'id':0x1,'text':'Trazodone'},{'id':0x2,'text':_0x3f4b85(0x1e8)},{'id':0x3,'text':_0x3f4b85(0x256)},{'id':0x4,'text':'Mirtazapine'}],'correct_choice_id':0x1,'solution':'<p><strong>Trazodone</strong>\x20causes\x20<strong>priapism</strong>.&nbsp;</p>\x0a<p>Trazodone\x20is\x20an<strong>\x20atypical&nbsp;antidepressant\x20drug</strong>.\x20It\x20is\x20a\x20<strong>serotonin\x20receptor\x20antagonist</strong>.\x20Other\x20drugs\x20which\x20belong\x20to\x20this\x20include\x20<strong>nefazodone,\x20mirtazapine,\x20and\x20mianserin</strong>.\x20Low\x20doses\x20of\x20trazodone\x20(50&ndash;200\x20mg)\x20have\x20been\x20used\x20widely,\x20both\x20alone\x20and\x20concurrently\x20with\x20SSRIs\x20or\x20SNRIs,\x20to\x20treat\x20<strong>insomnia</strong>.\x20Trazodone\x20use\x20is\x20associated\x20with\x20<strong>priapism</strong>\x20in\x20rare\x20instances.\x20Intracavernous\x20injection\x20of\x20<strong>phenylephrine</strong>\x20can\x20be\x20used\x20to\x20<strong>treat\x20priapism.</strong></p>\x0a<p>&nbsp;Other\x20options:</p>\x0a<p>Option\x20B:\x20Venlafaxine\x20is\x20a&nbsp;<strong>second-line</strong>&nbsp;drug\x20used\x20in\x20generalized\x20anxiety\x20disorder.\x20It\x20belongs\x20to\x20the\x20class\x20of&nbsp;serotonin-norepinephrine\x20reuptake\x20inhibitors&nbsp;<strong>(SNRIs).&nbsp;</strong>Venlafaxine\x20can\x20induce\x20sustained\x20diastolic\x20hypertension\x20(diastolic\x20blood\x20pressure\x20&gt;90\x20mmHg\x20at\x20consecutive\x20weekly\x20visits).\x20Venlafaxine\x20also\x20is\x20associated\x20with\x20an\x20increased\x20risk\x20of\x20perinatal\x20complications.</p>\x0a<p>Option\x20C:\x20Bupropion\x20is\x20a\x20first-line\x20drug\x20used\x20for&nbsp;<strong>nicotine\x20cessation</strong>&nbsp;and\x20has\x20the\x20added\x20benefit\x20of\x20causing&nbsp;<strong>weight\x20loss</strong>.\x20Weight\x20gain\x20is\x20commonly\x20seen\x20after\x20stopping\x20nicotine\x20use.\x20Hence\x20this\x20drug\x20can\x20be\x20used\x20in\x20this\x20patient\x20as\x20it\x20treats\x20both\x20of\x20these.</p>\x0a<p>Option\x20D:&nbsp;<strong>Mirtazapine&nbsp;</strong>is\x20used\x20in\x20major\x20depressive\x20disorder.\x20It\x20increases\x20appetite\x20and\x20causes\x20significant\x20weight\x20gain.</p>\x0a<p>&nbsp;</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x481),'choices':[{'id':0x1,'text':_0x3f4b85(0x41c)},{'id':0x2,'text':_0x3f4b85(0x3ac)},{'id':0x3,'text':_0x3f4b85(0x204)},{'id':0x4,'text':_0x3f4b85(0x301)}],'correct_choice_id':0x1,'solution':_0x3f4b85(0x3ca),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x24f),'choices':[{'id':0x1,'text':'Acarbose'},{'id':0x2,'text':_0x3f4b85(0x257)},{'id':0x3,'text':_0x3f4b85(0x34d)},{'id':0x4,'text':_0x3f4b85(0x488)}],'correct_choice_id':0x2,'solution':_0x3f4b85(0x36c),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'An\x20anti-diabetic\x20drug\x20causes\x20a\x20decrease\x20in\x20HbA1C\x20by\x20causing\x20an\x20increase\x20in\x20GIP\x20and\x20GLP-1\x20levels\x20and\x20a\x20decrease\x20in\x20glucagon\x20levels.\x20It\x20is\x20an\x20oral\x20drug\x20causing\x20a\x20reduction\x20in\x20both\x20pre\x20and\x20post-prandial\x20glucose.\x20The\x20drug\x20is:','choices':[{'id':0x1,'text':_0x3f4b85(0x356)},{'id':0x2,'text':_0x3f4b85(0x39a)},{'id':0x3,'text':'Liraglutide'},{'id':0x4,'text':'Metformin'}],'correct_choice_id':0x2,'solution':_0x3f4b85(0x283),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x306),'choices':[{'id':0x1,'text':_0x3f4b85(0x28e)},{'id':0x2,'text':'Pembrolizumab\x20used\x20in\x20NSCLC'},{'id':0x3,'text':'Nivolumab\x20plus\x20chemotherapy\x20used\x20in\x20NSCLC'},{'id':0x4,'text':_0x3f4b85(0x3b4)}],'correct_choice_id':0x1,'solution':_0x3f4b85(0x235),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20is\x20not\x20a\x20mechanism\x20for\x20thalidomide\x20teratogenicity?','choices':[{'id':0x1,'text':_0x3f4b85(0x3c7)},{'id':0x2,'text':_0x3f4b85(0x48f)},{'id':0x3,'text':_0x3f4b85(0x3a0)},{'id':0x4,'text':_0x3f4b85(0x373)}],'correct_choice_id':0x4,'solution':_0x3f4b85(0x33e),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x33b),'choices':[{'id':0x1,'text':'Suicidal\x20tendency'},{'id':0x2,'text':_0x3f4b85(0x20b)},{'id':0x3,'text':'Myocarditis'},{'id':0x4,'text':_0x3f4b85(0x41f)}],'correct_choice_id':0x2,'solution':_0x3f4b85(0x443),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x215),'choices':[{'id':0x1,'text':_0x3f4b85(0x2d8)},{'id':0x2,'text':_0x3f4b85(0x3e8)},{'id':0x3,'text':_0x3f4b85(0x34d)},{'id':0x4,'text':_0x3f4b85(0x434)}],'correct_choice_id':0x1,'solution':_0x3f4b85(0x343),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x486),'choices':[{'id':0x1,'text':_0x3f4b85(0x281)},{'id':0x2,'text':_0x3f4b85(0x444)},{'id':0x3,'text':'6-mercaptopurine'},{'id':0x4,'text':_0x3f4b85(0x493)}],'correct_choice_id':0x4,'solution':_0x3f4b85(0x3f5),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x2025\x20year\x20old\x20male\x20patient\x20presents\x20with\x20several\x20purpuric\x20skin\x20lesions\x20and\x20is\x20diagnosed\x20with\x20idiopathic\x20thrombocytopenic\x20purpura.\x20Which\x20of\x20the\x20following\x20tyrosine\x20kinase\x20inhibitors\x20can\x20be\x20used\x20in\x20his\x20condition?','choices':[{'id':0x1,'text':_0x3f4b85(0x1e7)},{'id':0x2,'text':_0x3f4b85(0x2d2)},{'id':0x3,'text':_0x3f4b85(0x202)},{'id':0x4,'text':_0x3f4b85(0x330)}],'correct_choice_id':0x4,'solution':'<p><strong>Fostamatinib</strong>\x20is\x20a<strong>\x20tyrosine\x20kinase\x20inhibitor</strong>\x20used\x20in\x20the\x20treatment\x20of\x20<strong>chronic\x20immune\x20thrombocytopenia</strong>\x20(<strong>idiopathic\x20thrombocytopenic\x20purpura</strong>).<br\x20/><br\x20/><strong>Fostamatinib</strong>\x20has\x20activity\x20against\x20<strong>spleen\x20tyrosine\x20kinase\x20(SYK)</strong>.\x20The\x20<strong>major\x20metabolite</strong>\x20of\x20fostamatinib,\x20<strong>R406</strong>,\x20<strong>inhibits\x20signal\x20transduction</strong>\x20of\x20<strong>Fc-activating\x20receptors</strong>\x20and\x20<strong>B-cell\x20receptors</strong>.\x20The\x20fostamatinib\x20metabolite<strong>\x20R406\x20reduces\x20antibody-mediated\x20destruction\x20of\x20platelets.<br\x20/><br\x20/>Idiopathic\x20thrombocytopenic\x20purpura\x20(ITP)</strong>\x20is\x20an\x20<strong>acquired</strong>\x20disorder\x20characterized\x20by\x20the\x20<strong>immune-mediated\x20destruction\x20of\x20platelets</strong>\x20and\x20possibly\x20<strong>inhibition\x20of\x20platelet\x20release</strong>\x20from\x20the\x20<strong>megakaryocyte</strong>.\x20It\x20is\x20an\x20autoimmune\x20disorder\x20caused\x20by\x20antibodies\x20directed\x20against\x20<strong>platelet\x20membrane\x20glycoproteins\x20IIb-IIIa\x20or\x20Ib-IX</strong>.\x20<strong>Secondary</strong>\x20<strong>causes</strong>\x20of\x20ITP\x20include\x20<strong>systemic\x20lupus\x20erythematosus\x20(SLE)</strong>,\x20<strong>HIV-AIDS</strong>,\x20and\x20<strong>Hepatitis\x20C</strong>.</p>\x0a<p>ITP\x20usually\x20presents\x20with\x20<strong>mucocutaneous\x20bleeding</strong>,\x20<strong>very\x20low\x20platelet\x20count</strong>,\x20and\x20<strong>normal\x20peripheral\x20blood\x20cells</strong>.\x20Patients\x20typically\x20exhibit\x20<strong>ecchymoses</strong>\x20and\x20<strong>petechiae</strong>\x20or\x20they\x20may\x20incidentally\x20discover\x20<strong>thrombocytopenia</strong>\x20during\x20a\x20routine\x20complete\x20blood\x20count.\x20Rarely,\x20<strong>life-threatening\x20bleeding</strong>\x20may\x20occur.\x20The\x20presence\x20of\x20<strong>wet\x20purpura\x20</strong>(<strong>blood\x20blisters\x20in\x20the\x20mouth</strong>)\x20and\x20<strong>retinal\x20hemorrhages</strong>\x20can\x20serve\x20as<strong>\x20warning\x20signs</strong>\x20of\x20potentially<strong>\x20life-threatening\x20bleeding</strong>.<br\x20/><br\x20/>The\x20treatment\x20of\x20ITP\x20is\x20as\x20follows:</p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x20100.046%;\x20height:\x20380.781px;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x204.59137%;\x20height:\x2022.3984px;\x22>\u00a0</td>\x0a<td\x20style=\x22width:\x2045.632%;\x20height:\x2022.3984px;\x22>Clinical\x20features</td>\x0a<td\x20style=\x22width:\x2049.7767%;\x20height:\x2022.3984px;\x22>Management</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x20153.594px;\x22>\x0a<td\x20style=\x22width:\x204.59137%;\x20height:\x20153.594px;\x22>1.\u00a0</td>\x0a<td\x20style=\x22width:\x2045.632%;\x20height:\x20153.594px;\x22>\x0a<p>Minor\x20bleeding\x20manifestations\x20(and/or)</p>\x0a<p>Platelet\x20count\x20&gt;\x205000/\x20μL</p>\x0a</td>\x0a<td\x20style=\x22width:\x2049.7767%;\x20height:\x20153.594px;\x22>\x0a<p>Prednisone\x20(OR)</p>\x0a<p>Anti-D\x20immunoglobulin\x20therapy\x20-\x20effective\x20only\x20in\x20Rh-positive\x20patients\x20(OR)</p>\x0a<p>Intravenous\x20immunoglobulin\x20(IVIG)</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x20159.992px;\x22>\x0a<td\x20style=\x22width:\x204.59137%;\x20height:\x20159.992px;\x22>2.\u00a0</td>\x0a<td\x20style=\x22width:\x2045.632%;\x20height:\x20159.992px;\x22>\x0a<p>Severe\x20ITP\x20(any\x20of\x20the\x20following):</p>\x0a<p>-\x20Significant\x20GI\x20/\x20intracranial\x20bleeding<br\x20/>-\x20Platelet\x20count\x20&lt;\x205000/μL<br\x20/>-\x20Signs\x20of\x20impending\x20bleeding\x20(retinal\x20or\x20large\x20oral\x20mucosal\x20bleeds)</p>\x0a</td>\x0a<td\x20style=\x22width:\x2049.7767%;\x20height:\x20159.992px;\x22>\x0a<p>Platelet\x20transfusion\x20(AND)</p>\x0a<p>High-dose\x20glucocorticoids\x20(AND)</p>\x0a<p>IVIG\x20/\x20Anti-D\x20immunoglobulins\x20+\x20Rituximab</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x204.59137%;\x20height:\x2022.3984px;\x22>3.\u00a0</td>\x0a<td\x20style=\x22width:\x2045.632%;\x20height:\x2022.3984px;\x22>Relapse\x20after\x20first-line\x20therapy</td>\x0a<td\x20style=\x22width:\x2049.7767%;\x20height:\x2022.3984px;\x22>Splenectomy</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x204.59137%;\x20height:\x2022.3984px;\x22>4.\u00a0</td>\x0a<td\x20style=\x22width:\x2045.632%;\x20height:\x2022.3984px;\x22>Unresponsive\x20to\x20all\x20other\x20therapy\x20or\x20relapse\x20after\x20splenectomy</td>\x0a<td\x20style=\x22width:\x2049.7767%;\x20height:\x2022.3984px;\x22>Thrombopoietin\x20receptor\x20agonists\x20-\x20romiplostim\x20(subcutaneous),\x20eltrombopag\x20(oral)</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong><br\x20/></strong>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20A\x20and\x20B:\x20<strong>Eltrombopag</strong>\x20and\x20<strong>Romiplostim\x20</strong>are\u00a0<strong>thrombopoietin\x20(TPO)\x20receptor\x20agonists\x20</strong>used\x20in\x20the\x20treatment\x20of\x20<strong>immune\x20thrombocytopenia</strong>\x20which\x20have\x20failed\x20to\x20respond\x20to\x20conventional\x20treatments.\x20Both\x20drugs\x20act\x20via\x20the\x20<strong>Mpl\x20receptor</strong>\x20to\x20increase\x20platelet\x20counts\x20and\x20not\x20via\u00a0tyrosine\x20kinase\x20inhibition.</p>\x0a<p>Option\x20C:\x20<strong>Bosutinib</strong>\x20is\x20a<strong>\x20BCR-ABL</strong>\x20<strong>tyrosine\x20kinase\x20inhibitor</strong>\x20indicated\x20in\x20<strong>CML</strong>.\u00a0</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x49c),'choices':[{'id':0x1,'text':'Pyrazinamide'},{'id':0x2,'text':_0x3f4b85(0x35d)},{'id':0x3,'text':_0x3f4b85(0x4a4)},{'id':0x4,'text':'Streptomycin'}],'correct_choice_id':0x2,'solution':_0x3f4b85(0x389),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x1ea),'choices':[{'id':0x1,'text':_0x3f4b85(0x357)},{'id':0x2,'text':_0x3f4b85(0x408)},{'id':0x3,'text':_0x3f4b85(0x276)},{'id':0x4,'text':_0x3f4b85(0x255)}],'correct_choice_id':0x3,'solution':'<p><strong>Hypothermia</strong>\x20is\x20<strong>not</strong>\x20<strong>associated</strong>\x20with\x20<strong>amitriptyline</strong>\x20use\x20or\x20<strong>tricyclic\x20antidepressant\x20toxicity</strong>.<br\x20/><br\x20/></p>\x0a<p><strong>Tricyclic\x20antidepressants\x20(TCAs)</strong>\x20such\x20as\x20<strong>amitriptyline</strong>\x20are\x20used\x20in\x20the\x20treatment\x20of\u00a0<strong>psychotic\x20depression</strong>,\x20<strong>insomnia</strong>,\x20and\x20several\x20<strong>pain</strong>\x20<strong>conditions</strong>.\x20Their\x20<strong>mechanism\x20of\x20action</strong>\x20is\x20<strong>inhibition\x20of\x20norepinephrine\x20and\x20serotonin\x20reuptake</strong>.\x20They\x20have\x20a\u00a0<strong>quinidine-like\x20sodium\x20channel\x20blockade\x20effect</strong>\u00a0on\u00a0<strong>cardiac</strong>\u00a0conduction.\x20Hence,\x20they\x20cause<strong>\u00a0QT\x20prolongation</strong>.\u00a0Other\x20<strong>cardiotoxic\x20effects</strong>\x20include\x20<strong>atrioventricular\x20(AV)\x20block</strong>\x20and<strong>\u00a0hypotension</strong>.\u00a0<strong>Rightward-axis\x20deviation</strong>\u00a0is\x20also\x20an\x20associated\x20finding.</p>\x0a<p>TCA\x20toxicity\x20can\x20result\x20in\u00a0<strong>ventricular\x20tachyarrhythmias\x20(Option\x20A)</strong>,\x20<strong>status\x20epilepticus</strong>,\x20<strong>hyperthermia</strong>,\x20and\x20<strong>coma</strong>.\x20It\u00a0can\x20also\x20result\x20in\u00a0<strong>anticholinergic\x20syndrome</strong>\u00a0due\x20to\x20muscarinic\x20receptor\x20antagonism.\x20Symptoms\x20include\x20<strong>dilated\x20pupils\x20(Option\x20D)</strong>,\x20high\x20temperature,\x20<strong>confusion\x20(option\x20B)</strong>,\x20dry\x20mouth,\u00a0<strong>urinary\x20retention,\x20tachycardia</strong>,\x20and\x20myoclonic\x20movements.\x20It\x20is\x20managed\x20with\u00a0<strong>intravenous\x20sodium\x20bicarbonate\x20bolus\x20(50-100\x20mEq)</strong>.\x20This\x20helps\x20in\x20the\x20<strong>reversal\x20of\x20sodium\x20channel\x20blockade</strong>.\u00a0<strong>Gastric\x20lavage</strong>\u00a0and\x20administration\x20of\x20<strong>activated\x20charcoal</strong>\x20can\x20be\x20carried\x20out\x20in\x20cases\x20of\x20<strong>recent\x20ingestion.</strong></p>\x0a<p><strong>Other\x20side\x20effects</strong>\x20of\x20TCAs\x20include\u00a0<strong>postural\x20hypotension\x20</strong>from\u00a0<strong>anti-alpha\x201\x20adrenergic</strong>\u00a0action\x20and\x20<strong>sedation\u00a0</strong>from\u00a0<strong>anti-histaminic</strong>\u00a0action.\x20ECG\x20changes\x20such\x20as\u00a0<strong>T\x20wave\x20inversion\u00a0or\x20suppression</strong>\x20are\x20also\x20common.\u00a0</p>\x0a<p>In\x20some\x20cases,\x20it\x20can\x20result\x20in\x20polymorphic\x20ventricular\x20tachycardias\x20with\x20QT\x20prolongation\x20known\x20as<strong>\u00a0torsades\x20de\x20pointes</strong>.\x20Recurrent\x20episodes\x20can\x20be\x20treated\x20with\u00a0<strong>intravenous\x20magnesium\x20sulfate</strong>.\u00a0<br\x20/><br\x20/><br\x20/></p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x48b),'choices':[{'id':0x1,'text':_0x3f4b85(0x2b9)},{'id':0x2,'text':_0x3f4b85(0x260)},{'id':0x3,'text':_0x3f4b85(0x337)},{'id':0x4,'text':_0x3f4b85(0x1e7)}],'correct_choice_id':0x1,'solution':_0x3f4b85(0x252),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x433),'choices':[{'id':0x1,'text':_0x3f4b85(0x437)},{'id':0x2,'text':'Dexamethasone'},{'id':0x3,'text':_0x3f4b85(0x28c)},{'id':0x4,'text':_0x3f4b85(0x22c)}],'correct_choice_id':0x1,'solution':_0x3f4b85(0x2d9),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x239),'choices':[{'id':0x1,'text':'Donepezil'},{'id':0x2,'text':_0x3f4b85(0x3f8)},{'id':0x3,'text':_0x3f4b85(0x25b)},{'id':0x4,'text':_0x3f4b85(0x270)}],'correct_choice_id':0x2,'solution':_0x3f4b85(0x47c),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x24b),'choices':[{'id':0x1,'text':'A'},{'id':0x2,'text':'B'},{'id':0x3,'text':'C'},{'id':0x4,'text':'D'}],'correct_choice_id':0x2,'solution':_0x3f4b85(0x379),'explanation_video':'','question_images':[_0x3f4b85(0x2a3)],'explanation_images':[]},{'text':_0x3f4b85(0x37a),'choices':[{'id':0x1,'text':_0x3f4b85(0x39f)},{'id':0x2,'text':_0x3f4b85(0x3e0)},{'id':0x3,'text':'Nifedipine'},{'id':0x4,'text':_0x3f4b85(0x476)}],'correct_choice_id':0x1,'solution':'<p><strong>Verapamil</strong>\x20is\x20a\x20<strong>potent\x20inhibitor\x20of\x20P-glycoprotein\x20drug\x20transporter\x20</strong>which\x20belongs\x20to\x20the\x20family\x20of\x20<strong>ATP-binding\x20cassette\x20(ABC)\x20transporters</strong>.<br\x20/><br\x20/>A\x20group\x20of\x20<strong>primary\x20active\x20transporters</strong>,\x20the\x20<strong>ATP-binding\x20cassette\x20(ABC)\x20family</strong>,\x20hydrolyze\x20ATP\x20to\x20export\x20substrates\x20across\x20membranes.\x20<strong>P-glycoprotein\x20(P-gp)</strong>\x20is\x20an\x20ATP-binding\x20cassette\x20(ABC)\x20transporter,\x20which\x20acts\x20as\x20an<strong>\x20efflux\x20membrane\x20transporter</strong>.\x20It\x20is\x20responsible\x20for<strong>\x20limiting\x20cellular\x20uptake\x20</strong>and\x20the\x20<strong>distribution\x20of\x20xenobiotics\x20and\x20toxic\x20substances</strong>.\x20P-glycoprotein\x20is\x20also\x20called\x20<strong>ABCB1\x20or\x20MDR1</strong>,\x20and\x20it\x20<strong>exports\x20bulky\x20neutral\x20</strong>or\x20<strong>cationic</strong>\x20<strong>compounds</strong>\x20<strong>from\x20cells</strong>.\x20<strong>MDR1</strong>\x20<strong>exports</strong>\x20many\x20drugs\x20as\x20well.\x20It\x20is\x20associated\x20with\x20multidrug\x20resistance\x20(MDR)\x20to\x20<strong>cancer\x20chemotherapeutics</strong>\x20through\x20the\x20<strong>multidrug\x20resistance\x20protein\x201\x20or\x20MDR1</strong>.<br\x20/><br\x20/><strong>Verapamil</strong>\x20can\x20cause<strong>\x20interactions\x20with\x20drugs</strong>\x20whose\x20disposition\x20is\x20dependent\x20upon\x20P-glycoprotein.\x20<strong>Drugs\x20that\x20inhibit\x20P-glycoprotein</strong>\x20are\x20-</p>\x0a<ol>\x0a<li><strong>Clarithromycin</strong></li>\x0a<li><strong>Erythromycin</strong></li>\x0a<li><strong>Amiodarone</strong></li>\x0a<li><strong>Quinidine</strong></li>\x0a<li><strong>Verapamil</strong></li>\x0a<li><strong>Diltiazem</strong></li>\x0a<li><strong>Cyclosporine</strong></li>\x0a<li><strong>Itraconazole</strong></li>\x0a<li><strong>Propafenone</strong></li>\x0a<li><strong>Flecainide</strong>.</li>\x0a</ol>\x0a<p>P-glycoprotein\x20pumps\x20play\x20a\x20major\x20role\x20in\x20the\x20elimination\x20of\x20certain\x20drugs\x20such\x20as\x20<strong>digoxin</strong>.\x20Drugs\x20that\x20inhibit\x20P-glycoprotein\x20can\x20thereby\x20decrease\x20their\x20elimination\x20and\x20lead\x20to\x20<strong>toxicity</strong>.\x20For\x20eg,\x20digoxin\x20is\x20metabolized\x20by\x20P-glycoprotein,\x20and\x20drugs\x20that\x20inhibit\x20it\x20increase\x20the\x20plasma\x20levels\x20of\x20digoxin\x20and\x20may\x20result\x20in\x20toxicity.</p>\x0a<p><strong>Increased\x20P-gp\x20expression</strong>:\x20<strong>Reduces\x20the\x20absorption</strong>\x20of\x20drugs\x20that\x20are\x20substrates\x20for\x20P-gp.<br\x20/><strong>Decreased\x20P-gp\x20expression</strong>:\x20Leads\x20to\x20<strong>supratherapeutic\x20plasma\x20concentrations</strong>\x20and\x20drug\x20toxicity.<br\x20/><br\x20/>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20B,\x20C,\x20and\x20D:\x20Although\x20diltiazem,\x20nifedipine,\x20and\x20amlodipine\x20have\x20been\x20reported\x20in\x20the\x20literature\x20to\x20act\x20as\x20p-glycoprotein\x20inhibitors,\x20verapamil\x20is\x20more\x20potent\x20and\x20commonly\x20used\x20for\x20p-glycoprotein\x20inhibition\x20in\x20trials,\x20and\x20would\x20be\x20the\x20best\x20answer.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x2ce),'choices':[{'id':0x1,'text':'Fidaxomycin'},{'id':0x2,'text':_0x3f4b85(0x2b7)},{'id':0x3,'text':'Zanamivir'},{'id':0x4,'text':'Cilastatin'}],'correct_choice_id':0x1,'solution':'<p><strong>Oral\x20Fidaxomicin\x20</strong>is\x20the\x20antibiotic\x20indicated\x20for\x20this\x20patient\x27s\x20condition\x20which\x20is\x20suggestive\x20of\u00a0<em><strong>Clostridium\x20difficile</strong>\u00a0</em>infection,\x20characterized\x20by\x20<strong>profuse\x20watery\x20diarrhea\x20</strong>and\u00a0<strong>leukocytosis</strong>\u00a0following\x20long\x20term\x20antibiotic\x20use\x20such\x20as\x20<strong>ampicillin</strong>.<br\x20/><br\x20/><em>C\x20difficle\x20infection\u00a0</em>is\x20most\x20commonly\x20associated\x20with\u00a0<strong>prolonged\x20antimicrobial\x20use</strong>\u00a0which\x20<strong>interferes</strong>\x20<strong>with</strong>\x20the\x20<strong>commensal\x20colonic\x20microflora</strong>.\x20The\x20most\x20commonly\x20implicated\x20antibiotics\x20are\u00a0<strong>cephalosporins,\u00a0ampicillin,\u00a0clindamycin,\u00a0</strong>and<strong>\u00a0fluoroquinolones</strong>.\x20Spores\x20of\x20toxigenic<em>\u00a0C.\x20difficile</em>\u00a0when\x20ingested,\x20survive\x20gastric\x20acidity\x20and\x20colonize\x20the\x20lower\x20intestinal\x20tract.\x20Here\x20they\x20produce\x20two\x20toxins:<strong>\x20toxin\x20A\x20(an\x20enterotoxin)</strong>\x20and<strong>\x20toxin\x20B\x20(a\x20cytotoxin)</strong>.\x20These\x20toxins\x20initiate\x20processes\x20that\x20<strong>disrupt\x20the\x20epithelial-cell\x20barrier\x20function</strong>,\x20<strong>diarrhea</strong>,\x20and\x20<strong>pseudomembrane</strong>\x20<strong>formation</strong>.<em>\u00a0</em>The\x20patient\x20presents\x20with\x20<strong>non\x20bloody\x20diarrhea</strong>,\x20<strong>fever</strong>,\x20<strong>abdominal\x20pain,</strong>\x20and\x20<strong>leukocytosis</strong>.<br\x20/><br\x20/>Clinical\x20features\u00a0can\x20range\x20from\x20asymptomatic\x20carriage\x20to\x20fulminant\x20colitis.\u00a0</p>\x0a<ul>\x0a<li><strong>Nonsevere\x20disease</strong>\u00a0-\u00a0Watery\x20diarrhea\x20(≥3\x20loose\x20stools\x20in\x2024\x20hours)\x20is\x20the\x20cardinal\x20symptom.\u00a0Other\x20manifestations\x20include\x20lower\x20abdominal\x20pain\x20and\x20cramping,\x20low-grade\x20fever,\x20nausea,\x20anorexia,\u00a0mucus,\x20or\x20occult\x20blood\x20in\x20the\x20stool.\u00a0Physical\x20examination\x20may\x20demonstrate\x20lower\x20abdominal\x20tenderness.\u00a0Unexplained\x20leukocytosis\x20in\x20hospitalized\x20patients\x20(even\x20in\x20the\x20absence\x20of\x20diarrhea)\x20may\x20reflect\x20underlying\x20CDI</li>\x0a<li><strong>Severe\x20colitis\x20-\u00a0</strong>Clinical\x20manifestations\x20of\x20severe\x20colitis\x20include\x20diarrhea,\x20lower\x20quadrant\x20or\x20diffuse\x20abdominal\x20pain,\x20abdominal\x20distention,\x20fever,\x20hypovolemia,\x20lactic\x20acidosis,\x20hypoalbuminemia,\x20elevated\x20creatinine,\x20and\x20marked\x20leukocytosis.</li>\x0a<li><strong>Fulminant\x20colitis</strong>\u00a0-\x20Characterized\x20by\x20hypotension\x20or\x20shock,\x20ileus,\x20or\u00a0<strong>megacolon.</strong></li>\x0a<li><strong>Recurrent\x20disease\x20-\u00a0</strong>resolution\x20of\x20CDI\x20followed\x20by\x20recurrence\x20of\x20symptoms\x20within\x20two\x20to\x20eight\x20weeks\x20after\x20treatment\x20has\x20been\x20stopped<strong>\u00a0</strong></li>\x0a</ul>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201108\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p><strong>Nucleic\x20acid\x20amplification</strong>\u00a0tests\x20including\x20polymerase\x20chain\x20reaction\x20(<strong>PCR</strong>)\x20assays,\x20for\u00a0<em>C.\x20difficile</em>\u00a0<strong>toxin\x20A\x20or\x20B\x20gene</strong>\x20<strong>in\x20stool</strong>,\x20are\x20widely\x20used\x20diagnostically.\x20<strong>Glutamate\x20dehydrogenase</strong>\x20is\x20an\x20enzyme\x20immunoassay\x20to\x20detect\u00a0<em>C.\x20difficile</em>\u00a0in\x20stool.\x20Confirmation\x20of\x20the\x20presence\x20of\x20toxin\x20in\x20the\x20stool\x20in\x20addition\x20to\x20PCR\x20or\x20glutamate\x20dehydrogenase\x20positivity\x20is\x20recommended.\u00a0</p>\x0a<p><strong>Oral\x20vancomycin</strong>,\u00a0<strong>fidaxomicin,\u00a0</strong>and<strong>\u00a0metronidazole\u00a0</strong>are\x20used\x20in\x20the\x20management\x20of\x20this\x20condition.\u00a0<strong>Fidaxomicin</strong>\x20acts\x20by\x20<strong>inhibiting\x20protein\x20synthesis</strong>\x20through\x20the\x20<strong>blockade\x20of\x20RNA\x20polymerase</strong>.\u00a0<br\x20/><br\x20/><strong>Management\x20of\x20nonsevere\x20to\x20severe\x20initial\x20disease:</strong></p>\x0a<table\x20style=\x22height:\x20135px;\x20width:\x20676px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20293.438px;\x22>\x0a<p><strong>Nonsevere\x20disease</strong></p>\x0aSupportive\x20clinical\x20data:\x20White\x20blood\x20cell\x20count\x20≤15,000\x20cells/mL\x20and\x20serum\x20creatinine\x20&lt;1.5\x20mg/dL</td>\x0a<td\x20style=\x22width:\x20353.969px;\x22>\x0a<ul>\x0a<li>Vancomycin\x20125\x20mg\x20orally\x204\x20times\x20daily\x20for\x2010\x20days,\u00a0<strong>OR</strong></li>\x0a<li><strong>Fidaxomicin</strong>\x20200\x20mg\x20orally\x20twice\x20daily\x20for\x2010\x20days</li>\x0a<li>If\x20above\x20agents\x20are\x20unavailable:\x20Metronidazole\u00a0500\x20mg\x20orally\x203\x20times\x20daily\x20for\x2010\x20days</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20293.438px;\x22>\x0a<p><strong>Severe\x20disease</strong></p>\x0aSupportive\x20clinical\x20data:\x20White\x20blood\x20cell\x20count\x20&gt;15,000\x20cells/mL\x20and/or\x20serum\x20creatinine\x20≥1.5\x20mg/dL</td>\x0a<td\x20style=\x22width:\x20353.969px;\x22>\u00a0\x0a<ul>\x0a<li>Vancomycin\u00a0125\x20mg\x20orally\x204\x20times\x20daily\x20for\x2010\x20days,\u00a0<strong>OR</strong></li>\x0a<li><strong>Fidaxomicin</strong>\x20200\x20mg\x20orally\x20twice\x20daily\x20for\x2010\x20days</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong><br\x20/>Management\x20of\x20recurrent\x20disease:<br\x20/></strong></p>\x0a<table\x20style=\x22height:\x20136px;\x20width:\x20674px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20300.734px;\x22>First\x20recurrence</td>\x0a<td\x20style=\x22width:\x20344.672px;\x22>\x0a<ul>\x0a<li>If\x20vancomycin\x20was\x20used\x20for\x20the\x20initial\x20episode:\x20Vancomycin\x20pulsed-tapered\x20regimen:\x0a<ul>\x0a<li>125\x20mg\x20orally\x204\x20times\x20daily\x20for\x2010\x20to\x2014\x20days,\x20then</li>\x0a<li>125\x20mg\x20orally\x20twice\x20daily\x20for\x207\x20days,\x20then</li>\x0a<li>125\x20mg\x20orally\x20once\x20daily\x20for\x207\x20days,\x20then</li>\x0a<li>125\x20mg\x20orally\x20every\x202\x20or\x203\x20days\x20for\x202\x20to\x208\x20weeks,\u00a0<strong>OR</strong></li>\x0a</ul>\x0a<ul>\x0a<li>Fidaxomicin\x20200\x20mg\x20orally\x20twice\x20daily\x20for\x2010\x20days</li>\x0a</ul>\x0a</li>\x0a<li>If\x20fidaxomicin\x20or\x20metronidazole\x20was\x20used\x20for\x20the\x20initial\x20episode:\x20Vancomycin\x20125\x20mg\x20orally\x204\x20times\x20daily\x20for\x2010\x20days</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20300.734px;\x22>Second\x20or\x20subsequent\x20recurrence</td>\x0a<td\x20style=\x22width:\x20344.672px;\x22>\u00a0\x0a<ul>\x0a<li>Vancomycin\x20pulsed-tapered\x20regimen\x20(outlined\x20above),\u00a0<strong>OR</strong></li>\x0a<li><strong>Fidaxomicin</strong>\x20200\x20mg\x20orally\x20twice\x20daily\x20for\x2010\x20days,\u00a0<strong>OR</strong></li>\x0a<li>Vancomycin\x20followed\x20by\x20rifaximin:\x0a<ul>\x0a<li>Vancomycin\x20125\x20mg\x20orally\x204\x20times\x20per\x20day\x20for\x2010\x20days,\x20then</li>\x0a<li>Rifaximin\x20400\x20mg\x203\x20times\x20daily\x20for\x2020\x20days,\u00a0<strong>OR</strong></li>\x0a</ul>\x0a</li>\x0a<li>FMT</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong><br\x20/>Management\x20of\x20fulminant\x20disease\x20-\u00a0</strong></p>\x0a<table\x20style=\x22height:\x20154px;\x20width:\x20673px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20265.938px;\x22>Initial\x20episode</td>\x0a<td\x20style=\x22width:\x20378.469px;\x22>\x0a<ul>\x0a<li>Enteric\x20vancomycin\x20plus\x20parenteral\x20metronidazole:\x0a<ul>\x0a<li>Vancomycin\u00a0500\x20mg\x20orally\x20or\x20via\x20nasogastric\x20tube\x204\x20times\x20daily,\u00a0<strong>AND</strong></li>\x0a<li>Metronidazole\x20500\x20mg\x20intravenously\x20every\x208\x20hours</li>\x0a</ul>\x0a</li>\x0a<li>If\x20ileus\x20is\x20present,\u00a0additional\x20considerations\x20include:\x0a<ul>\x0a<li>FMT\x20(administered\x20rectally)</li>\x0a<li>Rectal\x20vancomycin\x20(administered\x20as\x20a\x20retention\x20enema\x20500\x20mg\x20in\x20100\x20mL\x20normal\x20saline\x20per\x20rectum;\x20retained\x20for\x20as\x20long\x20as\x20possible\x20and\x20readministered\x20every\x206\x20hours)</li>\x0a</ul>\x0a</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20265.938px;\x22>Recurrent\x20episode</td>\x0a<td\x20style=\x22width:\x20378.469px;\x22>\u00a0\x0a<ul>\x0a<li>Antibiotics\x20as\x20for\x20initial\x20fulminant\x20episode\x20above</li>\x0a<li>Some\x20favor\x20FMT\x20in\x20the\x20context\x20of\x20a\x20first\x20or\x20second\x20recurrence\x20that\x20presents\x20as\x20a\x20fulminant\x20episode</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B\x20:\x20<strong>Clindamycin\u00a0</strong>is\x20implicated\x20as\x20a\x20<strong>risk\x20factor</strong>\x20for\x20development\x20of\x20clostridium\x20difficile\x20colitis\x20and\x20is\x20not\x20used\x20to\x20treat\x20it.</p>\x0a<p>Option\x20C\x20:\x20<strong>Zanamavir\u00a0</strong>is\x20a\x20neuraminidase\x20inhibitor\x20used\x20against\x20influenza\x20A\x20and\x20B\x20virus.</p>\x0a<p>Option\x20D\x20:\x20<strong>Cilastatin\u00a0</strong>is\x20a\u00a0<strong>reversible\x20dehydropeptidase\x20inhibitor\u00a0</strong>and\x20used\x20adjunctively\x20with\u00a0<strong>imipenem\u00a0</strong>to\x20prolong\x20its\x20action\x20as\x20it\x20rapidly\x20hydrolysed\x20by\u00a0<strong>renal\x20dehydropeptidase.\u00a0</strong>It\x20is\x20not\x20used\x20in\x20the\x20treatment\x20of\x20clostridium\x20difficile\x20colitis.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x324),'choices':[{'id':0x1,'text':'Lithium'},{'id':0x2,'text':_0x3f4b85(0x367)},{'id':0x3,'text':_0x3f4b85(0x224)},{'id':0x4,'text':_0x3f4b85(0x23c)}],'correct_choice_id':0x2,'solution':'<p><strong>Valproate</strong>\x20is\x20a\x20<strong>mood\x20stabilizer</strong>\x20with\x20the\x20side\x20effect\x20of\x20<strong>hepatotoxicity</strong>\x20and\x20<strong>hyperammonemia</strong>.<br\x20/><br\x20/><strong>Valproate</strong>\x20is\x20an<strong>\x20anti-epileptic\x20medication\x20</strong>and\u00a0also\x20used\x20as\x20a\x20<strong>mood\x20stabilizer\x20</strong>in\x20<strong>manic</strong>\x20<strong>episodes</strong>\x20as\x20well\x20as\x20in\x20<strong>bipolar\x20disorder.</strong>\x20The\x20<strong>repetitive\x20firing</strong>\x20caused\x20by\x20the\x20<strong>depolarization\x20of\x20cortical\x20or\x20spinal\x20cord\x20neurons</strong>\x20is\x20<strong>inhibited</strong>\x20by\x20valproate.\x20It\x20also\x20<strong>prolongs</strong>\x20the\x20<strong>sodium\x20channel\x20inactivation</strong>.\x20Valproate\x20can\x20cause\x20an<strong>\x20idiosyncratic\x20hepatic\x20toxicity</strong>\x20and\x20<strong>interfere\x20</strong>with\x20<strong>conversion\x20of\x20ammonia\x20to\x20urea</strong>\x20leading\x20to\x20<strong>hyperammonemia</strong>.\x20Valproate\x20is\x20<strong>contraindicated</strong>\x20in\x20patients\x20with<strong>\x20genetic\x20defects\x20in\x20urea\x20metabolism</strong>.<br\x20/><br\x20/>Valproate\x20therapy\x20<strong>reduces\x20carnitine\x20levels\x20in\x20tissues</strong>,\x20potentially\x20impacting\x20mitochondrial\x20function\x20and\x20leading\x20to\x20<strong>hyperammonemia</strong>\x20and\x20<strong>microvesicular\x20steatosis</strong>.\x20Genetic\x20factors\x20also\x20play\x20a\x20role,\x20as\x20individuals\x20who\x20are\x20heterozygous\x20for\x20mutations\x20in\x20the\x20gamma\x20polymerase\x20gene,\x20which\x20is\x20primarily\x20present\x20in\x20mitochondria,\x20are\x20more\x20susceptible\x20to\x20valproate-induced\x20liver\x20damage.\x20<strong>Intravenous\x20administration</strong>\x20of\x20<strong>carnitine</strong>\x20can\x20be\x20used\x20to\x20manage\x20this\x20condition.<br\x20/><br\x20/>The\x20side\x20effects\x20of\x20valproate\x20(mnemonic:\x20<strong>VALPROATE</strong>)</p>\x0a<p><strong>V</strong>omiting<br\x20/><strong>A</strong>lopecia<br\x20/><strong>L</strong>iver\x20toxicity<br\x20/><strong>P</strong>ancreatitis<br\x20/><strong>R</strong>ash<br\x20/><strong>O</strong>besity<br\x20/><strong>A</strong>norexia<br\x20/><strong>T</strong>eratogenicity<br\x20/><strong>E</strong>dema</p>\x0a<p>It\x20causes\x20<strong>congenital\x20anomalies</strong>\x20like\x20<strong>neural\x20tube\x20defects</strong>\x20(Spina\x20Bifida),\x20clefts,\x20and\x20<strong>cardiac\x20anomalies</strong>.\x20The<strong>\x20intelligence\x20quotient</strong>\x20score\x20of\x20school-going\x20children\x20who\x20were\x20exposed\x20in\x20utero\x20to\x20valproate\x20is\x20found\x20<strong>reduced</strong>.\x20It\x20also\x20contributes\x20to<strong>\x20poor\x20cognitive\x20development</strong>\x20in\x20children.\x20<strong>Folate\x20supplementation</strong>\x20reduces\x20the\x20chances\x20of\x20neural\x20tube\x20defects.</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Option\x20A\x20:\x20<strong>Lithium</strong>\x20is\x20a<strong>\x20mood\x20stabilizer</strong>\x20with\x20a\x20very\x20<strong>narrow\x20therapeutic\x20index</strong>\x20and\x20is\x20the\x20<strong>first\x20line</strong>\x20of\x20management\x20in<strong>\x20bipolar\x20disorder</strong>.\x20Its\x20<strong>adverse\x20effects\x20</strong>can\x20be\x20<strong>acute</strong>\x20such\x20as<strong>\x20tremors,\x20ataxia,\x20weakness,\x20polyuria,\x20polydipsia</strong>\x20or\x20<strong>chronic</strong>\x20such\x20as\x20<strong>nephrogenic\x20diabetes\x20insipidus,\x20thyroid\x20dysfunction</strong>,\x20and\x20<strong>hyperparathyroidism</strong>.\x20It\x20is\x20not\x20associated\x20with\x20hepatotoxicity\x20or\x20hyperammonemia.\u00a0<br\x20/><br\x20/>Option\x20C\x20:\x20<strong>Carbamazepine\u00a0</strong>is\x20a\x20<strong>sodium\x20channel\x20blocker</strong>\x20used\x20in\x20the\x20management\x20of\x20<strong>complex\x20partial\x20seizures,\x20GTCS,\x20simple\x20partial\x20seizures</strong>\x20and\x20<strong>trigeminal\x20neuralgia</strong>.\x20It\x20is\x20known\x20to\x20be\x20<strong>hepatotoxic</strong>\x20but\x20is<strong>\x20not\x20associated\x20</strong>with\x20<strong>hyperammonemia</strong>.\x20Other\x20adverse\x20effects\x20include\x20<strong>hypersensitivity</strong>\x20reactions,\x20<strong>eosinophilia</strong>,\x20<strong>agranulocytosis</strong>,\x20<strong>aplastic</strong>\x20<strong>anemia</strong>,\x20<strong>hyponatremia</strong>\x20and\x20<strong>stevens-johnson\x20syndrome</strong>.<br\x20/><br\x20/>Option\x20D\x20:\x20<strong>Topiramate\u00a0</strong>is\x20an<strong>\x20anti\x20epileptic\x20</strong>and\x20<strong>non-opioid\x20pain\x20medication</strong>\x20which\x20is\x20associated\x20with\x20<strong>significant\x20weight\x20loss</strong>\x20of\x20<strong>up\x20to\x207%</strong>\x20as\x20a\x20side\x20effect.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x451),'choices':[{'id':0x1,'text':_0x3f4b85(0x2f6)},{'id':0x2,'text':_0x3f4b85(0x366)},{'id':0x3,'text':_0x3f4b85(0x329)},{'id':0x4,'text':_0x3f4b85(0x33f)}],'correct_choice_id':0x2,'solution':_0x3f4b85(0x1fc),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20child\x20was\x20receiving\x20a\x20blood\x20transfusion.\x20At\x20what\x20serum\x20iron\x20level\x20will\x20desferrioxamine\x20be\x20administered\x20to\x20him?','choices':[{'id':0x1,'text':_0x3f4b85(0x3f2)},{'id':0x2,'text':'400\x20mcg/dL'},{'id':0x3,'text':_0x3f4b85(0x3c4)},{'id':0x4,'text':_0x3f4b85(0x48e)}],'correct_choice_id':0x4,'solution':_0x3f4b85(0x2ab),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x1fd),'choices':[{'id':0x1,'text':_0x3f4b85(0x46d)},{'id':0x2,'text':_0x3f4b85(0x210)},{'id':0x3,'text':_0x3f4b85(0x427)},{'id':0x4,'text':_0x3f4b85(0x358)}],'correct_choice_id':0x1,'solution':_0x3f4b85(0x402),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x342),'choices':[{'id':0x1,'text':_0x3f4b85(0x3dc)},{'id':0x2,'text':_0x3f4b85(0x2fa)},{'id':0x3,'text':'Blood\x20dyscrasia'},{'id':0x4,'text':_0x3f4b85(0x3c6)}],'correct_choice_id':0x2,'solution':_0x3f4b85(0x466),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20patient\x20with\x20hemophilia\x20on\x20antiretroviral\x20therapy\x20is\x20brought\x20in\x20altered\x20mental\x20status\x20following\x20complaints\x20of\x20nausea,\x20vomiting\x20and\x20headache.\x20Which\x20of\x20the\x20following\x20medications\x20was\x20he\x20taking?','choices':[{'id':0x1,'text':_0x3f4b85(0x28b)},{'id':0x2,'text':_0x3f4b85(0x4b2)},{'id':0x3,'text':_0x3f4b85(0x413)},{'id':0x4,'text':'Ritonavir'}],'correct_choice_id':0x2,'solution':_0x3f4b85(0x206),'explanation_video':'','question_images':[],'explanation_images':['https://dhmbxeygs57ff.cloudfront.net/uploads/a35d3bc243d84eabab61ffc2580066dcx769x673.JPEG']},{'text':_0x3f4b85(0x410),'choices':[{'id':0x1,'text':'Tall\x20peaked\x20T\x20waves'},{'id':0x2,'text':_0x3f4b85(0x258)},{'id':0x3,'text':'Tall\x20QRS\x20complexes'},{'id':0x4,'text':_0x3f4b85(0x3df)}],'correct_choice_id':0x1,'solution':_0x3f4b85(0x331),'explanation_video':'','question_images':[],'explanation_images':[_0x3f4b85(0x42b)]},{'text':'Which\x20of\x20the\x20following\x20drugs\x20can\x20be\x20used\x20in\x20diabetic\x20neuropathy,\x20post\x20herpetic\x20neuralgia\x20and\x20spinal\x20cord\x20injury?','choices':[{'id':0x1,'text':_0x3f4b85(0x352)},{'id':0x2,'text':_0x3f4b85(0x3cd)},{'id':0x3,'text':'Carbamazepine'},{'id':0x4,'text':_0x3f4b85(0x26f)}],'correct_choice_id':0x4,'solution':'<p><strong>Pregabalin</strong>\x20can\x20be\x20used\x20for\x20<strong>diabetic\x20neuropathy,</strong>\x20<strong>post\x20herpetic\x20neuralgia</strong>\x20and\x20<strong>spinal\x20cord\x20injury</strong>.\x20Although\x20<strong>amitriptyline</strong>\x20can\x20also\x20be\x20used\x20for\x20these\x20conditions,\x20<strong>pregabalin</strong>\x20is\x20found\x20to\x20be\x20<strong>recommended</strong>\x20over\x20amitriptyline\x20considering\x20<strong>safety\x20and\x20efficacy\x20</strong>and\x20hence\x20is\x20the\x20best\x20option.</p>\x0a<p><strong>Pregabalin</strong>\x20is\x20an\x20<strong>anti</strong>-<strong>epileptic</strong>\x20drug.\x20Its\x20<strong>analgesic\x20effect</strong>\x20is\x20mediated\x20by\x20<strong>binding</strong>\x20<strong>to\x20α2δ</strong>,\x20a\x20<strong>protein</strong>\x20that\x20is\x20a\x20<strong>subunit</strong>\x20of\x20<strong>voltage-gated\x20calcium\x20channels</strong>\x20and\x20causes\x20a\x20<strong>decrease\x20in\x20glutamate\x20release</strong>\x20at\x20<strong>excitatory\x20synapses</strong>.\x20Decreased\x20neurotransmitter\x20release\x20is\x20associated\x20with\x20<strong>reduced\x20neuronal\x20hyperexcitability</strong>.\x20It\x20is\x20used\x20in\x20the\x20management\x20of\x20<strong>neuropathic\x20pain</strong>\x20<strong>associated\x20with\x20diabetic\x20peripheral\x20neuropathy</strong>,\x20<strong>spinal\x20cord\x20injury</strong>\x20or\x20<strong>postherpetic\x20neuralgia</strong>.\u00a0</p>\x0a<p>Currently,\x20only\x20<strong>duloxetine\x20and\x20pregabalin</strong>\x20are\x20<strong>approved\x20by\x20the\x20U.S.\x20Food\x20and\x20Drug\x20Administration</strong>\x20and\x20the\x20European\x20Medicines\x20Agency\x20to\x20treat\x20<strong>painful\x20diabetic\x20neuropathy</strong>.\u00a0Diabetic\x20Neuropathy\x20is\x20the\x20<strong>most\x20common\x20cause\x20of\x20peripheral\x20neuropathy</strong>\x20in\x20<strong>developed\x20countries</strong>.\x20<strong>Risk\x20factors</strong>\x20include\x20<strong>long-standing,\x20poorly\x20controlled\x20DM</strong>\x20and\x20the\x20<strong>presence</strong>\x20<strong>of</strong>\x20<strong>retinopathy\x20and\x20nephropathy</strong>.</p>\x0a<p><strong>Side\x20effects</strong>\x20of\x20<strong>pregabalin</strong>\x20include\x20<strong>sedation</strong>\x20and\x20<strong>peripheral\x20edema</strong>.</p>\x0a<p>Other\x20options\x20:\u00a0</p>\x0a<p>Option\x20A\x20:\x20<strong>Tricyclic\x20antidepressants\x20(TCAs)</strong>\x20such\x20as\x20<strong>amitriptyline</strong>\x20are\x20used\x20in\x20the\x20<strong>treatment\x20of\x20several\x20pain\x20conditions</strong>\x20such\x20as\x20<strong>diabetic\x20neuropathy,\x20post\x20herpetic\x20neuralgia</strong>\x20and\x20following\x20<strong>spinal\x20cord\x20injury</strong>.\x20Their\x20mechanism\x20of\x20action\x20is\x20<strong>inhibition\x20of\x20norepinephrine\x20and\x20serotonin\x20reuptake.</strong>\x20Although\x20both\x20pregabalin\x20and\x20amitriptyline\x20are\x20among\x20the\x20first\x20line\x20drugs\x20for\x20neuropathic\x20pain,\x20amitriptyline\x20would\x20be\x20the\x20<strong>next\x20best\x20option</strong>\x20in\x20this\x20question,\x20owing\x20to\x20its\x20<strong>side\x20effect\x20profile</strong>\x20and\x20good\x20yet\x20<strong>controversial\x20efficacy\x20in\x20pain\x20control</strong>.\x20It\x20is\x20a\x20<strong>non\x20FDA\x20approved</strong>\x20<strong>drug</strong>\x20for\x20<strong>diabetic\x20neuropathy\x20(off\x20label\x20indication).\x20</strong>Side\x20effects\x20associated\x20with\x20amitriptyline\x20include\x20<strong>anticholinergic\x20side\x20effects</strong>\x20(dry\x20mouth,\x20tachycardia,\x20hyperthermia),\x20<strong>cardiac\x20effects\x20(arrhythmias)</strong>\x20and\x20<strong>sedation</strong>.</p>\x0a<p>Option\x20B\x20:\x20<strong>Phenytoin</strong>\x20is\x20an\x20<strong>antiepileptic</strong>\x20drug\x20that\x20is\x20not\x20used\x20in\x20the\x20treatment\x20of\x20pain.</p>\x0a<p>Option\x20C\x20:\u00a0<strong>Carbamazepine</strong>\x20is\x20an\x20<strong>iminostilbine</strong>\x20<strong>derivative</strong>.\x20It\x20<strong>blocks\x20voltage-activated\x20sodium\x20channels</strong>,\x20slowing\x20their\x20rate\x20of\x20recovery\x20and\x20limiting\x20the\x20repetitive\x20firing\x20of\x20action\x20potentials.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>generalized,\x20focal-to-bilateral\x20and\x20idiopathic\x20tonic-clonic\x20seizures,\x20focal\x20seizures,\x20neuropathic\x20pain</strong>\x20associated\x20with\x20<strong>trigeminal\x20and\x20glossopharyngeal\x20neuralgias</strong>.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x3f4b85(0x438),'choices':[{'id':0x1,'text':'Aztreonam'},{'id':0x2,'text':_0x3f4b85(0x27a)},{'id':0x3,'text':_0x3f4b85(0x4a5)},{'id':0x4,'text':_0x3f4b85(0x1f2)}],'correct_choice_id':0x3,'solution':_0x3f4b85(0x3b7),'explanation_video':'','question_images':[],'explanation_images':[_0x3f4b85(0x4a9)]}],quizName=_0x3f4b85(0x49f);const quizFilename=_0x3f4b85(0x292);let hierarchy=['Marrow',_0x3f4b85(0x2ae),_0x3f4b85(0x269)];if(window['location']['pathname']['endsWith'](_0x3f4b85(0x341))){const customData=JSON[_0x3f4b85(0x249)](localStorage[_0x3f4b85(0x25a)](_0x3f4b85(0x3d0)));if(customData){const TDpLCr=_0x3f4b85(0x396)[_0x3f4b85(0x3dd)]('|');let injbvn=0x0;while(!![]){switch(TDpLCr[injbvn++]){case'0':quizName=customData[_0x3f4b85(0x2d7)];continue;case'1':document[_0x3f4b85(0x3ce)](_0x3f4b85(0x26c))[_0x3f4b85(0x463)]=hierarchy[_0x3f4b85(0x3ad)]('\x20>\x20');continue;case'2':document[_0x3f4b85(0x494)]=quizName+'\x20-\x20Brain\x20And\x20Scalpel';continue;case'3':questionsData=customData['questions'];continue;case'4':hierarchy=customData[_0x3f4b85(0x38b)];continue;case'5':document['getElementById']('totalQuestions')[_0x3f4b85(0x463)]=questionsData[_0x3f4b85(0x491)];continue;}break;}}}let currentQuestionIndex=0x0,selectedOption=null,currentMode='study',timer=null,timeRemaining=0x0,questionStartTime=Date[_0x3f4b85(0x274)](),quizStartTime=Date[_0x3f4b85(0x274)](),isQuizCompleted=![],questionStates=new Array(questionsData[_0x3f4b85(0x491)])[_0x3f4b85(0x417)](null)[_0x3f4b85(0x20e)](()=>({'status':'not_attempted','bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData[_0x3f4b85(0x491)]};function saveProgress(){const _0x2f8682=_0x3f4b85,_0x150249={'LzLnd':'incomplete','abEQR':_0x2f8682(0x359)};if(isQuizCompleted)return;const _0x14550d=JSON[_0x2f8682(0x249)](localStorage['getItem'](_0x2f8682(0x359)))||{};_0x14550d[quizFilename]={'questionStates':questionStates,'stats':stats,'currentQuestionIndex':currentQuestionIndex,'currentMode':currentMode,'status':_0x150249[_0x2f8682(0x35b)],'lastSeen':new Date()[_0x2f8682(0x4ba)]()},localStorage['setItem'](_0x150249[_0x2f8682(0x200)],JSON['stringify'](_0x14550d));}function loadProgress(){const _0x1bb031=_0x3f4b85,_0x14e832={'TKpre':_0x1bb031(0x359),'eGIRt':_0x1bb031(0x247),'gMCIX':_0x1bb031(0x305)},_0x352636=JSON[_0x1bb031(0x249)](localStorage[_0x1bb031(0x25a)](_0x14e832[_0x1bb031(0x372)]))||{},_0x1640ab=_0x352636[quizFilename];if(_0x1640ab){const _0x344f8d=_0x14e832[_0x1bb031(0x1eb)][_0x1bb031(0x3dd)]('|');let _0x3535d1=0x0;while(!![]){switch(_0x344f8d[_0x3535d1++]){case'0':currentQuestionIndex=_0x1640ab[_0x1bb031(0x26b)];continue;case'1':currentMode=_0x1640ab[_0x1bb031(0x2fb)];continue;case'2':console['log'](_0x14e832[_0x1bb031(0x3db)]);continue;case'3':stats=_0x1640ab[_0x1bb031(0x268)];continue;case'4':return!![];case'5':questionStates=_0x1640ab[_0x1bb031(0x1f9)];continue;}break;}}return![];}function _0x37ce(){const _0x3ac59c=['glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','xftcE','key','testModeReviewLegend','<p>In\x20the\x20above\x20clinical\x20scenario,\x20the\x20most\x20likely\x20cause\x20of\x20itching\x20around\x20the\x20vulvovaginal\x20area\x20is&nbsp;<strong>canagliflozin</strong>.\x20The&nbsp;side\x20effects\x20associated\x20with\x20canagliflozin\x20are\x20<strong>urinary\x20tract\x20infections</strong>,&nbsp;<strong>genital\x20mycotic\x20infections</strong>\x20due\x20to\x20the\x20high\x20glucose\x20content\x20of\x20the\x20urine,&nbsp;<strong>increased\x20risk\x20of\x20fractures</strong>,\x20and\x20<strong>lower\x20extremity\x20amputations</strong>.</p>\x0a<p>Canagliflozin\x20is\x20a\x20<strong>sodium-glucose\x20transporter\x202</strong>\x20(SGLT-2)\x20<strong>inhibitor</strong>.\x20Other\x20SGLT-2\x20inhibitors\x20include\x20dapagliflozin\x20and\x20empagliflozin.\x20They\x20act\x20by&nbsp;inhibiting\x20the&nbsp;SGLT-2\x20transporter\x20which\x20is\x20present\x20on\x20the\x20<strong>proximal</strong>\x20segment\x20of\x20the\x20<strong>renal\x20tubule</strong>.\x20It\x20is\x20responsible\x20for\x20the\x20reabsorption\x20of\x2080-90%\x20of\x20filtered\x20glucose.&nbsp;It&nbsp;inhibits\x20glucose\x20reabsorption\x20resulting\x20in\x20glycosuria\x20and\x20a\x20change\x20in\x20the\x20renal\x20threshold.</p>\x0a<p>SGLT2\x20inhibitors\x20can\x20cause\x20<strong>mild\x20weight\x20loss</strong>\x20and\x20reduction\x20in\x20blood\x20pressure.\x20Drugs\x20like&nbsp;empagliflozin\x20and\x20canagliflozin\x20are\x20found\x20to\x20<strong>reduce</strong>\x20major\x20<strong>cardiovascular\x20events</strong>.</p>\x0a<p>The\x20common\x20side\x20effects\x20include\x20<strong>urinary\x20tract\x20infections</strong>\x20and<strong>\x20genital\x20mycotic\x20infections</strong>\x20due\x20to\x20the\x20high\x20glucose\x20content\x20of\x20the\x20urine.&nbsp;There\x20is\x20a\x20risk\x20of\x20the\x20development\x20of\x20<strong>diabetic\x20ketoacidosis</strong>.\x20It\x20increases\x20the\x20<strong>risk\x20of\x20fractures</strong>\x20and\x20<strong>lower\x20limb\x20amputations</strong>\x20due\x20to\x20the\x20creation\x20of\x20an\x20imbalance\x20with\x20the\x20minerals\x20and\x20circulating\x20parathormone\x20and\x20vitamin\x20D.\x20Since\x20SGLT2\x20inhibitors\x20depend\x20on\x20the\x20rate\x20of\x20glucose\x20filtration\x20to\x20be\x20effective,\x20potency\x20decreases\x20if\x20given\x20in\x20stage\x203\x20kidney\x20disease\x20(GFR\x2060&ndash;30\x20mL/min).</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:&nbsp;<strong>Acarbose\x20is\x20an\x20a</strong><strong>lpha-glucosidase\x20inhibitor.\x20</strong>It&nbsp;reduces\x20the\x20intestinal\x20absorption\x20of\x20glucose\x20by\x20inhibiting\x20the\x20intestinal\x20brush\x20border\x20enzyme,\x20alpha-glucosidase.\x20These\x20drugs\x20also\x20increase\x20GLP-1\x20levels\x20in\x20circulation.\x20They&nbsp;<strong>reduce\x20post-prandial\x20glucose</strong>&nbsp;levels.</p>\x0a<p>Option\x20C:&nbsp;<strong>Linagliptin</strong>&nbsp;is\x20a&nbsp;<strong>dipeptidyl-peptidase-4&nbsp;</strong>(DPP-4)<strong>&nbsp;inhibitor</strong>.\x20It\x20is\x20used\x20in\x20type\x202\x20diabetes\x20as\x20monotherapy\x20or\x20in\x20combination\x20therapy\x20when\x20metformin\x20is\x20not\x20tolerated\x20or\x20contraindicated.\x20It&nbsp;binds\x20extensively\x20to\x20plasma\x20proteins\x20and\x20is\x20cleared<strong>&nbsp;primarily\x20by\x20the\x20hepatobiliary\x20system.&nbsp;</strong>Hence,\x20no\x20dosage\x20adjustment\x20is\x20needed\x20in\x20renal\x20failure.&nbsp;<strong>Dipeptidyl\x20peptidase-4\x20inhibitors&nbsp;</strong>enhance\x20the\x20release\x20of\x20insulin\x20postprandially,\x20decrease\x20glucagon,\x20and\x20thereby\x20lower\x20mealtime\x20as\x20well\x20as\x20fasting\x20glucose.\x20They\x20are\x20weight\x20neutral.</p>\x0a<p>Option\x20D:&nbsp;<strong>Liraglutide</strong>&nbsp;is\x20also\x20a&nbsp;<strong>GLP-1\x20receptor\x20agonist</strong>&nbsp;and\x20is\x20given\x20only\x20in\x20the&nbsp;<strong>subcutaneous\x20injectable</strong>&nbsp;form.\x20It\x20was\x20recently\x20approved\x20in\x20the\x20treatment\x20of&nbsp;<strong>obesity.</strong></p>\x0a<p>&nbsp;</p>','16NHDRZG','EyJTH','DchZL','hvZWj','yLyJm','TKpre','Inhibition\x20of\x20IL2,\x20IL4,\x20IL5','crifC','\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>','JfKUO','addEventListener','zcnuM','<p><strong>Sodium\x20valproate</strong>\x20has\x20an\x20<strong>inhibitory\x20action</strong>\x20on\x20the\x20<strong>metabolism</strong>\x20and\x20<strong>degradation</strong>\x20of\x20<strong>GABA</strong>,\x20and\x20also<strong>\x20increases\x20its\x20synthesis</strong>.<br\x20/><br\x20/><strong>Valproate</strong>\x20is\x20an\x20<strong>anti-epileptic\x20</strong>medication\x20and\x20also\x20used\x20as\x20a\x20<strong>mood\x20stabilizer</strong>\x20in\x20<strong>bipolar\x20disorder</strong>.\x20Valproate\x20<strong>acts\x20via\x20multiple\x20mechanisms</strong>.\x20It\x20<strong>blocks</strong>\x20<strong>both</strong>\x20<strong>sodium</strong>\x20and\x20<strong>calcium</strong>\x20<strong>channels</strong>.\x20It\x20<strong>prolongs\x20sodium\x20channel\x20inactivation</strong>\x20and\x20<strong>attenuates\x20calcium-mediated\x20\x27T\x27\x20current</strong>.\x20It\x20<strong>inhibits\x20metabolism\x20and\x20degradation</strong>\x20of\x20the\x20inhibitory\x20neurotransmitter\x20<strong>GABA</strong>\x20and\x20<strong>increases\x20its\x20synthesis</strong>\x20from\x20<strong>glutamic\x20acid</strong>\x20(Option\x20A).\x20It\x20also\x20<strong>inhibits\x20excitatory\x20NMDA\x20glutamate\x20receptors</strong>.\x20The\x20<strong>repetitive\x20firing</strong>\x20caused\x20by\x20the\x20<strong>depolarization\x20of\x20cortical\x20or\x20spinal\x20cord\x20neurons</strong>\x20is\x20<strong>inhibited</strong>\x20by\x20valproate.</p>\x0a<p>Valproate\x20is\x20a<strong>\u00a0broad\x20spectrum\x20antiseizure\x20drug</strong>\x20used\x20in\x20<strong>partial\x20seizures,\x20generalised\x20tonic-clonic\x20seziures\x20(GTCS),\x20absence\x20seizures,\x20myoclonic\x20seziures</strong>\x20and\x20<strong>atonic\x20seziures</strong>.\x20It\x20can\x20be\x20used\x20in\x20absence\x20seizures,\x20but\x20it\x20is\x20preferred\x20when\x20the\x20child\x20also\x20suffers\x20from\x20GTCS.\x20It\x20is\x20the\x20<strong>drug\x20of\x20choice</strong>\x20for\x20<strong>juvenile\x20myoclonic\x20epilepsy</strong>.\u00a0</p>\x0a<p>The<strong>\x20side\x20effects\x20</strong>of\x20valproate\x20(mnemonic:\x20VALPROATE)</p>\x0a<p><strong>V</strong>omiting<br\x20/><strong>A</strong>lopecia<br\x20/><strong>L</strong>iver\x20toxicity<br\x20/><strong>P</strong>ancreatitis<br\x20/><strong>R</strong>ash<br\x20/><strong>O</strong>besity<br\x20/><strong>A</strong>norexia<br\x20/><strong>T</strong>eratogenicity<br\x20/><strong>E</strong>dema</p>\x0a<p>It\x20causes\x20<strong>congenital\x20anomalies</strong>\x20like\x20<strong>neural\x20tube\x20defects\x20(Spina\x20Bifida)</strong>,\x20<strong>clefts</strong>,\x20and\x20<strong>cardiac\x20anomalies</strong>.\x20The\x20<strong>intelligence\x20quotient</strong>\x20score\x20of\x20school-going\x20children\x20who\x20were\x20<strong>exposed\x20in\x20utero\x20to\x20valproate</strong>\x20is\x20found\x20<strong>reduced</strong>.\x20It\x20also\x20contributes\x20to\x20<strong>poor\x20cognitive\x20development</strong>\x20in\x20children.\x20<strong>Folate\x20supplementation</strong>\x20<strong>reduces</strong>\x20the\x20chances\x20of\x20<strong>neural\x20tube\x20defects.</strong></p>\x0a<p>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20C\x20:\x20Drugs\x20such\x20as\x20<strong>vigabatrine\x20and\x20tiagabine</strong>\x20<strong>inhibit\x20GABA\x20reuptake</strong>\x20by\x20inhibiting\x20the\x20GABA\x20reuptake\x20transporter.\x20<strong>Vigabatrine</strong>\x20is\x20the\x20<strong>drug\x20of\x20choice</strong>\x20for\x20<strong>infantile\x20spasms\x20(West\x20syndrome</strong>)\x20seen\x20in\x20<strong>tuberous\x20sclerosis</strong>.</p>\x0a<p>Option\x20D\x20:\x20<strong>Flumazenil</strong>\x20acts\x20as\x20an\x20<strong>antagonist</strong>\x20at\x20the\x20<strong>GABA\x20receptor</strong>\x20and\x20is\x20used\x20as\x20an\x20<strong>antidote\x20for\x20benzodiazepine\x20overdose</strong>.\x20<strong>Benzodiazepines</strong>\x20act\x20by\x20<strong>promoting\x20GABA\x20inhibition</strong>\x20by\x20<strong>binding\x20to\x20the\x20GABA\x20receptor</strong>\x20itself\x20and\x20<strong>inhibiting\x20nerve\x20transmission</strong>.</p>','Which\x20of\x20the\x20following\x20drugs\x20acts\x20via\x20the\x20ATP-binding\x20cassette\x20transporter?','AFKMO','WNDWa','AseYs','xDbhP','</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>','bFUNr','NVeqB','search','.m3u8','bawgE','endsWith','contains','Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','info','<p>The\x20given\x20clinical\x20features\x20are\x20suggestive\x20of<strong>\x20hypothyroidism\x20with\x20goiter,</strong>\x20which\x20is\x20a\x20known\x20<strong>adverse\x20effect\x20of\x20ethionamide</strong>.</p>\x0a<p><strong>Mutidrug-resistant\x20tuberculosis\x20(MDR-TB)</strong>\x20is\x20treated\x20with\x20<strong>2nd\x20line\x20agents</strong>\x20that\x20include\x20<strong>ethionamide\x20(ETH)</strong>.\x20ETH\x20is\x20not\x20a\x20first-line\x20agent\x20due\x20to\x20its\x20<strong>gastrointestinal\x20side\x20effects</strong>.\x20Ethionamide\x20<strong>inhibits\x20activity\x20of\x20the\x20InhA\x20gene\x20product</strong>,\x20resulting\x20in\x20<strong>inhibition\x20of\x20mycolic\x20acid\x20synthesis</strong>.\x20It\x20is\x20<strong>structurally\x20related\x20to\x20thionamides</strong>\x20(propylthiouracil\x20and\x20methimazole)\x20and\x20therefore<strong>\x20causes\x20hypothyroidism</strong>\x20by\x20<strong>preventing\x20organification\x20of\x20iodine\x20in\x20thyroid\x20hormone\x20synthesis.</strong>\x20<strong>Another\x20antitubercular\x20</strong>drug\x20that\x20can\x20cause<strong>\x20hypothyroidism\x20</strong>is<strong>\x20Para-amino\x20salicylic\x20acid\x20(PAS)</strong>.\u00a0</p>\x0a<p>ETH/PAS-induced\x20hypothyroidism\x20should\x20be<strong>\x20treated\x20with\x20thyroxine\x20replacement\x20</strong>therapy,\x20instead\x20of\x20changing\x20the\x20regimen.\x20Thyroid\x20function\x20usually\x20optimizes\x20within\x202\x20months\x20after\x20completing\x20MDR\x20therapy.<br\x20/><br\x20/><strong>Ethionamide</strong>\x20also\x20causes\x20<strong>hepatotoxicity</strong>\x20and\x20<strong>neurological</strong>\x20<strong>adverse</strong>\x20<strong>effects</strong>\x20and\x20may\x20require\x20<strong>pyridoxine\x20supplementation</strong>.</p>\x0a<p><strong>MDR-TB</strong>\x20is\x20when\x20there\x20is\x20<strong>resistance\x20to\x20atleast\x20isoniazid\x20and\x20rifampicin\x20</strong>which\u00a0are\x20the\x20most\x20potent\x20first-line\x20drugs.\u00a0The\x20treatment\x20of\x20MDR-TB\x20is\x20curated\x20with\x20drugs\x20grouped\x20into\x20different\x20classes\x20by\x20the\x20world\x20health\x20organization\x20(WHO).</p>\x0a<p><strong>Group\x20A:\x20Levofloxacin,\x20bedaquiline,\x20linezolid</strong><br\x20/><strong>Group\x20B:\x20Clofazimine,\x20cycloserine</strong><br\x20/><strong>Group\x20C:\x20Ethambutol,\x20pyrazinamide,\x20delamanid,\x20ethionamide</strong><br\x20/><br\x20/>In\x20patients<strong>\x20treated\x20previously</strong>\x20or\x20with\x20<strong>additional\x20drug\x20resistance</strong>,\x20a\x20<strong>longer\x20MDR-TB\x20regimen</strong>\x20of\x20<strong>18-20\x20months</strong>\x20is\x20recommended.\x20Drugs\x20belonging\x20to\x20<strong>group\x20A\x20are\x20preferred\x20along\x20with\x20one\x20drug\x20from\x20group\x20B</strong>\x20whenever\x20possible.\x20A<strong>\x20shorter\x20regimen\x20of\x206\x20months</strong>\x20including\x20<strong>bedaquiline</strong>\x20with\x20other\x20drugs\x20can\x20be\x20used\x20in\x20<strong>patients\x20not\x20treated\x20before</strong>\x20and\x20<strong>without\x20extensive\x20disease.</strong>\x20In\x20<strong>pregnant</strong>\x20<strong>women</strong>\x20with\x20MRD-TB,\x20drugs\x20such\x20as\x20<strong>bedaquiline</strong>\x20and\x20<strong>delamanid</strong>\x20should\x20be\x20<strong>avoided</strong>.</p>\x0a<p>Other\x20options\x20:<br\x20/><br\x20/>Option\x20A\x20:\x20<strong>Pyrazinamide\x20inhibits\x20fatty\x20acid\x20synthase-I\x20</strong>leading\x20to<strong>\x20inhibition\x20of\x20cell\x20membrane\x20synthesis</strong>.\x20Pyrazinamide\x20causes\x20<strong>hyperuricemia</strong>\x20and\x20<strong>hepatotoxicity</strong>.\u00a0<br\x20/><br\x20/>Option\x20C\x20:\x20Adverse\x20effects\x20of\x20<strong>cycloserine</strong>\x20are\x20mainly\x20<strong>neurological</strong>.\x20Half\x20of\x20the\x20patients\x20on\x20cycloserine\x20(1g/day)\x20experience\x20<strong>neuropsychiatric</strong>\x20<strong>symptoms</strong>.\x20It\x20ranges\x20from\x20<strong>headaches\x20to\x20psychosis,\x20seizures,\x20and\x20suicidal\x20ideas</strong>.</p>\x0a<p>Option\x20D\x20:\x20<strong>Streptomycin</strong>\x20is\x20an\x20<strong>aminoglycoside</strong>\x20which\x20binds\x20to\x20the\x20<strong>30S\x20ribosomal</strong>\x20subunit\x20and\x20<strong>interferes\x20with\x20the\x20initiation\x20of\x20protein\x20synthesis</strong>.\x20\u00a0It\x20is\x20a\x20<strong>second-line\x20agent\x20</strong>for\x20the\x20treatment\x20of\x20active\x20tuberculosis.\x20Streptomycin\x20produces\x20<strong>ototoxicity,\x20vestibulotoxicity,\x20optic\x20nerve\x20dysfunction,\x20including\x20scotomas,\x20and\x20peripheral\x20neuritis.</strong></p>','ghWYY','hierarchy','eLHyB','BRuKl','Bookmarked','border-gray-600','src','mYBHl','pCfRa','Jyqvb','scoreCircle','Bvvve','3|0|4|2|5|1','JlgcA','SYqsz','filter','Alogliptin','open','testModeLegend','HYwcV','Npqnd','Verapamil','Cereblon\x20binding','phYNF','syORs','floor','startAt','T790M\x20mutation','zwugb','mMhUp','green','A-3,\x20B-4,\x20C-1,\x20D-2','CKySY','href','BRCA','join','Mark\x20for\x20Review','166LUITua','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','ZsUSJ','explanation_audio_hin','nwNLT','Nivolumab\x20is\x20used\x20in\x20NSCLC','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','Vemurafenib','<p><strong>Linezolid</strong>\x20is\x20a\x20<strong>protein\x20synthesis\x20inhibitor</strong>\x20that\x20acts\x20by\x20<strong>inhibiting</strong>\x20the<strong>\x2050s\x20ribosomal</strong>\x20<strong>subunit</strong>.<br\x20/><br\x20/>Linezolid\x20binds\x20to\x20the\x20<strong>P\x20site</strong>\x20of\x20the\x20<strong>50s\x20ribosomal\x20subunit</strong>\x20and\x20<strong>inhibits\x20bacterial\x20protein\x20synthesis.</strong>\x20It\x20is\x20an\x20<strong>oxazolidinone</strong>\x20that\x20is\x20active\x20against\x20<strong>various\x20resistant\x20organisms</strong>\x20including\x20<strong>MRSA</strong>.\x20It\x20has\x20<strong>excellent</strong>\x20<strong>oral\x20bioavailability</strong>.\x20Linezolid\x20is\x20used\x20to\x20treat\x20infections\x20caused\x20by\x20<strong>gram-positive\x20bacteria</strong>,\x20particularly\x20<strong>vancomycin-resistant\x20enterococcus\x20</strong>and\x20<strong>methicillin-resistant\x20Staphylococcus\x20aureus</strong>.\x20Linezolid\x20is\x20also\x20approved\x20for\x20the\x20treatment\x20of\x20<strong>community-acquired\x20pneumonia\x20</strong>due\x20to<strong>\x20S.\x20pneumoniae</strong>\x20and\x20<strong>nosocomial\x20pneumonia</strong>\x20due\x20to\x20<strong>S.\x20aureus.</strong><br\x20/><br\x20/>The\x20<strong>intrinsic\x20resistance</strong>\x20of\x20<strong>gram-negative\x20bacteria\x20</strong>to\x20linezolid\x20is\x20mediated\x20by\x20<strong>endogenous\x20efflux\x20pumps.</strong><br\x20/><br\x20/>Linezolid\x20is\x20associated\x20with\x20the\x20<strong>side\x20effect\x20of\x20myelosuppression\x20</strong>(anemia,\x20leukopenia,\x20pancytopenia,\x20and\x20thrombocytopenia).\x20<strong>Thrombocytopenia\x20is\x20the\x20most\x20common\x20side\x20effect</strong>.\x20Linezolid\x20has<strong>\x20MAOI\x20(monoamine\x20oxidase\x20inhibitors)\x20activity\x20</strong>and\x20therefore\x20can\x20<strong>precipitate\x20serotonin\x20syndrome\x20with\x20concomitant\x20use\x20of\x20SSRI\x20(paroxetine)\x20</strong>or\x20with\x20other\x20<strong>serotonergic\x20medications.\u00a0</strong><strong><br\x20/><br\x20/></strong>Other\x20adverse\x20effects\x20include\x20<strong>peripheral\x20neuropathy,\x20optic\x20neuropathy,\x20lactic\x20acidosis</strong>.<br\x20/><br\x20/>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20A\x20:\x20<strong>Aztreonam</strong>\x20is\x20a\x20<strong>monobactam</strong>,\x20and\x20acts\x20similar\x20to\x20penicillin\x20by<strong>\x20inhibiting\x20peptiglycan\x20crosslinking\x20</strong>and\x20inhibiting\x20bacterial\x20cell\x20wall\x20synthesis.</p>\x0a<p>Option\x20B\x20:\x20<strong>Daptomycin</strong>\x20is\x20a\x20<strong>cyclic\x20lipopeptide</strong>\x20antibiotic.\x20It\x20acts\x20by<strong>\x20depolarising\x20bacterial\x20membranes</strong>\x20resulting\x20in\x20loss\x20of\x20membrane\x20potential\x20and\x20cell\x20death.\u00a0</p>\x0a<p>Option\x20D\x20:\x20<strong>Rifampicin\u00a0</strong>is\x20an\x20anti\x20tubercular\x20antibiotic\x20that\x20acts\x20by\u00a0<strong>inhibiting\x20bacterial\x20DNA-dependent\x20RNA\x20polymerase.</strong></p>','navBtn_','eUrXz','sVBXn','pfeSb','gray','timeDisplay','notAttempted','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','Marked','It\x20is\x20not\x20absorbed\x20from\x20the\x20stomach','padStart','MTtRT','450\x20mcg/dL','PGEtE','Hepatitis','Release\x20of\x20reactive\x20oxygen\x20species\x20and\x20free\x20radicles','<table\x20style=\x22width:\x20240.562px;\x20height:\x20165px;\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2033px;\x22>\x0a<td\x20style=\x22width:\x20116px;\x20height:\x2033px;\x22>A.\x20Mirabegron</td>\x0a<td\x20style=\x22width:\x20101.562px;\x20height:\x2033px;\x22>&nbsp;3.\x20Beta\x203</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2028px;\x22>\x0a<td\x20style=\x22width:\x20116px;\x20height:\x2028px;\x22>B.\x20Indacaterol</td>\x0a<td\x20style=\x22width:\x20101.562px;\x20height:\x2028px;\x22>&nbsp;4.\x20Beta\x202</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2030px;\x22>\x0a<td\x20style=\x22width:\x20116px;\x20height:\x2030px;\x22>C.\x20Betaxolol</td>\x0a<td\x20style=\x22width:\x20101.562px;\x20height:\x2030px;\x22>&nbsp;1.\x20Beta\x201</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2031.5px;\x22>\x0a<td\x20style=\x22width:\x20116px;\x20height:\x2031.5px;\x22>D.\x20Isoproterenol</td>\x0a<td\x20style=\x22width:\x20101.562px;\x20height:\x2031.5px;\x22>&nbsp;2.\x20Beta&nbsp;</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong>Mirabegron</strong>&nbsp;is\x20a&nbsp;<strong>&beta;3-adrenergic\x20receptor\x20agonist</strong>&nbsp;which\x20is\x20used\x20for&nbsp;<strong>bladder\x20incontinence</strong>.\x20Activation\x20of\x20this\x20receptor\x20in\x20the\x20bladder\x20leads\x20to\x20detrusor\x20muscle\x20relaxation\x20and\x20increased\x20bladder\x20capacity.\x20This\x20action\x20prevents\x20voiding\x20and\x20provides\x20relief\x20for\x20those\x20with\x20an\x20overactive\x20bladder\x20and\x20urinary\x20incontinence.&nbsp;</p>\x0a<p><strong>Indacaterol</strong>\x20is\x20a\x20very\x20long\x20acting\x20beta\x202\x20agonists<strong>&nbsp;(V-LABA)&nbsp;</strong>and\x20can\x20be\x20used\x20once\x20daily\x20in\x20COPD\x20maintenance<strong>.</strong></p>\x0a<p><strong>Betaxolol\x20</strong>is\x20a\x20&beta;<sub>1</sub>&nbsp;selective\x20third-generation\x20&beta;-blocker\x20with\x20additional\x20<strong>calcium\x20entry\x20blockade</strong>\x20activity\x20and\x20a\x20slight\x20membrane-stabilizing\x20property.\x20It\x20does\x20not\x20have\x20agonist\x20activity.</p>\x0a<p><strong>Isoproterenol</strong>\x20is\x20a<strong>&nbsp;non-selective\x20beta\x20agonist\x20(&beta;<sub>1</sub>=&beta;<sub>2</sub>)\x20with\x20no&nbsp;&alpha;\x20action</strong>.\x20The\x20direct\x20action\x20on\x20cardiac&nbsp;<strong>&beta;<sub>1</sub></strong>&nbsp;receptors\x20causes\x20an\x20increased\x20risk\x20of&nbsp;<strong>tachycardia</strong>&nbsp;and\x20arrhythmias.\x20The\x20decrease\x20in\x20peripheral\x20vascular\x20resistance\x20is\x20due\x20to&nbsp;<strong>&beta;<sub>2</sub></strong>&nbsp;action\x20causing\x20a<strong>&nbsp;fall\x20in\x20diastolic\x20blood\x20pressure.</strong>&nbsp;Isoproterenol\x20currently\x20may\x20be\x20used\x20as\x20a<strong>&nbsp;cardiac\x20stimulant</strong>&nbsp;in\x20patients\x20with<strong>&nbsp;bradycardia\x20or\x20heart\x20block,&nbsp;</strong>particularly\x20in\x20anticipation\x20of\x20inserting\x20an\x20artificial\x20cardiac\x20pacemaker.</p>','YJAuP','<p><strong>Cyclosporine</strong>\x20induced\x20cholestasis\x20is\x20due\x20to\x20<strong>MDR1\x20transporter</strong>.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20111\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>ABC\x20transporters\x20such\x20as\x20MRP2,\x20<strong>MDR1</strong>,\x20BCRP,\x20BSEP,\x20and\x20MDR3\x20in\x20the<strong>\x20bile\x20canalicular\x20membrane\x20of\x20hepatocytes</strong>\x20mediate\x20the\x20<strong>efflux\x20(excretion)\x20of\x20drugs\x20and\x20their\x20metabolites,\x20bile\x20salts,\x20and\x20phospholipids</strong>\x20against\x20a\x20steep\x20concentration\x20gradient\x20from\x20liver\x20to\x20bile.\x20This\x20<strong>primary\x20active\x20transport</strong>\x20is\x20driven\x20by\x20<strong>ATP\x20hydrolysis</strong>.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a<p>Cyclosporine,\x20an\x20<strong>MDR1\x20substrate&nbsp;</strong>can\x20cause\x20cholestatic\x20liver\x20injury\x20through\x20the\x20following\x20mechanisms:</p>\x0a<ul>\x0a<li><strong>Competitive\x20inhibition\x20of\x20ATP\x20dependent\x20transporters.</strong></li>\x0a<li><strong>Inhibition</strong>\x20of\x20<strong>intrahepatic\x20vesicle\x20transport</strong>\x20and\x20targeting\x20of\x20ATP\x20dependent\x20transporters\x20to\x20the\x20canalicular\x20membrane.</li>\x0a<li><strong>Impairment\x20of\x20bile\x20secretion</strong>\x20partly\x20by\x20<strong>increasing\x20canalicular\x20membrane\x20fluidity</strong>\x20without\x20affecting\x20the\x20expression\x20of\x20canalicular\x20transporters.&nbsp;</li>\x0a</ul>\x0a<p><strong>Cyclosporine</strong>\x20is\x20an\x20immunomodulatory\x20drug\x20that&nbsp;<strong>inhibits\x20calcineurin\x20activity</strong>\x20by<strong>&nbsp;</strong>forming\x20a\x20complex\x20with\x20<strong>cyclophilin</strong>,\x20a\x20cytoplasmic-receptor\x20protein\x20present\x20in\x20target\x20cells,\x20to\x20form\x20a\x20<strong>cyclosporine-cyclophilin\x20complex</strong>.Calcineurin\x20is\x20a\x20calcium/calmodulin-dependent\x20phosphatase\x20required\x20for\x20the\x20induction\x20of\x20T\x20cell\x20lymphokine\x20production\x20and\x20proliferation.</p>\x0a<p>This\x20drug-receptor\x20complex\x20specifically\x20and\x20competitively\x20binds\x20to\x20and\x20<strong>inhibits\x20calcineurin</strong>,\x20a\x20calcium\x20and\x20calmodulin-dependent\x20phosphatase.\x20This,\x20in\x20turn,\x20inhibits\x20the\x20translocation\x20of\x20a\x20family\x20of\x20transcription\x20factors\x20(NF-AT),\x20leading\x20to\x20reduced\x20transcriptional\x20activation\x20of\x20cytokine\x20genes\x20for\x20interleukin\x20(IL)-2,\x20tumor\x20necrosis\x20factor\x20(TNF)-alpha,\x20IL-3,\x20IL-4,\x20CD40L,\x20granulocyte-macrophage\x20colony-stimulating\x20factor,\x20and\x20interferon-gamma.\x20Ultimately,\x20the\x20proliferation\x20of\x20T\x20lymphocytes\x20is\x20reduced,\x20resulting\x20in\x20<strong>immunomodulation.</strong></p>\x0a<p>Its\x20uses\x20are\x20as\x20follows:</p>\x0a<ul>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>In\x20solid\x20organ\x20transplantation,\x20to\x20prevent\x20organ\x20rejection\x20in\x20kidney,\x20liver,\x20and\x20heart\x20allogeneic\x20transplants</li>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>In\x20patients\x20with\x20rheumatoid\x20arthritis,\x20when\x20the\x20disease\x20has\x20not\x20adequately\x20responded\x20to\x20methotrexate</li>\x0a<li\x20style=\x22font-weight:\x20400;\x22\x20aria-level=\x221\x22>Cyclosporine\x20reportedly\x20is\x20effective\x20in\x20Behçet&rsquo;s\x20disease,\x20acute\x20ocular\x20syndrome,\x20endogenous\x20uveitis,\x20atopic\x20dermatitis,\x20inflammatory\x20bowel\x20disease,\x20and\x20nephrotic\x20syndrome.</li>\x0a</ul>\x0a<p>Adverse\x20effects\x20of\x20cyclosporine\x20include\x20a\x20<strong>decrease</strong>\x20in\x20glomerular\x20filtration\x20rate\x20(<strong>GFR</strong>)&nbsp;and\x20<strong>metabolic\x20disturbances</strong>\x20like\x20hypomagnesemia,\x20hyperkalemia,\x20dyslipidemia,\x20gynecomastia,\x20hypertrichosis;\x20<strong>neurotoxicity</strong>\x20in\x20the\x20form\x20of\x20convulsions.&nbsp;There\x20is\x20an\x20increased\x20risk\x20of\x20developing\x20skin\x20and\x20lymphoproliferative\x20malignancies\x20in\x20cyclosporine-treated\x20psoriasis\x20patients.</p>','Lapatinib','nav-btn-incorrect','Phenytoin','getElementById','\x22\x20data-src=\x22','customQuizData','nWOOD','video[data-src]','jSHqR','Ynjhs','correct_choice_id','FRAJl','correct','explanation_images','AiqDl','LpeQj','gMCIX','Rashes','split','</span><span>','Prolonged\x20PR\x20intervals','Diltiazem','hxQSh','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','YutKE','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','timed_study','AJsWE','gcyXU','Degludec','TNTBc','NiwBt','Denotes\x20safety\x20and\x20efficacy\x20after\x20experiments\x20on\x20humans','cUgNB','nrWTx','<p>The\x20drug\x20of\x20choice\x20for\x20the&nbsp;<strong>reversal\x20</strong>of<strong>\x20respiratory\x20depression</strong>\x20is<strong>&nbsp;naloxone</strong>.&nbsp;<strong>Naloxone</strong>\x20is\x20a\x20<strong>competitive\x20antagonist\x20at\x20&mu;-opioid\x20receptors</strong>\x20and\x20rapidly\x20reverses\x20the\x20effects\x20of\x20opioid\x20toxicity\x20when\x20administered.</p>\x0a<p>Opioid\x20overdose\x20<strong>symptoms</strong>:</p>\x0a<ul>\x0a<li>Triad\x20of\x20coma,\x20respiratory\x20depression,\x20and\x20pinpoint\x20pupils\x20(miosis).</li>\x0a<li>Hypotension,\x20bradycardia</li>\x0a<li>Shallow\x20breathing</li>\x0a<li>Hypothermia</li>\x0a</ul>\x0a<p>Naloxone\x20is\x20a\x20pure\x20opioid\x20antagonist\x20which\x20reverses\x20all\x20effects,<strong>&nbsp;except\x20sedation</strong>.&nbsp;Naloxone\x20is\x20also\x20used\x20for\x20reversing\x20neonatal\x20asphyxia\x20due\x20to\x20opioid\x20usage\x20in\x20labor.</p>\x0a<p>Other\x20options</p>\x0a<p>Option\x20B\x20-&nbsp;<strong>Meperidine\x20(pethidine)</strong>&nbsp;is\x20a&nbsp;<strong>mu-opioid\x20receptor</strong>&nbsp;(MOR)<strong>&nbsp;agonist</strong>.\x20It\x20has\x20a&nbsp;<strong>strong\x20analgesic</strong>&nbsp;effect\x20on\x20the&nbsp;<strong>central\x20nervous\x20system</strong>.&nbsp;It\x20is\x20mainly\x20used\x20as\x20an<strong>&nbsp;analgesic&nbsp;</strong>but\x20can\x20also\x20be\x20used\x20in\x20post-anesthetic\x20shivering.&nbsp;It\x20has\x20a\x20greater\x20ability\x20to\x20enter\x20the\x20CNS\x20and\x20produce\x20analgesia\x20at\x20lower\x20systemic\x20concentrations\x20compared\x20to\x20morphine.\x20Therefore,&nbsp;<strong>constipation</strong>,\x20urinary\x20retention,\x20and\x20nausea\x20are&nbsp;<strong>less</strong>&nbsp;frequent\x20compared\x20to\x20morphine.</p>\x0a<p>Meperidine\x20can\x20cross\x20the\x20placenta\x20and\x20cause\x20significant&nbsp;<strong>respiratory\x20depression</strong>&nbsp;in\x20the\x20fetus.&nbsp;In\x20patients\x20or\x20addicts\x20who\x20are\x20tolerant\x20to\x20the\x20depressant\x20effects\x20of\x20meperidine,\x20large\x20doses\x20repeated\x20at\x20short\x20intervals\x20may\x20produce\x20an&nbsp;<strong>excitatory\x20syndrome</strong>&nbsp;that\x20includes\x20hallucinations,\x20tremors,\x20muscle\x20twitches,\x20etc.</p>\x0a<div\x20class=\x22ng-scope\x22>Option\x20C\x20-<strong>Atropine</strong>\x20is\x20an&nbsp;<strong>anticholinergic</strong>&nbsp;drug.\x20It\x20acts\x20through&nbsp;<strong>reversible,\x20competitive\x20inhibition</strong>&nbsp;of\x20the\x20postsynaptic\x20muscarinic\x20acetylcholine\x20receptors.\x20It\x20is\x20indicated\x20in\x20the\x20treatment\x20of\x20organophosphate/muscarinic\x20poisoning,\x20in\x20bradycardia,\x20and\x20to\x20reduce\x20salivary\x20secretions.\x0a<p>The\x20adverse\x20effects\x20of\x20atropine\x20are\x20due\x20to\x20the\x20antimuscarinic\x20effects,\x20including\x20xerostomia,\x20blurring\x20of\x20vision,\x20photophobia,\x20tachycardia,\x20flushing,\x20warm,\x20dry\x20skin,\x20constipation,\x20urinary\x20retention,\x20anhidrosis,\x20delirium,\x20and\x20coma.\x20Intoxication\x20with\x20atropine\x20results\x20in\x20all\x20the\x20above\x20symptoms\x20along\x20with\x20convulsions,\x20and\x20circulatory\x20collapse\x20due\x20to\x20respiratory\x20failure.\x20Death\x20may\x20occur\x20secondary\x20to\x20respiratory\x20paralysis.</p>\x0a</div>\x0a<p>Option\x20D\x20-&nbsp;<strong>Buprenorphine</strong>&nbsp;is\x20a&nbsp;<strong>partial&nbsp;&mu;\x20agonist</strong>&nbsp;and\x20an&nbsp;<strong>antagonist</strong>&nbsp;at&nbsp;<strong>&delta;</strong>&nbsp;and&nbsp;<strong>&kappa;</strong>&nbsp;receptors.\x20It\x20is\x20used\x20as\x20an\x20analgesic\x20and\x20in\x20the\x20management\x20of\x20opioid\x20dependence.</p>\x0a<p>&nbsp;</p>','urtyO','EMGhD','stringify','350\x20mcg/dL','log','YLiRv','<p><strong>5-aminosalicylic\x20acid</strong>\x20is\x20is\x20effective\x20in\x20<strong>inducing\x20and\x20maintaining\x20remission</strong>\x20and\x20is\x20considered\x20to\x20be\x20the<strong>\x20first\x20line\x20agents</strong>\x20for\u00a0<strong>mild\x20to\x20moderate</strong>\x20<strong>ulcerative\x20colitis,\u00a0</strong>seen\x20in\x20this\x20patient\x20with<strong>\x202-3\x20bloody\x20stools\x20per\x20day</strong>.<br\x20/><br\x20/><strong>Treatment</strong>\x20of\x20<strong>ulcerative\x20colitis</strong>\x20differs\x20based\x20on\x20the\x20<strong>severity\x20of\x20the\x20disease</strong>\x20and\x20involves\x20medical\x20and\x20surgical\x20management.\x20Patients\x20with\x20<strong>mild\x20to\x20moderate\x20disease</strong>\x20are\x20treated\x20with\x20<strong>topical\x20or\x20systemic\x205-aminosalicylate\x20drugs</strong>\x20such\x20as\x20<strong>Salazopyrine/Sulfasalazine</strong>\x20and\x20<strong>Mesalamine\x20(5\x20ASA)</strong>\x20which\x20are<strong>\x20first-line\x20therapy.</strong>\x20<strong>Glucocorticoids\x20(option\x20A),\x20immunosuppressants</strong>,\x20and\x20<strong>biologics</strong>\x20are\x20effective\x20in\x20patients\x20with\x20<strong>moderate</strong>\x20<strong>to</strong>\x20<strong>severe</strong>\x20disease.\x20<br\x20/><br\x20/><strong>Azathioprine\x20</strong>and\x20<strong>cyclosporin</strong>\x20are\x20used\x20as<strong>\x20steroid-sparing</strong>\x20agents.<strong>\x20Anti-TNF\x20alpha\x20inhibitors\x20(infliximab,\x20adalimumab)\x20</strong>can\x20be\x20used\x20as\x20<strong>anti-inflammatories</strong>.</p>\x0a<p><strong>Surgery</strong>\x20is\x20recommended\x20for\x20patients\x20who\x20<strong>do\x20not\x20improve\x20after\x20medical\x20treatment\x20</strong>or\x20with<strong>\x20toxic\x20megacolon</strong>,\x20and\x20<strong>perforation</strong>.\x20Indications\x20for\x20<strong>elective\x20surgery</strong>\x20include\x20<strong>failure\x20of\x20medical\x20therapy</strong>,\x20<strong>growth\x20retardation</strong>,<strong>\x20extraintestinal\x20disease</strong>,\x20and\x20<strong>malignant\x20change</strong>.<br\x20/><br\x20/><strong>Ulcerative\x20colitis\x20</strong>is\x20an\x20<strong>inflammatory\x20bowel\x20disease</strong>\x20resulting\x20in<strong>\x20superficial\x20erosions</strong>\x20confined\x20to\x20the\x20<strong>mucosa\x20and\x20submucosa</strong>\x20of\x20the\x20colon.\x20It\x20<strong>starts\x20from\x20the\x20rectum</strong>\x20and\x20extends\x20proximally\x20in\x20a\x20<strong>continuous</strong>\x20manner.\x20The\x20clinical\x20features\x20include\x20abdominal\x20pain,\x20diarrhea,\x20<strong>rectal\x20bleeding</strong>,\x20tenesmus,\x20and\x20passage\x20of\x20mucus.\x20Other\x20symptoms\x20include\x20anorexia,\x20nausea,\x20vomiting,\x20fever,\x20and\x20weight\x20loss.<br\x20/><br\x20/>Ulcerative\x20colitis\x20is\x20<strong>graded</strong>\x20based\x20on\x20the\x20<strong>frequency\x20of\x20bowel\x20movements\x20</strong>and\x20<strong>systemic\x20involvement</strong>.\u00a0</p>\x0a<p>-\x20<strong>Mild</strong>\x20disease\x20-\x20<strong>≤4\x20stools\x20per\x20day</strong>\x20with/without\x20<strong>rectal\x20bleeding</strong>;<br\x20/>-\x20<strong>Moderate</strong>\x20disease\x20-\x20<strong>≥4\x20stools\x20per\x20day</strong>\x20with<strong>\x20few\x20systemic\x20signs</strong>\x20of\x20illness;\u00a0<br\x20/>-\x20<strong>Severe</strong>\x20disease\x20-<strong>\x20≥6\x20blood\x20stools\x20per\x20day\x20</strong>with\x20<strong>fever,\x20tachycardia\x20(≥90\x20beats/min)</strong>,\x20<strong>anemia\x20(hemoglobin\x20&lt;10.5\x20g/dL)</strong>,\x20and\x20elevated\x20levels\x20of\x20<strong>inflammatory\x20markers\x20(ESR\x20≥30\x20mm/h)</strong><br\x20/>-\x20<strong>Fulminant</strong>\x20disease\x20-\x20<strong>&gt;10\x20stools\x20per\x20day</strong>\x20with\x20<strong>severe\x20anemia</strong>\x20requiring\x20blood\x20transfusion\x20and\x20<strong>progressive\x20colonic\x20dilation\x20(toxic\x20megacolon)</strong><br\x20/><br\x20/>Investigations\x20show\x20<strong>elevated\x20C-reactive\x20protein</strong>,\x20<strong>platelet\x20count,\x20erythrocyte\x20sedimentation\x20rate,\x20fecal\x20calprotectin,\x20and\x20fecal\x20lactoferrin</strong>.\x20A\x20<strong>colonoscopy</strong>\x20reveals\x20<strong>loss\x20of\x20typical\x20vascular\x20pattern</strong>,\x20<strong>erythema</strong>,\x20<strong>friability</strong>,\x20<strong>regenerative</strong>\x20<strong>mucosal</strong>\x20<strong>nodules</strong>,\x20<strong>pseudopolyps</strong>,\x20and\x20<strong>ulcerations</strong>.\u00a0</p>\x0a<p><strong>Extraintestinal\x20manifestations</strong>\x20associated\x20with\x20IBD\x20include\x20<strong>ocular\x20features\x20</strong>(episcleritis,\x20and\x20uveitis),\x20<strong>dermatological</strong>\x20manifestations\x20(erythema\x20nodosum,\x20pyoderma\x20gangrenosum),\x20<strong>rheumatological</strong>\x20(arthropathies,\x20sacroiliitis,\x20ankylosing\x20spondylitis)\x20and\x20<strong>primary\x20sclerosing\x20cholangitis</strong>.\x20Complications\x20include\x20<strong>toxic\x20megacolon</strong>,\x20hemorrhage,\x20strictures,\x20and\x20perforations.\x20These\x20patients\x20are\x20also\x20at\x20increased\x20risk\x20of\x20<strong>colon\x20cancer</strong>.<br\x20/><br\x20/>Other\x20options\u00a0<br\x20/><br\x20/>Option\x20B\x20&amp;\x20C\x20:\x20Azathioprine\x20and\x206-mercaptopurine\x20are\x20not\x20first\x20line\x20agents\x20for\x20ulcerative\x20colitis.</p>','NJKdb','sawLT','Rivastigmine','VUMcs','IBOBj','Buprenorphine','AQMZY','zcFtm','onAdp','UmYeZ','frgvE','return\x20(function()\x20','<p><strong>Methadone</strong>\x20is\x20the\x20<strong>causative\x20drug</strong>\x20for\x20this\x20patient\x27s\x20presentation\x20of\x20<strong>syncope</strong>\x20and<strong>\x20prolonged\x20QT\x20interval\x20</strong>after\x20<strong>coadministration</strong>\x20other\x20QT\x20prolonging\x20drugs\x20such\x20as\x20<strong>fluoxetine</strong>.<br\x20/><br\x20/>Unlike\x20other\x20opioids,\x20<strong>QT\x20prolongation</strong>\x20is\x20primarily\x20a<strong>\x20side\x20effect\x20of\x20methadone</strong>,\x20which\x20is\x20<strong>additive</strong>\x20<strong>with\x20other\x20agents</strong>\x20known\x20to\x20cause\x20<strong>QT\x20prolongation</strong>\x20such\x20as\x20<strong>fluoxetine</strong>.\x20<strong>Serious\x20cardiac\x20arrhythmias\x20</strong>including\x20<strong>torsades\x20de\x20pointes</strong>\x20have\x20been\x20noted\x20with\x20methadone\x20use.<strong>\x20Normal\x20QTc\x20</strong>is\x20about\x20<strong>440\x20ms</strong>.\x20Values\x20of\x20<strong>more\x20than\x20440\x20ms\x20in\x20males</strong>\x20and\x20<strong>460\x20ms\x20in\x20females</strong>\x20are\x20considered\x20to\x20be\x20<strong>prolonged</strong>.\x20QT\x20prolongation\x20can\x20present\x20as\x20<strong>syncope</strong>\x20or\x20<strong>cardiac\x20arrest</strong>.<br\x20/><br\x20/><strong>Methadone</strong>\x20is\x20a\x20<strong>synthetic\x20opioid</strong>\x20that\x20is\x20<strong>chemically\x20different</strong>\x20but\x20has<strong>\x20similar\x20pharmacological</strong>\x20<strong>action</strong>\x20to\x20that\x20of\x20<strong>morphine</strong>\x20(Option\x20B).\x20It\x20is\x20a\x20<strong>long-acting\x20mu-opioid\x20receptor\x20agonist</strong>.\x20Although\x20an\x20effective\x20analgesic,\x20the\x20<strong>primary\x20use</strong>\x20of\x20methadone\x20hydrochloride\x20is\x20<strong>detoxification\x20and\x20maintenance</strong>\x20<strong>therapy</strong>\x20treatment\x20for<strong>\x20opioid\x20use\x20disorder</strong>.\x20Methadone\x20is\x20also\x20used\x20for\x20the\x20<strong>management\x20of\x20chronic\x20pain</strong>.<br\x20/><br\x20/><strong>Side\x20effects\x20</strong>of\x20methadone\x20are\x20<strong>similar\x20to\x20that\x20of\x20morphine\x20</strong>such\x20as\x20<strong>lethargy,\x20constipation,\x20respiratory\x20depression,\x20and\x20hypotension</strong>.\x20Like\x20other\x20opioids,\x20methadone\x20will\x20produce\x20<strong>tolerance\x20and\x20dependence</strong>.\x20Development\x20of\x20physical\x20dependence\x20during\x20the\x20long-term\x20administration\x20of\x20methadone\x20can\x20be\x20demonstrated\x20following\x20abrupt\x20drug\x20withdrawal\x20or\x20administration\x20of\x20an\x20opioid\x20antagonist.\u00a0<br\x20/><br\x20/>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20B\x20:\x20Morphine\x20is\x20not\x20associated\x20with\x20QT\x20prolongation.</p>\x0a<p>Option\x20C\x20:\x20<strong>Meperidine</strong>,\x20also\x20known\x20as\x20<strong>pethidine</strong>,\x20though\x20chemically\x20unrelated\x20to\x20morphine\x20interacts\x20with\x20µ\x20opioid\x20receptors\x20and\x20its\x20actions\x20are\x20blocked\x20by\x20naloxone.\x20Apart\x20from\x20usual\x20opioid\x20side\x20effects,\x20pethidine\x20produces\x20some\x20<strong>atropinic\x20effects</strong>\x20like\x20dry\x20mouth,\x20blurred\x20vision,\x20tachycardia.\x20Pethidine\x20injected\x20in\x20patients\x20receiving\x20a\x20selective\x20serotonin\x20reuptake\x20inhibitor\x20(SSRI)\x20may\x20produce<strong>\x20serotonin\x20syndrome</strong>.\x20It\x20is\x20occasionally\x20used\x20to\x20<strong>control\x20shivering\x20during\x20recovery\x20from\x20anaesthesia</strong>.</p>\x0a<p>Option\x20D\x20:\x20<strong>Propoxyphene</strong>\x20is\x20a<strong>\x20methadone\x20analogue\x20</strong>that\x20was\x20used\x20to\x20treat\x20mild-tomoderate\x20pain.\x20Due\x20to\x20reports\x20of\x20<strong>cardiotoxicity</strong>,\x20it\x20was\x20<strong>withdrawn</strong>\x20<strong>in\x20UK,\x20Europe,\x20and\x20USA</strong>\x20and\x20it\x20was<strong>\x20banned\x20in\x20India\x20in\x202013</strong>.</p>','reviewQuestionsContainer','attachMedia','Osimertinib\x20is\x20used\x20in\x20NSCLC\x20with\x20which\x20of\x20the\x20following\x20mutation?','dLFUM','\x22\x20data-option-index=\x22','Confusion','totalAttempted','OseBe','yfOWn','fhFce','jDEnU','timeSpent','bWhrc','A\x2060-year-old\x20patient\x20with\x20chronic\x20kidney\x20disease\x20suddenly\x20develops\x20chest\x20pain\x20and\x20palpitations.\x20He\x20had\x20previously\x20complained\x20about\x20feeling\x20weak\x20for\x20the\x20past\x20week.\x20Serum\x20potassium\x20was\x20found\x20to\x20be\x206.5mEq/L.\x20Which\x20of\x20the\x20following\x20is\x20likely\x20to\x20be\x20found\x20in\x20this\x20patients\x20ECG?','NZxhy','studyModeLegend','Darunavir','bBNYo','beIsz','Vismodegib','fill','apply','nav-btn-marked-review','toggle','nav-btn-correct','MDR\x201','gyGpX','exception','Cerebral\x20bleeding','accuracyScore','mFDbC','foUXU','SDTNc','TXQKv','Incorrect','incorrectAnswers','Meperidine','div','WnCwJ','Yhoju','https://dhmbxeygs57ff.cloudfront.net/uploads/1d540d18f4024d5cb2c7fa069efee6a3x1280x1585.JPEG','PxqYT','referrer','JVxOx','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','.option-button','LmfgH','MGWIl','What\x20is\x20the\x20most\x20useful\x20drug\x20to\x20treat\x20doxorubicin\x20induced\x20cardiotoxicity?','Rosiglitazone','HWUnB','createElement','Dexrazoxane','Which\x20of\x20the\x20following\x20antibiotics\x20acts\x20by\x20inhibiting\x20the\x2050s\x20ribosome?','study','Option\x20','CDzvT','JhXkH','QlPPj','correctAnswers','GtQnp','aFuPt','className','SnDVv','<p\x20class=\x22p1\x22><strong>Agranulocytosis</strong>\x20is\x20a&nbsp;rare\x20but\x20very\x20severe\x20side\x20effect\x20of\x20<strong>clozapine</strong>\x20that\x20<strong>requires\x20regular\x20monitoring.&nbsp;</strong></p>\x0a<p\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>A\x20patient\x20who\x20is\x20on\x20clozapine\x20should\x20undergo\x20<strong>regular\x20hematological\x20monitoring</strong>\x20due\x20to\x20the\x20risk\x20of\x20<strong>agranulocytosis</strong>.\x20Avoid\x20combining\x20clozapine\x20with\x20other\x20agranulocytosis-causing\x20drugs\x20like\x20carbamazepine,\x20phenytoin,\x20propylthiouracil,\x20and\x20sulfonamides.</span></p>\x0a<p\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>Adverse\x20effects\x20of\x20clozapine\x20are:</span></p>\x0a<ul>\x0a<li\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>Sedation\x20and\x20weight\x20gain-\x20H<sub>1</sub>\x20antagonism</span></li>\x0a<li\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>Syncope,\x20tachycardia,\x20hypotension-&nbsp;&alpha;<sub>1</sub>\x20antagonism</span></li>\x0a<li\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>Hypersalivation/sialorrhea-\x20M<sub>4&nbsp;</sub>agonism</span></li>\x0a<li\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>Seizures-\x20dose-dependant</span></li>\x0a<li\x20class=\x22p1\x22><span\x20style=\x22font-size:\x2010pt;\x22>Agranulocytosis-\x20dose-independent</span></li>\x0a</ul>\x0a<p><span\x20style=\x22font-size:\x2010pt;\x22>Clozapine\x20reduces\x20the\x20seizure\x20threshold\x20thus<strong>\x20increasing</strong>\x20the\x20risk\x20of\x20<strong>seizures.&nbsp;</strong></span><span\x20style=\x22font-size:\x2010pt;\x22>Clozapine,\x20an\x20atypical\x20antipsychotic,\x20is\x20an\x20antagonist\x20of\x205HT<sub>2A</sub>,\x20D<sub>1</sub>,\x20D<sub>3</sub>,\x20D<sub>4,&nbsp;</sub>and&nbsp;&alpha;-receptors.&nbsp;</span><span\x20style=\x22font-size:\x2010pt;\x22>Clozapine\x20is\x20used\x20in\x20<strong>treatment-resistant</strong>\x20<strong>schizophrenia,\x20suicidal\x20patients\x20with\x20schizophrenia,</strong>\x20severe\x20psychotic\x20depression,\x20and\x20Huntington\x27s\x20disease.\x20&nbsp;</span></p>\x0a<p>&nbsp;</p>','Azathioprine','Qbvkz','iXZrQ','aKFEa','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','ZPkOV','GhuDN','MKORB','WogLv','True\x20about\x20therapeutic\x20index\x20of\x20a\x20drug\x20is:','KblcZ','solutionContainer','Halsted','Which\x20of\x20the\x20following\x20pathogens\x20is\x20correctly\x20matched\x20with\x20its\x20intrinsic\x20drug\x20resistance?','gFVef','ybgQR','iSdJK','resume','No\x20questions\x20available\x20for\x20this\x20quiz.','totalTimeResult','ZHyQU','NadUd','Jnyvc','incorrect','cprfP','prototype','Which\x20of\x20the\x20following\x20is\x20true\x20statement\x20regarding\x20lithium?','QFKLI','dihKk','replace','hidden','textContent','dfMDc','jctyK','<p><strong>Hyponatremia</strong>\x20occurs\x20<strong>more\x20frequently</strong>\x20in\x20the\x20case\x20of\x20<strong>oxcarbazepine</strong>\x20than\x20carbamazepine.</p>\x0a<p>Both\x20carbamazepine\x20and\x20oxcarbazepine\x20are<strong>\x20sodium-channel\x20blockers\x20</strong>that\x20<strong>stabilize\x20neuronal\x20membranes</strong>.\x20Oxcarbazepine\x20is\x20the\x2010-keto\x20analog\x20of\x20carbamazepine\x20and\x20and\x20cannot\x20form\x20an\x20epoxide\x20metabolite.\x20<strong>Carbamazepine</strong>\x20<strong>potentiates</strong>\x20the\x20action\x20of<strong>\x20antidiuretic\x20hormone</strong>\x20(ADH).\x20It\x20can\x20result\x20in\x20<strong>water\x20retention</strong>\x20with\x20decreased\x20osmolarity\x20and\x20<strong>hyponatremia</strong>,\x20especially\x20in\x20elderly\x20patients\x20with\x20cardiac\x20disease.\x20Although\x20<strong>hyponatremia\x20may\x20occur\x20more\x20commonly\x20with\x20oxcarbazepine</strong>\x20than\x20with\x20carbamazepine,\x20most\x20adverse\x20effects\x20of\x20oxcarbazepine\x20are\x20similar\x20to\x20those\x20of\x20carbamazepine.\x20<br\x20/><br\x20/>Carbamazepine\x20and\x20oxcarbazepine\x20can\x20cause\x20<strong>leukopenia,\x20aplastic\x20anemia,\x20hepato-toxicity</strong>\x20in\x20the\x20elderly.\u00a0<br\x20/><br\x20/><strong>Oxcarbazepine</strong>\x20shows\x20<strong>lesser\x20hypersensitivity</strong>\x20reaction.\x20Hence,<strong>\x20rashes\x20(option\x20A)\x20are\x20more\x20commonly\x20seen\x20with\x20carbamazepine\x20</strong>than\x20with\x20oxcarbazepine.<br\x20/><br\x20/>Studies\x20have\x20shown\x20that\x20<strong>carbamazepine</strong>\x20<strong>elevates\x20enzyme\x20gamma-glutamyl\x20transpeptidases\x20(GGT)\x20more\x20frequently</strong>\x20than\x20oxcarbazepine\x20because\x20of\x20<strong>enzyme</strong>\x20<strong>P450\x20induction</strong>.\x20Hepatotoxicity\x20from\x20oxcarbazepine\x20occurs\x20less\x20commonly\x20compared\x20to\x20carbamazepine\x20(Option\x20D).\u00a0<br\x20/><br\x20/><strong>Side\x20effects\x20of\x20carbamazepine</strong>\x20therapy\x20include:\x20<strong>mnemonic:\x20HEADS</strong></p>\x0a<p><strong>H</strong>ypersensitivity\x20reactions<br\x20/><strong>E</strong>osinophilia<br\x20/><strong>A</strong>granulocytosis:\x20report\x20symptoms\x20like\x20sore\x20throat/fever<br\x20/><strong>A</strong>plastic\x20anemia<br\x20/><strong>A</strong>taxia<br\x20/><strong>D</strong>ilutional\x20hyponatremia<br\x20/><strong>D</strong>iplopia,\x20blurred\x20vision<br\x20/><strong>S</strong>plenomegaly<br\x20/><strong>S</strong>tevens-Johnson\x20syndrome</p>\x0a<p><strong>Carbamazepine</strong>\x20is\x20most\x20effective\x20in\x20<strong>complex\x20partial\x20seizures</strong>.\x20It\x20is\x20also\x20used\x20in\x20<strong>GTCS</strong>\x20and\x20<strong>simple\x20partial\x20seizures</strong>,\x20<strong>trigeminal\x20and\x20related\x20neuralgias</strong>,\x20and\x20<strong>manic\x20depressive\x20psychosis.\x20Oxcarbazepine</strong>\x20has\x20been\x20used\x20to\x20treat<strong>\x20intractable\x20trigeminal\x20neuralgia\x20refractory</strong>\x20to\x20other\x20anticonvulsants.\u00a0</p>\x0a<p>Mechanism\x20of\x20action\x20of\x20some\x20common\x20antiepileptics:</p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x2051.1244%;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>Mechanism\x20of\x20action</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>Antiepileptics</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>Sodium-channel\x20blockers</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Phenytoin</p>\x0a<p>Carbamazepine,\x20Oxcarbamazepine</p>\x0a<p>Eslicarbazepine</p>\x0a<p>Lamotrigine</p>\x0a<p>Topiramate</p>\x0a<p>Felbamate</p>\x0a<p>Valproate</p>\x0a<p>Rufinamide</p>\x0a<p>Levetiracetam</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>Calcium-channel\x20blockers</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Valproate</p>\x0a<p>Lamotrigine</p>\x0a<p>Ethosuximide</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>GABA\x20A\x20receptor\x20modulators</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Benzodiazepines</p>\x0a<p>Phenobarbital</p>\x0a<p>Felbamate</p>\x0a<p>Primidone</p>\x0a<p>Topiramate</p>\x0a<p>Carbamazepine,\x20Oxcarbamazepine</p>\x0a<p>Stiripentol</p>\x0a<p>Clobazam</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>GABA\x20uptake\x20inhibitors</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Tiagabine</p>\x0a<p>Vigabatrin</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>NMDA\x20receptor\x20antagonist</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>Felbamate</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>AMPA/Kainate\x20receptor\x20antagonist</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Phenobarbital</p>\x0a<p>Topiramate</p>\x0a<p>Perampanel</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>HCN\x20channel\x20activity\x20enhancers</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>Lamotrigine</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>Inhibitors\x20of\x20brain\x20carbonic\x20anhydrase</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Acetazolamide</p>\x0a<p>Zonisamide</p>\x0a<p>Topiramate</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2037.3106%;\x22>Potassium-channel\x20openers</td>\x0a<td\x20style=\x22width:\x2062.6894%;\x22>\x0a<p>Retigabine</p>\x0a<p>Topiramate</p>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>\u00a0</p>','target','click','isArray','cCfSM','BPUfV','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22','Methadone','Correct','NiRDi','A\x20patient\x20underwent\x20a\x20hysterectomy\x20and\x20was\x20given\x20morphine\x20in\x20the\x20post-operative\x20period\x20and\x20in\x20the\x20ward\x20for\x20pain.\x20She\x20now\x20presents\x20with\x20respiratory\x20depression\x20and\x20pin\x20point\x20pupils.\x20What\x20is\x20the\x20drug\x20used\x20to\x20treat\x20this\x20condition?','fLFVT','bookmarkedQuestions','button','appendChild','QZjVu','Amlodipine','closest','PbddP','solutionAudio','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','QvVOf','<p><strong>Rivastigmine\x20transdermal\x20patch</strong>\x20can\x20be\x20prescribed\x20to\x20patients\x20with\x20<strong>dementia</strong>\x20who\x20are\x20<strong>non\x20compliant\x20on\x20oral</strong>\x20medications.</p>\x0a<p>Rivastigmine\x20is\x20a<strong>\x20cholinesterase\x20inhibitor\x20</strong>that\x20is\x20available\x20as\x20a\x20<strong>transdermal\x20patch</strong>\x20for\x20use\x20in\x20<strong>alzheimer\x27s\x20disease</strong>\x20and\x20<strong>dementia</strong>.\x20It\x20can\x20be\x20applied\x20for\x20<strong>over\x2024\x20hours</strong>.\x20<strong>Transdermal\x20delivery</strong>\x20<strong>reduces\x20the\x20fluctuation\x20</strong>and\x20<strong>avoids\x20direct\x20gastric\x20irritation</strong>\x20effects\x20associated\x20with\x20<strong>oral\x20formulations</strong>.<br\x20/><br\x20/><strong>Alzheimer\x27s\x20disease</strong>\x20is\x20the<strong>\x20most\x20common\x20cause\x20</strong>of\x20<strong>dementia</strong>\x20in\x20the\x20<strong>elderly</strong>.\x20The\x20characteristic\x20feature\x20of\x20Alzheimer\x27s\x20is\x20the\x20<strong>degeneration\x20of\x20cholinergic\x20neurons</strong>\x20leading\x20to\x20<strong>reduced\x20levels\x20of\x20acetylcholine</strong>.\x20<br\x20/><br\x20/>Treatment\x20includes\x20<strong>cholinesterase</strong>\x20<strong>inhibitors</strong>\x20like\x20<strong>Donepezil</strong>,\x20<strong>Rivastigmine</strong>\x20and\x20<strong>Galantamine</strong>\x20and\x20<strong>NMDA\x20receptor\x20antagonist</strong>\x20like\x20<strong>memantine</strong>.\x20The\x20<strong>cholinesterase\x20inhibitors</strong>\x20cause\x20significant\x20side\x20effects\x20such\x20as<strong>\x20nausea,\x20vomiting,\x20diarrhea\x20</strong>and<strong>\x20peripheral\x20cholinergic\x20effects</strong>,\x20which\x20can\x20be\x20avoided\x20by\x20using\x20a\x20transdermal\x20formulation.<br\x20/><br\x20/><strong>Anticholinesterase\x20drugs<br\x20/><br\x20/></strong></p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x20100.046%;\x20height:\x20156.789px;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22><strong>Reversible\x20inhibitors</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>\u00a0</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22><strong>Carbamates</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22><strong>Non-Carbamates</strong></td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>Physostigmine,\x20Neostigmine,\x20Pyridostigmine,\x20Rivastigmine</td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>Edrophonium,\x20Tacrine,\x20Donepezil,\x20Galantamine</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>\u00a0</td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>\u00a0</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22><strong>Irreversible\x20inhibitors</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>\u00a0</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22><strong>Carbamates</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22><strong>Organophosphates</strong></td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>Carbaryl,\x20Propoxur</td>\x0a<td\x20style=\x22width:\x2048.6654%;\x20height:\x2022.3984px;\x22>Dyflos,\x20Echthiophate,\x20Malathion,\x20Diazinon,\x20Tabun,\x20Sarin,\x20Soman</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><br\x20/>Other\x20options\x20:<br\x20/><br\x20/>Options\x20A,\x20C\x20and\x20D:\x20Donepezil,\x20galantamine\x20and\x20memantine\x20are\x20currently\x20available\x20in\x20the\x20oral\x20form\x20and\x20transdermal\x20formulations\x20are\x20under\x20development\x20and\x20yet\x20to\x20be\x20available\x20in\x20the\x20market.</p>','solution','performanceModal','LGCFZ','answered','Cyclosporine-induced\x20cholestasis\x20is\x20due\x20to\x20which\x20receptor?','selectedAnswer','zsaaD','correctCount','classList','A\x20patient\x20diagnosed\x20with\x20ulcerative\x20colitis\x20presents\x20with\x202-3\x20episodes\x20of\x20bloody\x20stools\x20per\x20day.\x20What\x20should\x20be\x20given\x20to\x20manage\x20this\x20patient\x20?','incorrectCount','Liraglutide','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','question_video','Which\x20of\x20the\x20following\x20is\x20beneficial\x20in\x20reducing\x20the\x20painful\x20crisis\x20of\x20sickle\x20cell\x20anemia?','UtBGn','RqnjM','500\x20mcg/dL','Supression\x20of\x20angiogenesis','oXKth','length','MykuD','5-aminosalicylic\x20acid','title','bjwJf','location','pAbJw','quizFile','Drug\x20used\x20for\x20trastuzumab-resistant\x20her\x202\x20positive\x20breast\x20cancer\x20is:','none','border-green-500','A\x2040-year-old\x20woman\x20with\x20multidrug-resistant\x20tuberculosis\x20presents\x20with\x20fatigue,\x20constipation,\x20weight\x20gain,\x20and\x20neck\x20swelling.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20implicated\x20in\x20this\x20case?','iSqBV','ArrowLeft','058\x20Pharmacology\x20Ini-Cet\x202023','push','LcCPU','trace','border-red-500','Cycloserine','Linezolid','Bookmark','No\x20question\x20text\x20available','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','https://dhmbxeygs57ff.cloudfront.net/uploads/daaf90ecdf2b4851873eddbe9c1c2392x1280x1258.JPEG','DCEvO','fPEZx','<p>The\x20true\x20statement\x20about\x20<strong>lithium</strong>\x20is\x20it\x20can<strong>\x20cause\x20fine\x20tremors\x20in\x20the\x20therapeutic\x20range.</strong></p>\x0a<p>Lithium\x20has\x20a\x20very\x20narrow\x20therapeutic\x20index\x20of&nbsp;<strong>0.8-1.2\x20mEq/L.</strong>&nbsp;The\x20severity\x20of\x20lithium\x20toxicity\x20is\x20often\x20divided\x20into\x20the\x20following\x20three\x20grades:&nbsp;</p>\x0a<table\x20style=\x22height:\x20351px;\x22\x20width=\x22495\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20111.148px;\x22><strong>Grade</strong></td>\x0a<td\x20style=\x22width:\x20165.289px;\x22>\x0a<p><strong>Sr.\x20lithium\x20concentration&nbsp;</strong>(in\x20mEq/L)</p>\x0a</td>\x0a<td\x20style=\x22width:\x20196.562px;\x22><strong>Symptoms</strong></td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20111.148px;\x22><strong>Mild\x20symptoms</strong></td>\x0a<td\x20style=\x22width:\x20165.289px;\x22><strong>1.5-2.5&nbsp;</strong></td>\x0a<td\x20style=\x22width:\x20196.562px;\x22>Nausea,\x20vomiting,&nbsp;<strong>tremor</strong>,\x20and\x20fatigue</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20111.148px;\x22><strong>Moderate\x20intoxication</strong></td>\x0a<td\x20style=\x22width:\x20165.289px;\x22><strong>2.5-3.5&nbsp;</strong></td>\x0a<td\x20style=\x22width:\x20196.562px;\x22><strong>Confusion</strong>,\x20agitation,\x20delirium,\x20tachycardia,\x20and\x20hypertonia</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20111.148px;\x22><strong>Severe\x20intoxication</strong></td>\x0a<td\x20style=\x22width:\x20165.289px;\x22><strong>&gt;3.5&nbsp;</strong></td>\x0a<td\x20style=\x22width:\x20196.562px;\x22>Coma,&nbsp;<strong>seizures</strong>,\x20hyperthermia,\x20and\x20hypotension</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>A\x20fine\x20tremor\x20is\x20common\x20in\x20patients\x20taking\x20lithium\x20at\x20therapeutic\x20doses.&nbsp;Therapeutic\x20lithium\x20tremor\x20is\x20generally\x20symmetric,\x20limited\x20to\x20the\x20arms,\x20and\x20nonprogressive.\x20The\x20tremor\x20from&nbsp;<strong>lithium\x20toxicity</strong>&nbsp;is&nbsp;<strong>coarser</strong>&nbsp;and&nbsp;<strong>more\x20disabling</strong>,\x20may\x20also\x20affect\x20the\x20legs,\x20and\x20occurs\x20with\x20other\x20symptoms\x20of\x20toxicity.&nbsp;Other\x20adverse\x20effects\x20include&nbsp;mental\x20confusion,&nbsp;<strong>hypothyroidism</strong>,&nbsp;<strong>nephrogenic</strong>&nbsp;<strong>diabetes\x20insipidus,</strong>&nbsp;and&nbsp;edema.\x20Lithium\x20use\x20in\x20early\x20pregnancy\x20causes&nbsp;<strong>Ebstein\x20anomaly</strong>&nbsp;in\x20the\x20fetus<strong>(Option\x20D)</strong>.\x20Fetal\x20lithium\x20exposure\x20is\x20associated\x20with&nbsp;<strong>neonatal\x20goiter,\x20CNS\x20depression,\x20hypotonia\x20(floppy\x20baby\x20syndrome),\x20and\x20cardiac\x20murmur.</strong></p>\x0a<p>As\x20lithium\x20is\x20readily\x20dialyzed,\x20lithium\x20overdose\x20or\x20toxicity\x20is\x20treated\x20with&nbsp;<strong>hemodialysis</strong>.</p>\x0a<p><strong>Lithium</strong>&nbsp;is\x20a&nbsp;<strong>mood\x20stabilizer</strong>&nbsp;with\x20a\x20very\x20narrow\x20therapeutic\x20index.\x20Lithium\x20is\x20administered\x20<strong>orally</strong>.\x20Lithium\x20is\x20almost<strong>\x20completely\x20absorbed</strong>\x20from\x20the\x20GI\x20tract(<strong>Option\x20A</strong>).\x20It\x20is\x20the&nbsp;<strong>first\x20line</strong>&nbsp;of\x20management\x20in&nbsp;<strong>bipolar\x20disorder</strong>.</p>\x0a<p>Lithium\x20is\x20also&nbsp;<strong>used</strong>\x20in\x20the\x20<strong>management</strong>\x20of\x20<strong>mania\x20and\x20has\x20anti-suicidal\x20properties.\x20(Option\x20C)</strong>\x20It\x20has\x20a\x20narrow\x20therapeutic\x20index,\x20and\x20blood\x20levels\x20in\x20excess\x20of\x20this\x20may\x20cause\x20symptoms\x20of\x20toxicity.\x20<strong>Therapeutic\x20drug\x20monitoring</strong>\x20is\x20done\x20by\x20measuring\x20lithium\x20<strong>levels\x2012\x20hours\x20after\x20the\x20last\x20dose</strong>.</p>\x0a<p>&nbsp;</p>','bTSMA','isSupported','vWZSg','NRhSA','AwLbI','Tipranavir','ynURX','Lipmy','rbfvK','prevBtn','hAfrX','2331uEPduG','get','toISOString','gTxvu','AgHlZ','qvelb','(((.+)+)+)+$','A-2,\x20B-3,\x20C-4,\x20D-1','PeIBN','dIIxX','Eltrombopag','Venlafaxine','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','A\x20patient\x20on\x20amitriptyline\x20was\x20found\x20in\x20an\x20unconscious\x20state.\x20Which\x20of\x20the\x20following\x20does\x20not\x20suggest\x20amitriptyline\x20toxicity?','eGIRt','zLIpG','display','questionIndex','</span></div>','LSthS','preventDefault','Rifampicin','gnfiP','UgmhG','RucHQ','Cssez','markReviewText','aIXfS','questionStates','NNZyd','3kEUslx','<p>Among\x20the\x20given\x20options,\x20<strong>Candida\x20krusei\x20</strong>shows\x20an\x20<strong>intrinsic\x20resistance</strong>\x20to\x20<strong>fluconazole</strong>.\x20<br\x20/><br\x20/>The\x20<strong>primary</strong>\x20or\x20<strong>intrinsic\x20resistance</strong>\x20of\x20<strong>C.\x20krusei\x20</strong>to\x20<strong>azoles</strong>\x20(<strong>fluconazole</strong>\x20and\x20<strong>itraconazole</strong>)\x20is\x20mediated\x20through\x20<strong>reduced\x20susceptibility\x20of\x20the\x20target\x20enzyme</strong>\x20<strong>(lanosterol\x2014α-demethylase)\x20to\x20inhibition</strong>\x20by\x20these\x20drugs.\x20However,\x20<strong>improved\x20susceptibility</strong>\x20is\x20seen\x20with\x20<strong>newer\x20generation\x20azoles</strong>\x20such\x20as\x20<strong>voriconazole</strong>.</p>\x0a<p><strong>Life-threatening\x20systemic\x20infections</strong>\x20caused\x20by\x20<strong>Candida</strong>\x20and\x20<strong>Aspergillus</strong>\x20species\x20are\x20usually\x20seen\x20in\x20<strong>severely\x20ill</strong>\x20and\x20<strong>immunocompromised</strong>\x20patients\x20such\x20as\x20<strong>HIV</strong>,\x20<strong>chemotherapy</strong>-<strong>induced</strong>\x20<strong>neutropenia</strong>,\x20and\x20<strong>transplant</strong>\x20<strong>recipients</strong>\x20on\x20<strong>immunosuppressants</strong>.\x20<strong>C.\x20albicans</strong>\x20and\x20<strong>C.\x20dubliniensis</strong>\x20are\x20<strong>most\x20susceptible</strong>\x20to\x20<strong>currently\x20available\x20azoles</strong>,\x20<strong>C.\x20glabrata</strong>\x20is\x20<strong>less\x20susceptible</strong>,\x20whereas\x20<strong>C.\x20krusei</strong>\x20is\x20<strong>intrinsically\x20resistant</strong>\x20to\x20<strong>fluconazole</strong>.\x20Resistance\x20occurs\x20due\x20to\x20<strong>overexpression\x20or\x20point\x20mutation</strong>\x20in\x20the\x20gene\x20encoding\x20the\x20target\x20enzyme<strong>\x20lanosterol\x2014α-demethylase</strong>.\x20<strong>Voriconazole</strong>\x20is\x20the\x20preferred\x20therapy\x20for\x20<strong>multi-drug\x20resistant\x20infection</strong>\x20with<strong>\x20C.\x20krusei</strong>.</p>\x0a<p><strong>C.\x20albicans</strong>\x20and\x20<strong>C.\x20glabrata</strong>\x20(Option\x20C)\x20showing\x20<strong>resistance\x20to\x20Amphotericin\x20B</strong>\x20has\x20been\x20increasingly\x20reported\x20over\x20the\x20past\x20several\x20years.\x20But\x20this\x20is\x20a\x20<strong>secondary\x20resistance</strong>\x20due\x20to\x20<strong>alteration</strong>\x20or\x20a\x20<strong>decrease</strong>\x20in\x20the<strong>\x20amount\x20of\x20ergosterol</strong>\x20in\x20the\x20cell\x20membrane.\x20Amphotericin\x20B\x20is\x20indicated\x20to\x20treat\x20C.\x20glabrata\x20that\x20has\x20developed\x20resistance\x20to\x20azoles.</p>\x0a<p><strong>Aspergillus\x20fumigatus</strong>,\x20the\x20most\x20common\x20species\x20to\x20cause\x20Aspergillus\x20infection\x20worldwide,\x20also\x20shows\x20an\x20<strong>intrinsic\x20resistance\x20to\x20fluconazole</strong>.\x20It\x20is\x20<strong>susceptible\x20to\x20echinocandins</strong>\x20like\x20micafungin,\x20which\x20acts\x20by\x20<strong>inhibiting\x20beta-(1,3)-D-glucan\x20synthase</strong>,\x20an\x20enzyme\x20necessary\x20for\x20the\x20synthesis\x20of\x20the\x20cell\x20wall.</p>\x0a<p>Other\x20options<br\x20/><br\x20/>Option\x20A\x20:\x20<strong>Aspergillus\x20niger</strong>\x20is\x20a\x20common\x20cause\x20of\x20<strong>otomycosis</strong>\x20and\x20is<strong>\x20susceptible\x20to\x20azoles</strong>\x20like\x20<strong>voriconazole</strong>,\x20amphotericin\x20B,\x20and\x20echinocandins.<br\x20/><br\x20/>Option\x20D\x20:\x20The\x20<strong>drug\x20of\x20choice</strong>\x20for\x20treatment\x20of\x20<strong>sporotrichosis</strong>\x20is\x20<strong>itraconazole</strong>.</p>','A\x20patient\x20on\x20fluoxetine\x20was\x20started\x20on\x20a\x20pain\x20control\x20drug\x20for\x20neuropathic\x20pain.\x20He\x20developed\x20an\x20episode\x20of\x20syncope\x20after\x202\x20weeks.\x20ECG\x20reveals\x20QT\x20interval\x20of\x20477\x20ms.\x20Which\x20of\x20the\x20following\x20is\x20the\x20causative\x20drug?','gzbXi','Wtclx','abEQR','\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>','Bosutinib','ubfOL','MRP\x201','reduce','<p>This\x20patient\x20was\x20most\x20likely\x20taking\x20<strong>tipranavir</strong>,\x20as\x20it\x20is\x20known\x20to\x20be\x20associated\x20with\x20an\x20<strong>increased\x20risk\x20of\x20intracranial\x20hemorrhage\x20and\x20hepatotoxicity\x20</strong>which\x20is\x20the\x20likely\x20cause\x20of\x20<strong>altered\x20mental\x20status</strong>\x20in\x20this\x20patient\x20with\x20<strong>hemophilia</strong>\x20following\x20complaints\x20of\x20<strong>nausea,\x20vomiting\x20and\x20headache</strong>.<br\x20/><br\x20/><strong>Tipranavir\u00a0</strong>is\x20a\x20<strong>protease\x20inhibitor\x20(PI)\x20</strong>used\x20in\x20patients\x20who\x20are\x20resistant\x20to\x20other\u00a0PIs.\x20It\x20is\x20often\x20combined\x20with\x20<strong>ritonavir,\u00a0</strong>to\x20achieve\x20better\x20therapeutic\x20outcomes.\x20It\x20should\x20be\x20avoided\x20in\x20patients\x20with\u00a0<strong>head\x20trauma\x20</strong>or\u00a0<strong>bleeding\x20diathesis</strong>,\x20such\x20as\x20<strong>hemophilia</strong>\x20as\x20it\x20is\x20associated\x20with\x20an\x20<strong>increased\x20risk\x20of\x20intracranial</strong>\x20<strong>hemorrhage</strong>.\x20Other\x20common\x20adverse\x20effects\x20of\x20tipranavir\x20include\x20nausea,\x20vomiting,\x20diarrhea,\x20abdominal\x20pain,\x20urticarial\x20or\x20maculopapular\x20rash,\x20and\x20liver\x20toxicity.</p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x2049.1969%;\x20height:\x20134.39px;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22><strong>Antiretroviral\x20drug</strong></td>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22><strong>Mechanism\x20of\x20action</strong></td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Nucleotide/\x20nucleoside\x20reverse\x20transcriptase\x20inhibitors</td>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Inhibits\x20reverse\x20transcriptase</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Non-nucleoside\x20reverse\x20transcriptase\x20inhibitors</td>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Inhibits\x20reverse\x20transcriptase\x20by\x20binding\x20to\x20an\x20allosteric\x20site\x20of\x20the\x20enzyme</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22><strong>Protease\x20inhibitors</strong></td>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22><strong>Inhibits\x20the\x20viral\x20protease\x20enzyme\x20necessary\x20to\x20produce\x20mature\x20virions\x20upon\x20budding\x20from\x20the\x20host\x20membrane.</strong></td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Entry\x20inhibitors</td>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>\x0a<p>Interferes\x20with\x20binding,\x20fusion,\x20and\x20entry\x20of\x20HIV\x20-1\x20into\x20the\x20cell\x20by\x20blocking\x20a\x20target.</p>\x0a<p>Maraviroc\x20works\x20by\x20targetting\x20CCR5,\x20a\x20coreceptor\x20located\x20on\x20human\x20helper\x20T-cells</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Integrase\x20inhibitors</td>\x0a<td\x20style=\x22width:\x2050%;\x20height:\x2022.3984px;\x20text-align:\x20center;\x22>Inhibits\x20the\x20viral\x20enzyme\x20integrase,\x20which\x20is\x20responsible\x20for\x20the\x20integration\x20of\x20viral\x20DNA\x20into\x20the\x20DNA\x20of\x20the\x20infected\x20cell.</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong>Other\x20Options\x20:</strong>\u00a0</p>\x0a<p>Option\x20A,\x20C\x20and\x20D\x20:\x20Lopinavir,\x20Darunavir\x20and\x20Ritonavir\x20are\x20protease\x20inhibitors\x20that\x20can\x20cause\x20nausea\x20and\x20vomiting,\x20although\x20they\x20are\x20not\x20contraindicated\x20in\x20patients\x20with\x20bleeding\x20diathesis\x20and\x20not\x20associated\x20with\x20an\x20increased\x20risk\x20of\x20intracranial\x20hemorrhage.</p>\x0a<p><strong><br\x20/></strong>The\x20illustration\x20below\x20shows\x20the\x20mechanism\x20of\x20action\x20of\x20various\x20antiretroviral\x20drugs.</p>','ShoZW','pop','hCLHx','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22','Agranulocytosis','No\x20solution\x20provided','4863320JSDIAH','map','GlUgb','Morphine','explanation_video','snvQQ','MIWdw','kGPxV','Which\x20of\x20the\x20following\x20newly\x20approved\x20anti-diabetic\x20drugs\x20can\x20be\x20given\x20for\x20heart\x20failure\x20with\x20reduced\x20ejection\x20fraction\x20and\x20impaired\x20renal\x20function?','KBelv','ywIZI','EtPSO','bookmarkBtn','lhTED','FAXjM','RAoCd','bjxDW','modeModal','zJseE','XfHRH','cImuC','qdwDH','kyWrU','Carbamazepine','question_audio','Oiren','CFRyk','xWPmc','kkYEc','optionsContainer','application/vnd.apple.mpegurl','Amifostine','LFpUL','GVCgI','dzrhX','bPvCs','solutionVideo','QunjU','bFLXZ','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','<p>Keynote\x20189\x20trial\x20is\x20a\x20<strong>efficacy\x20and\x20safety\x20study\x20of</strong>\x20<strong>pembrolizumab\x20and\x20chemotherapy\x20in\x20metastatic\x20non-small\x20cell\x20carcinoma\x20of\x20lung.</strong></p>\x0a<p>Keynote\x20189\x20trial\x20is\x20an\x20<strong>efficacy\x20and\x20safety\x20study\x20of\x20pembrolizumab</strong>\x20(MK-3475)\x20<strong>combined\x20with\x20pemetrexed/platinum\x20chemotherapy</strong>\x20versus\x20pemetrexed/platinum\x20chemotherapy\x20alone\x20in\x20participants\x20<strong>with\x20advanced\x20or\x20metastatic\x20nonsquamous\x20non-small\x20cell\x20lung\x20cancer\x20(NSCLC)</strong>\x20who\x20have\x20not\x20previously\x20received\x20systemic\x20therapy\x20for\x20advanced\x20disease.\x20Participants\x20will\x20be\x20randomly\x20assigned\x20to\x20receive\x20pembrolizumab\x20combined\x20with\x20pemetrexed/platinum.</p>\x0a<p\x20class=\x22a-article-h2\x20f-h12\x22><strong><span\x20style=\x22font-size:\x2012pt;\x22>Methods</span></strong></p>\x0a<p\x20class=\x22f-body\x22>In\x20this\x20<strong>double-blind,\x20phase\x203\x20trial</strong>,\x20patients\x20were\x20<strong>randomly\x20assigned</strong>\x20(in\x20a\x202:1\x20ratio).\x20616\x20patients\x20with\x20metastatic\x20nonsquamous\x20NSCLC\x20without\x20sensitizing\x20<em>EGFR</em>&nbsp;or&nbsp;<em>ALK</em>&nbsp;mutations\x20who\x20had\x20received\x20no\x20previous\x20treatment\x20for\x20metastatic\x20disease\x20to\x20receive\x20pemetrexed\x20and\x20a\x20platinum-based\x20drug\x20plus\x20either\x20200\x20mg\x20of\x20pembrolizumab\x20or\x20placebo\x20every\x203\x20weeks\x20for\x204\x20cycles,\x20followed\x20by\x20pembrolizumab\x20or\x20placebo\x20for\x20up\x20to\x20a\x20total\x20of\x2035\x20cycles\x20plus\x20pemetrexed\x20maintenance\x20therapy.\x20Crossover\x20to\x20pembrolizumab\x20monotherapy\x20was\x20permitted\x20among\x20the\x20patients\x20in\x20the\x20placebo-combination\x20group\x20who\x20had\x20verified\x20disease\x20progression.\x20The\x20primary\x20endpoints\x20were\x20overall\x20survival\x20and\x20progression-free\x20survival,\x20as\x20assessed\x20by\x20a\x20blinded,\x20independent\x20central\x20radiologic\x20review.</p>\x0a<p\x20class=\x22a-article-h2\x20f-h12\x22><strong><span\x20style=\x22font-size:\x2012pt;\x22>Conclusions</span></strong></p>\x0a<p\x20class=\x22f-body\x22><span\x20class=\x22O1056PNEJMcme1801005DONENA2rxbnh\x20O1056PNEJMcme1801005DONENB2rxbng\x20O1056PNEJMcme1801005DONENC2rxbnf\x20O1056PNEJMcme1801005DONEND2rxbne\x20\x22>In\x20patients\x20with\x20previously\x20untreated\x20metastatic\x20nonsquamous\x20NSCLC\x20without&nbsp;<em>EGFR</em>&nbsp;or&nbsp;<em>ALK</em>&nbsp;mutations,\x20the\x20addition\x20of\x20<strong>pembrolizumab</strong>\x20to\x20standard\x20chemotherapy\x20of\x20pemetrexed\x20and\x20a\x20platinum-based\x20drug\x20resulted\x20in\x20significantly<strong>\x20longer\x20overall\x20survival\x20and\x20progression-free\x20survival\x20than\x20chemotherapy\x20alone.</strong></span><strong>&nbsp;</strong></p>','ShzZY','statsBar','nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','An\x20elderly\x20patient\x20with\x20dementia\x20is\x20not\x20compliant\x20with\x20oral\x20medications.\x20Which\x20of\x20the\x20following\x20will\x20be\x20beneficial\x20in\x20this\x20case?','setItem','\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>','Topiramate','WuHax','5937459UTHQph','toString','yXNAS','UWnMk','FjttR','NoKnW','jdXzY','oFpCD','aRKaJ','5|3|0|1|2|4','qOyTL','parse','<p>The\x20nomogram\x20used\x20for\x20<strong>vancomycin\x20dosing</strong>\x20is\x20the&nbsp;<strong>Matzke\x20nomogram.</strong></p>\x0a<p>The\x20Matzke\x20nomogram\x20includes\x20<strong>dosing\x20intervals\x20</strong>ranging\x20from\x200.5\x20to\x2012\x20days\x20on\x20a\x20continuum\x20of\x20CL<sub>cr</sub>(<strong>Creatinine\x20clearance</strong>)\x20values\x20from\x200\x20to\x20120\x20mL/min.\x20It\x20is\x20designed\x20to<strong>\x20guide\x20</strong>the\x20<strong>determination\x20of\x20the\x20initial\x20empiric\x20dose\x20</strong>and\x20<strong>interval\x20of\x20intravenous\x20(IV)\x20vancomycin</strong>\x20in\x20<strong>hospitalized\x20adults</strong>\x20who\x20are<strong>\x20not\x20receiving\x20hemodialysis</strong>.&nbsp;The\x20nomogram\x20does\x20not\x20apply\x20to\x20patients\x20who\x20exhibit\x20highly\x20variable\x20vancomycin\x20pharmacokinetics.\x20These\x20patients\x20include\x20the\x20critically\x20ill,\x20those\x20with\x20burn\x20injuries\x20affecting\x20more\x20than\x2020\x20percent\x20of\x20their\x20body\x20surface,\x20patients\x20with\x20rapidly\x20changing\x20renal\x20function,\x20pregnant\x20women,\x20those\x20with\x20liver\x20failure/ascites,\x20individuals\x20at\x20the\x20extremes\x20of\x20weight,\x20patients\x20who\x20are\x20acutely\x20post-transplant,\x20and\x20those\x20with\x20cystic\x20fibrosis</p>\x0a<p>The\x20<strong>Rumack-Matthew\x20nomogram\x20</strong>uses\x20the\x20serum\x20acetaminophen\x20concentration,&nbsp;in\x20relation\x20to\x20the&nbsp;time\x20after\x20ingestion,\x20to\x20<strong>assess\x20potential\x20hepatotoxicity</strong>&nbsp;after\x20a&nbsp;single,\x20acute\x20ingestion\x20of\x20<strong>acetaminophen</strong>.&nbsp;</p>','Sodium\x20valproate\x20has\x20an\x20inhibitory\x20action\x20at\x20which\x20of\x20the\x20following\x20sites?','aEtYX','correctResult','SKDAA','A\x20diabetic\x20patient\x20was\x20started\x20on\x20a\x20drug\x20that\x20decreased\x20her\x20HbA1C\x20from\x207.6\x20to\x206.7.\x20She\x20started\x20complaining\x20of\x20itching\x20around\x20vulvovaginal\x20area\x20.\x20What\x20was\x20the\x20most\x20likely\x20drug\x20she\x20was\x20started\x20on?','728dLJxxd','Salazar','<p><strong>Hydroxyurea</strong>\x20is\x20beneficial\x20in\x20reducing\x20the\x20<strong>painful\x20vasoocclusive\x20crisis</strong>\x20of\x20<strong>sickle\x20cell\x20anemia.</strong>\u00a0<br\x20/><br\x20/><strong>Hydroxyurea</strong>\x20is\x20a\x20<strong>myelosuppressive\x20agent</strong>\x20that\x20is\x20effective\x20in\x20<strong>reducing\x20the\x20frequency</strong>\x20of\x20<strong>painful\x20episodes</strong>\x20like\x20<strong>dactylitis</strong>\x20and\x20<strong>acute\x20chest\x20syndrome</strong>,\x20<strong>decreasing\x20the\x20rate\x20of\x20hospitalization</strong>,\x20and\x20<strong>requirement\x20for\x20blood\x20transfusion</strong>.\x20It\x20is\x20<strong>safe</strong>\x20and\x20<strong>well-tolerated</strong>\x20in\x20<strong>children</strong>\x20and\x20<strong>infants</strong>.\x20Hydroxyurea\x20is\x20approved\x20for\x20<strong>long-term\x20maintenance\x20of\x20sickle\x20cell\x20disease</strong>,\x20and\x20is\x20recommended\x20for\x20patients\x20of\x20<strong>all\x20ages</strong>\x20regardless\x20of\x20symptoms.\u00a0</p>\x0a<p>Hydroxyurea\x20<strong>increases\x20fetal\x20hemoglobin</strong>\x20levels\x20by\x20an\x20unknown\x20mechanism\x20and\x20<strong>interferes\x20with\x20the\x20polymerization\x20of\x20abnormal\x20HbS</strong>.\u00a0</p>\x0a<p><strong>Newer\x20drugs</strong>\x20for\x20management\x20of\x20<strong>acute\x20painful\x20crisis</strong>\x20of\x20sickle\x20cell\x20anemia\x20include\x20<strong>L-glutamine</strong>\x20and\x20<strong>crizanlizumab</strong>.\x20For\x20individuals\x20<strong>&gt;5\x20years</strong>\x20of\x20age\x20with\x20sickle\x20cell\x20disease\x20who\x20have\x20<strong>pain\x20despite\x20hydroxyurea</strong>\x20(or\x20who\x20<strong>cannot\x20tolerate\x20hydroxyurea</strong>),\x20<strong>L-glutamine</strong>\x20is\x20recommended,\x20regardless\x20of\x20whether\x20they\x20are\x20receiving\x20hydroxyurea.\x20The\x20mechanism\x20of\x20action\x20of\x20this\x20drug,\x20is\x20that\x20it\x20<strong>reduces\x20oxidative\x20stress</strong>\x20in\x20sickle\x20erythrocytes.\x20<strong>Crizanlizumab</strong>\x20is\x20a\x20<strong>P-selectin-blocking\x20monoclonal\x20antibody</strong>\x20which\x20is\x20given\x20<strong>intravenously</strong>\x20every\x20month\x20to\x20reduce\x20acute\x20painful\x20episodes.</p>\x0a<p><strong>Sickle\x20cell\x20anemia</strong>\x20is\x20an\x20<strong>autosomal\x20recessive</strong>\x20disorder\x20that\x20occurs\x20due\x20to\x20the<strong>\x20point\x20mutation</strong>\x20in\x20the<strong>\x20β-globin\x20gene\x20</strong>which\x20results\x20in\x20the\x20<strong>replacement\x20of\x20glutamate\x20</strong>residue\x20with\x20<strong>valine</strong>.\x20This\x20causes\x20the\x20production\x20of\x20<strong>sickle-shaped\x20red\x20blood\x20cells</strong>\x20due\x20to\x20the\x20<strong>polymerization</strong>\x20of\x20<strong>deoxygenated</strong>\x20<strong>hemoglobin\x20(HbS)</strong>.\x20<strong>Factors</strong>\x20that\x20predispose\x20to\x20<strong>sickling</strong>\x20are\x20<strong>infection</strong>,\x20<strong>dehydration</strong>,\x20and\x20<strong>acidosis</strong>.\x20Sickle\x20cell\x20disease\x20causes\x20<strong>hemolytic\x20anemia</strong>\x20due\x20to\x20<strong>increased\x20erythrocyte\x20destruction</strong>.\x20The\x20anemia\x20is\x20generally\x20well\x20compensated.\x20Complications\x20occur\x20due\x20to\x20abnormal\x20erythrocyte\x20configurations\x20that\x20increase\x20hemoglobin\x20polymerization\x20leading\x20to\x20a\x20<strong>painful\x20vaso-occlusive\x20state</strong>.\u00a0</p>\x0a<p><strong>Clinical\x20features\x20</strong>of\x20sickle\x20cell\x20anemia\x20:\u00a0</p>\x0a<p>-\x20<strong>Moderately\x20severe\x20hemolytic\x20anemia</strong>\x20with\x20<strong>jaundice</strong>.<br\x20/>-\x20<strong>Painful\x20bone\x20crisis</strong>\x20:\x20<strong>hand-foot\x20syndrome\x20</strong>or\x20<strong>dactylitis</strong>\x20of\x20the\x20bones\x20of\x20hands\x20and\x20feet.<br\x20/>-\x20<strong>Acute\x20chest\x20syndrome</strong>\x20typically\x20presents\x20with\x20fever,\x20cough,\x20chest\x20pain,\x20and\x20pulmonary\x20infiltrates.<br\x20/>-\x20<strong>Hyposthenuria</strong>\x20:\x20inability\x20to\x20concentrate\x20urine.<br\x20/>-\x20<strong>Aplastic</strong>\x20<strong>crisis</strong>\x20stems\x20from\x20the\x20infection\x20of\x20red\x20cell\x20progenitors\x20by\x20parvovirus\x20B19,\x20which\x20causes\x20a\x20transient\x20cessation\x20of\x20erythropoiesis\x20and\x20a\x20sudden\x20worsening\x20of\x20the\x20anemia.<br\x20/>-\x20Spleen\x20:\x20In\x20children,\x20<strong>splenic\x20sequestration</strong>\x20<strong>crises</strong>\x20occur\x20which\x20results\x20in\x20<strong>splenomegaly</strong>\x20due\x20to<strong>\x20red\x20pulp\x20congestion</strong>.\x20In\x20adolescence\x20or\x20early\x20adulthood,\x20<strong>autosplenectomy</strong>\x20occurs\x20due\x20to\x20splenic\x20infarction,\x20fibrosis,\x20and\x20progressive\x20shrinkage.<br\x20/>-\x20Increased\x20<strong>susceptibility\x20to\x20infection</strong>\x20with\x20<strong>encapsulated</strong>\x20<strong>organisms</strong>\x20like\x20pneumococcal,\x20meningococcal,\x20and\x20Haemophilus\x20influenza\x20septicemia,\x20but\x20can\x20be\x20reduced\x20by\x20vaccination\x20and\x20prophylactic\x20antibiotics.<br\x20/>-\x20Other\x20clinical\x20features\x20include\x20<strong>priapism</strong>,<strong>\x20leg\x20ulcers,\x20stroke,\x20retinopathy,\x20pigment\x20gallstones</strong>,\x20and\x20<strong>growth\x20retardation</strong>.</p>\x0a<p>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20B\x20:\x20<strong>Methotrexate</strong>\x20interferes\x20with\x20folate\x20metabolism\x20by\x20acting\x20as\x20a<strong>\x20competitive\x20inhibitor</strong>\x20of\x20the\x20enzyme\x20<strong>dihydrofolate\x20reductase</strong>.\x20This\x20starves\x20cells\x20for\x20tetrahydrofolate\x20and\x20makes\x20them\x20unable\x20to\x20synthesize\x20purines\x20and\x20thymidine\x20monophosphate.\x20It\x20does\x20not\x20treat\x20painful\x20crisis\x20of\x20sickle\x20cell\x20anemia.</p>\x0a<p>Option\x20C\x20:\x20<strong>Methionine</strong>\x20is\x20an\x20<strong>essential\x20amino\x20acid</strong>\x20involved\x20in\x20the\x20synthesis\x20of\x20folate\x20and\x20vitamin\x20B12.\x20It\x20is\x20not\x20used\x20in\x20the\x20management\x20of\x20sickle\x20cell\x20anemia.<br\x20/><br\x20/>Option\x20D\x20:\x20<strong>Eltrombopag\x20</strong>is\x20a\x20<strong>thrombopoetin\x20analog</strong>\x20used\x20to\x20treat\x20immune\x20thrombocytopenia.\x20It\x20is\x20not\x20used\x20in\x20the\x20treatment\x20of\x20painful\x20sickle\x20cell\x20crisis.</p>','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>','L858R\x20mutation','Mydriasis','Bupropion','Canagliflozin','Flat\x20T\x20waves','index.html','getItem','Galantamine','tJUNh','urupu','qHLUp','GxFDB','Methotrexate\x20+\x20leukovorin','block','gdmjB','style','UyWNc','XNvUz','dataset','bDlZa','stats','Pharmacology','YxHnM','currentQuestionIndex','quizHierarchy','DUhnr','lrNeL','Pregabalin','Memantine','innerHTML','round','DdGVS','now','timed_exam','Hypothermia','piGla','rwahU','Ratio\x20of\x20median\x20lethal\x20dose\x20in\x2050%\x20of\x20population\x20to\x20median\x20effective\x20dose\x20in\x2050%\x20of\x20population','Daptomycin','Atropine','mgXFm','qWTjw','DyXYA','ftqKs','tLYhr','Budesonide','NUYTe','<p><strong>Alogliptin</strong>\x20is\x20a\u00a0<strong>dipeptidyl\x20peptidase-4\x20(DPP)\x20inhibitor.</strong>\x20<strong>Glucagon-like\x20peptide\x20(GLP)\x20and\x20glucose-dependent\x20insulinotropic\x20polypeptide\x20(GIP)</strong>\x20are\x20both\x20<strong>incretins</strong>\x20that\x20promote\x20the\x20exocytosis\x20of\x20insulin\x20into\x20circulation.\x20Both\x20these\x20<strong>incretins</strong>\x20are<strong>\x20rapidly\x20inactivated</strong>\x20by\x20<strong>dipeptidyl\x20peptidase</strong>.\x20So,\x20<strong>inhibition\x20of\x20dipeptidyl\x20peptidase</strong>\x20<strong>enhances</strong>\x20the\x20action\x20of\x20<strong>incretins</strong>\x20and\x20facilitates\x20insulin\x20release.\u00a0<strong>Dipeptidyl\x20peptidase-4\x20inhibitors\u00a0</strong>enhance\x20the\x20release\x20of\x20insulin\x20postprandially,\x20decrease\x20glucagon,\x20and\x20thereby\x20lower\x20mealtime\x20as\x20well\x20as\x20fasting\x20glucose.\u00a0</p>\x0a<p>Other\x20DPP-4\x20inhibitors\x20include\x20<strong>saxagliptin,\x20linagliptin,\x20alogliptin,</strong>\x20and\x20<strong>vildagliptin.\u00a0</strong>They\x20are\x20weight\x20neutral.</p>\x0a<p>DPP-4\x20inhibitors\x20are\x20associated\x20with<strong>\x20severe</strong><strong>\u00a0joint\x20pain\x20which</strong>\x20reduces\x20on\x20discontinuation\x20of\x20the\x20drug.\x20Linagliptin\x20is\x20cleared\x20primarily\x20by\x20hepatobiliary\x20system,\x20with\x20little\x20renal\x20clearance.\x20Only\x20saxagliptin\x20is\x20metabolized\x20by\x20the\x20liver\x20and\x20must\x20be\x20used\x20in\x20lower\x20doses\x20if\x20used\x20along\x20with\x20a\x20cytochrome\x20p450\x20enzyme\x20inhibitor\x20drug.\x20Other\x20drugs\x20are\x20renally\x20excreted\x20and\x20hence\x20must\x20be\x20used\x20with\x20<strong>caution</strong>\x20in\u00a0<strong>renal\x20insufficiency.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A\x20-\u00a0<strong>Pramlintide</strong>\u00a0is\x20an\u00a0<strong>amylin\x20agonist</strong>.\x20It\x20reduces\x20postprandial\x20glycemia\x20and\x20leads\x20to\u00a0<strong>weight\x20loss</strong>.</p>\x0a<p>Option\x20C\x20-\u00a0<strong>Liraglutide</strong>\u00a0is\x20also\x20a\u00a0<strong>GLP-1\x20receptor\x20agonist</strong>\u00a0and\x20is\x20given\x20only\x20in\x20the\u00a0<strong>subcutaneous\x20injectable</strong>\u00a0form.\x20It\x20was\x20recently\x20approved\x20for\x20the\x20treatment\x20of\u00a0<strong>obesity.</strong></p>\x0a<p>Option\x20D\x20-\u00a0<strong>Metformin</strong>\x20belongs\x20to\x20the\u00a0<strong>biguanides</strong>\u00a0class\x20of\x20oral\x20hypoglycemic\x20agents.\x20It\x20acts\x20by\x20activation\x20of\x20AMP-dependent\x20protein\x20kinase\x20(<strong>AMPK</strong>).\x20This\x20results\x20in\x20reduced\x20hepatic\x20glucose\x20production.\u00a0<strong>Side\x20effects</strong>\u00a0of\u00a0<strong>metformin</strong>\u00a0are\u00a0<strong>l</strong><strong>actic\x20acidosis,\u00a0</strong>gastrointestinal\x20disturbance,\x20and\u00a0<strong>vitamin\x20B12\x20deficiency.</strong></p>\x0a<div\x20class=\x22ng-star-inserted\x22>\u00a0</div>','owJBK','YnElJ','yqFFD','Naloxone','text','oyArL','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','Lopinavir','Aprepitant','diYcU','Pembrolizumab\x20plus\x20chemotherapy\x20used\x20in\x20NSCLC','NxnbN','PDioO','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','058-pharmacology-ini-cet-2023-0db2c741.html','HTXol','cZOVQ','AkQhU','XxHQB','constructor','<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-','nav-btn-bookmarked','ZTppK','rQLUb','GwpgS','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','wdJZA','BocXt','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20','gkbGB','markedForReview','https://cdn1.dailyrounds.org/uploads/0d14e58f54894d9d9389bff9d61b97e6.JPEG','timerContainer','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','includes','vOpmN','questionText','canPlayType','lPGXf','<p><strong>IV\x20desferrioxamine</strong>\x20(also\x20known\x20as\u00a0<strong>deferoxamine)</strong>\u00a0is\x20indicated\x20when<strong>\x20serum\x20iron\x20levels</strong>\x20are\x20<strong>greater\x20than\x20500\x20mcg/dL</strong>\x20in\x20cases\x20of\x20<strong>iron\x20toxicity.</strong></p>\x0a<p><strong>Desferrioxamine</strong>\x20is\x20selectively\x20used\x20as\x20a\x20<strong>chelating\x20agent\x20</strong>to\x20manage\x20cases\x20of\x20<strong>acute\x20iron\x20poisoning,</strong>\x20<strong>hemochromatosis</strong>,\x20and\x20patients\x20with\x20<strong>iron</strong>\x20<strong>overload</strong>\x20from\x20<strong>repetitive\x20blood\x20transfusions</strong>.\x20Desferrioxamine\x20can\x20be\x20<strong>administered\x20intramuscularly</strong>,\x20<strong>intravenously</strong>,\x20or\x20<strong>subcutaneously</strong>\x20but\x20<strong>not\x20orally</strong>.</p>\x0a<p><strong>Deferiprone</strong>\x20and\x20<strong>deferasirox</strong>\x20are\x20both\x20<strong>oral\x20drugs</strong>\x20and\x20can\x20be\x20given\x20in<strong>\x20transfusion\x20related\x20siderosis</strong>\x20but\x20are\x20less\x20effective\x20than\x20desferrioxamine.\x20Although,\x20they\x20can\x20be\x20preferred\x20because\x20of\x20the\x20ease\x20of\x20administration\x20through\x20oral\x20route\x20and\x20multiple\x20transfusions\x20required\x20for\x20beta\x20thalassemia\x20patients.<br\x20/><br\x20/>Iron\x20exhibits<strong>\x20toxic\x20effects</strong>\x20by\x20<strong>hydration\x20of\x20the\x20ferric\x20(F<sup>3+</sup>)\x20ion</strong>\x20which<strong>\x20generates\x20H<sup>+</sup></strong>.\x20Non\x20transferrin\x20bound\x20iron\x20catalyses\x20<strong>free\x20radical\x20formation\x20</strong>which\x20causes\x20<strong>mitochondrial\x20injury,\x20lipid\x20peroxidation,\x20increased\x20capillary\x20permeability,\x20vasodilation,\x20and\x20organ\x20toxicity</strong>.<br\x20/><br\x20/><strong>Clinical\x20features</strong>\x20of\x20iron\x20toxicity\x20include<strong>\x20initial\x20nausea,\x20vomiting,\x20abdominal\x20pain</strong>\x20and\x20<strong>diarrhea</strong>.\x20In\x20<strong>severe\x20cases\x20</strong>there\x20is<strong>\x20high\x20anion\x20gap\x20metabolic\x20acidosis</strong>,\x20<strong>cardiovascular\x20and\x20CNS\x20depression</strong>,\x20<strong>hepatitis</strong>,\x20<strong>coagulopathy</strong>,\x20and\x20<strong>seizures</strong>.<br\x20/><br\x20/>In\x20the\x20case\x20of<strong>\x20toxic\x20iron\x20ingestion</strong>,\x20<strong>radiopaque\x20iron\x20tablets</strong>\x20may\x20be\x20seen\x20on\x20<strong>abdominal\x20x-ray</strong>.</p>\x0a<p><strong>Management</strong>\x20of\x20iron\x20toxicity\x20includes\x20the\x20following\x20:\u00a0</p>\x0a<ul>\x0a<li><strong>Whole-bowel\x20irrigation</strong>\x20for<strong>\x20large\x20ingestions</strong>,\x20<strong>endoscopy</strong>\x20and\x20<strong>gastrostomy</strong>\x20if\x20clinical\x20toxicity\x20and\x20large\x20number\x20of\x20tablets\x20are\x20still\x20visible\x20on\x20x-ray.</li>\x0a<li><strong>\x20IV\x20hydration</strong>.</li>\x0a<li><strong>\x20Sodium\x20bicarbonate</strong>\x20for\x20<strong>acidemia</strong>.</li>\x0a<li><strong>IV\x20desferrioxamine</strong>\x20for\x20<strong>systemic</strong>\x20<strong>toxicity</strong>,\x20<strong>iron\x20level\x20&gt;90\x20μmol/L</strong>\x20(<strong>500</strong>\x20<strong>μg/dL</strong>).</li>\x0a</ul>','fHUKP','531138UxFkte','PYQ','A-1,\x20B-2,\x20C-3,\x20D-4','akaXv','LbsqM','LxmIT','SdSQI','Cyiko','qLJMz','dMpJL','Clindamycin','querySelectorAll','Hydroxyurea','<p><strong>Lapatinib</strong>\x20is\x20used\x20for\x20<strong>trastuzumab-resistant\x20HER-2\x20neu-positive\x20breast\x20carcinoma</strong>.</p>\x0a<p>Lapatinib\x20is\x20an\x20orally\x20bioavailable,\x20small-molecule<strong>\x20inhibitor\x20of\x20the\x20EGFR\x20and\x20HER2\x20tyrosine\x20kinases</strong>.\x20Lapatinib\x20is\x20metabolized\x20by\x20<strong>CYP3A4</strong>.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201406\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201406\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201406\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p><strong>Lapatinib</strong>\x20in\x20combination<strong>\x20with\x20capecitabine</strong>\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20patients\x20with<strong>\x20metastatic\x20HER2-positive\x20trastuzumab-refractory\x20breast\x20cancer.</strong>\x20<strong>Lapatinib</strong>\x20is\x20also\x20used\x20in\x20combination<strong>\x20with\x20</strong>the\x20aromatase\x20inhibitor\x20<strong>letrozole</strong>\x20to\x20treat<strong>\x20postmenopausal\x20women\x20with\x20hormone\x20receptor-positive,\x20metastatic\x20breast\x20cancer\x20that\x20overexpresses\x20HER2.</strong></p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201406\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Frequent<strong>\x20adverse\x20effects</strong>\x20include\x20acneiform\x20rash,\x20diarrhea,\x20cramping,\x20and\x20exacerbation\x20of\x20gastroesophageal\x20reflux.<strong>\x20Cardiac\x20toxicity</strong>\x20appears\x20less\x20pronounced\x20than\x20with\x20trastuzumab,\x20although\x20lapatinib\x20should\x20be\x20used\x20with\x20caution\x20in\x20combination\x20with\x20cardiotoxic\x20drugs.\x20A\x20dose-dependent\x20<strong>prolongation</strong>\x20of\x20the\x20<strong>QT\x20interval</strong>\x20has\x20been\x20reported;\x20thus,\x20careful\x20monitoring\x20of\x20patients\x20with\x20heart\x20disease\x20is\x20recommended.\x20<strong>Hepatotoxicity</strong>\x20that\x20may\x20be\x20severe\x20has\x20been\x20observed.</p>\x0a<p><strong>Trastuzumab</strong>&nbsp;is\x20a\x20monoclonal\x20antibody\x20that<strong>\x20inhibits\x20the\x20HER2\x20receptor</strong>.\x20It\x20is\x20used\x20in\x20the\x20<strong>treatment\x20of\x20HER2-positive\x20breast\x20cancer.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p><strong>Option\x20A:&nbsp;</strong><strong>Vismodegib</strong>&nbsp;is\x20a&nbsp;<strong>hedgehog\x20pathway\x20inhibitor</strong>&nbsp;used\x20to\x20treat&nbsp;<strong>metastatic\x20and\x20locally\x20advanced\x20BCCs</strong>.</p>\x0a<p><strong>Option\x20C</strong>:&nbsp;<strong>Vemurafenib</strong>&nbsp;is\x20a&nbsp;<strong>BRAF\x20inhibitors</strong>&nbsp;used\x20in\x20metastatic\x20melanoma\x20and\x20thyroid\x20cancers\x20with\x20BRAF\x20V600E\x20mutation.</p>\x0a<p><strong>Option\x20D</strong>:&nbsp;<strong>Erlotinib</strong>&nbsp;is\x20a\x20protein\x20kinase\x20antagonists\x20which\x20is\x20the\x20first\x20line\x20treatment\x20of&nbsp;<strong>non-small\x20cell\x20lung\x20carcinoma</strong>&nbsp;with\x20EGFR\x20deletion\x20of\x20exon\x2019\x20or\x20L858R\x20mutation</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a<p>&nbsp;</p>','add','LptAR','ZtvLP','toLowerCase','yxZou','aurmL','NAcvF','YYusY','<p>The\x20therapeutic\x20index\x20of\x20a\x20drug\x20denotes\x20the\x20<strong>safety\x20and\x20efficacy</strong>\x20of\x20the\x20drug\x20in\x20the\x20<strong>population</strong>\x20(option\x20B),\x20not\x20the\x20individual\x20(option\x20C).</p>\x0a<p>The\x20therapeutic\x20index\x20is\x20calculated\x20with\x20the\x20following\x20equations:</p>\x0a<p>LD<sub>50</sub>/ED<sub>50</sub>\x20or\x20TD<sub>50</sub>/ED<sub>50</sub></p>\x0a<p>where\x20LD<sub>50</sub>\x20is\x20the\x20median\x20lethal\x20dose,\x20TD<sub>50</sub>\x20is\x20the\x20mean\x20toxic\x20dose,\x20and\x20ED<sub>50</sub>\x20is\x20the\x20median\x20effective\x20dose\u00a0</p>\x0a<p>The\x20<strong>therapeutic\x20index\x20</strong>(TI)\x20describes\x20a\x20relationship\x20between\x20the\x20doses\x20of\x20a\x20drug\x20that\x20causes\x20lethal\x20or\x20toxic\x20effects\x20with\x20the\x20dose\x20that\x20causes\x20therapeutic\x20effects.\x20It\x20is\x20also\x20called\x20the\x20therapeutic\x20ratio.\x20The\x20therapeutic\x20index\x20is\x20used\x20to\x20<strong>assess\x20the\x20safety\x20</strong>of\x20the\x20drug\x20administered.</p>\x0a<p><strong>Median\x20lethal\x20dose</strong>\x20(LD<sub>50</sub>)\x20and<strong>\x20median\x20toxic\x20dose</strong>\x20(TD<sub>50</sub>)</p>\x0a<ul>\x0a<li>LD<sub>50</sub>\x20is\x20the\x20dose\x20of\x20the\x20drug\x20at\x20which\x2050%\x20of\x20the\x20experimental\x20animals\x20die</li>\x0a<li>In\x20human\x20trials,\x20TD<sub>50</sub>\x20can\x20be\x20considered.\x20It\x20is\x20the\x20dose\x20of\x20the\x20drug\x20that\x20causes\x20adverse\x20effects\x20in\x2050%\x20of\x20the\x20population\x20(Option\x20D)</li>\x0a<li>The\x20larger\x20the\x20LD<sub>50</sub>\x20or\x20TD<sub>50</sub>,\x20the\x20safer\x20the\x20drug\u00a0</li>\x0a</ul>\x0a<p><strong>Median\x20effective\x20dose</strong>\x20(ED<sub>50</sub>)\x20is\x20the\x20quantity\x20of\x20a\x20drug\x20that\x20can\x20produce\x20the\x20desired\x20therapeutic\x20effects\x20in\x2050%\x20of\x20the\x20population.</p>\x0a<p><strong>Therapeutic\x20window</strong>\x20refers\x20to\x20a\x20range\x20of\x20concentrations\x20at\x20which\x20the\x20likelihood\x20of\x20efficacy\x20is\x20high\x20and\x20the\x20probability\x20of\x20adverse\x20effects\x20is\x20low.</p>\x0a<p>Note:\x20Option\x20D\x20is\x20incorrect\x20as\x20it\x20does\x20not\x20make\x20the\x20necessary\x20distinction\x20that\x20the\x20therapeutic\x20index\x20is\x20the\x20ratio\x20of\x20the\x20median\x20lethal\x20dose\x20in\x2050%\x20of\x20animals\x20(as\x20the\x20human\x20population\x20cannot\x20be\x20used\x20for\x20lethal\x20studies)\x20to\x20the\x20median\x20effective\x20dose\x20in\x2050%\x20of\x20the\x20population.\x20LD<sub>50</sub>\x20is\x20measured\x20in\x20animals,\x20not\x20in\x20humans.\x20Option\x20B\x20is\x20a\x20better\x20choice.</p>','No\x20solution\x20available.','You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','REgdg','pathname','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','JTrSZ','fromCharCode','HubcE','LMrRd','MtTxr','A\x2012\x20year\x20old\x20boy\x20presents\x20with\x20complaints\x20of\x20profuse\x20watery\x20stools\x20and\x20an\x20elevated\x20WBC\x20count\x20of\x2016000\x20cells/mm3.\x20He\x20has\x20been\x20on\x20treatment\x20with\x20amoxicillin\x20for\x20the\x20past\x201\x20week.\x20What\x20is\x20the\x20treatment\x20of\x20choice\x20for\x20his\x20condition?','hyBCI','strokeDashoffset','Thjdy','Romiplostim','T890M\x20mutation','quizPerformanceData','markReviewBtn','LiXNM','name','Empaglifozin','<p><strong>Dexrazoxane</strong>\x20is\x20the\x20drug\x20of\x20choice\x20to\x20treat\x20<strong>doxorubicin</strong>\x20<strong>induced</strong>\x20<strong>cardiomyopathy</strong>.<br\x20/><br\x20/><strong>Doxorubicin</strong>\x20is\x20an\x20<strong>anthracycline</strong>\x20group\x20of\x20anticancer\x20antibiotics\x20that\x20acts\x20by\x20<strong>inhibiting\x20topoisomerase\x20II</strong>,\x20and\x20is\x20known\x20to\x20cause\x20<strong>cardiotoxicity</strong>.\x20<strong>Dexrazoxane</strong>\x20is\x20a\x20<strong>cardioprotective</strong>\x20<strong>iron-chelating\x20agent\x20</strong>that\x20is\x20indicated\x20for\x20use\x20along\x20with\x20<strong>high\x20dose\x20doxorubicin</strong>\x20to\x20<strong>avoid\x20cardiotoxicity</strong>.\u00a0<br\x20/><br\x20/><strong>Dexrazoxane</strong>\x20is\x20currently\x20approved\x20to\x20<strong>prevent\x20or\x20reduce\x20anthracycline-induced\x20cardiotoxicity</strong>\x20in\x20women\x20with<strong>\x20metastatic\x20breast\x20cancer\x20</strong>who\x20have\x20received\x20a\x20<strong>total\x20cumulative\x20dose\x20of\x20doxorubicin\x20of\x20300\x20mg/m2</strong>\x20.</p>\x0a<p>Doxorubicin-induced\x20cardiomyopathy\x20takes\x20two\x20forms:</p>\x0a<p>-\x20<strong>Acute</strong>:\x20<strong>pericarditis-myocarditis\x20syndrome</strong>,\x20arrhythmias,\x20ST\x20and\x20T\x20wave\x20changes\x20in\x20ECG.\x20Occurs\x20within\x20the\x20first\x202–3\x20days,\x20is\x20transient\x20and\x20in\x20most\x20cases\x20asymptomatic.<br\x20/>-\x20<strong>Chronic</strong>:\x20Dose\x20dependendent\x20<strong>dilated\x20cardiomyopathy\x20associated\x20with\x20heart\x20failure</strong>.\u00a0</p>\x0a<p><strong>Doxorubicin,\x20daunorubicin\x20and\x20epirubicin</strong>\x20share\x20<strong>similar\x20cardiotoxicity</strong>\x20profile.\x20<strong>Idarubicin</strong>\x20has<strong>\x20least\x20cardiotoxicity</strong>\x20when\x20compared\x20to\x20other\x20anthracyclines.<br\x20/><br\x20/><strong>Endomyocardial\x20biopsy\x20</strong>showing\x20<strong>vacuolar\x20degeneration</strong>\x20and\x20<strong>myofibrillar</strong>\x20<strong>loss</strong>\x20is\x20seen\x20in\x20cardiotoxicity\x20due\x20to\x20anthracyclines.<br\x20/><br\x20/><strong>Difference</strong>\x20between\x20cardiotoxicity\x20due\x20to\x20<strong>anthracyclins\x20and\x20trastuzumab</strong>:</p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x20100.046%;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x2048.6654%;\x22><strong>Anthracyclins</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x22>Trastuzumab</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2048.6654%;\x22><strong>Irreversible</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x22>Reversible</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2048.6654%;\x22><strong>Dose-dependent</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x22>Not\x20dose-dependent</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2048.6654%;\x22><strong>Biopsy\x20shows\x20myocyte\x20destruction</strong></td>\x0a<td\x20style=\x22width:\x2048.6654%;\x22>Biopsy\x20does\x20not\x20show\x20myocyte\x20destruction</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><br\x20/><strong>Anthracyclines</strong>\x20like\x20doxorubicin\x20can\x20result\x20in\x20a\x20<strong>radiation\x20recall\x20reaction</strong>,\x20where\x20<strong>erythema\x20and\x20desquamation\x20of\x20skin</strong>\x20are\x20observed\x20at\x20sites\x20of\x20<strong>previous\x20radiation\x20injury.</strong>\x20The\x20risk\x20of\x20cardiotoxicity\x20also\x20increases\x20with\x20previous\x20irradiation.\x20Therefore,\x20careful\x20monitoring\x20and\x20dosage\x20adjustments\x20are\x20required\x20for\x20doxorubicin.<br\x20/><br\x20/>Other\x20options\x20:\u00a0<br\x20/><br\x20/>Option\x20B,\x20C\x20and\x20D\x20:\x20Dexamethasone,\x20aprepitant\x20and\x20amifostine\x20are\x20not\x20used\x20in\x20the\x20management\x20of\x20anthracycline\x20induced\x20cardiotoxicity.</p>','forEach','MyqBc','Previous\x20progress\x20cleared.','KnjWp','oCOYl','DYvqz','ASqrF','GkTJd','CToOp','EmFUp','questionReviewSection','GYWpm','nagoN','wZvSY','Pethidine','remove','onclick','sMhDd','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22','60shCVZG','vXlSi','solutionText','ysIrD','choices','bookmarkText','<div\x20class=\x22mt-4\x22><img\x20src=\x22','console','oPGiQ','Aspergillus\x20niger\x20-\x20Voriconazole','pcFMD','flex','4|1|3|2|0|5','Hyponatremia','currentMode','qgPRR','Iiqrm','SSUsD','bookmarked','gLbCP','OAT1B1','qKXcx','M790T\x20mutation','RYCyS','Progress\x20loaded.','What\x20is\x20true\x20about\x20keynote\x20189\x20trial?','bxsnw','nbFfJ','DOMContentLoaded','IHiyH','GVqhu','It\x20is\x20not\x20teratogenic','aOrmR','rVPyB','EYHcj','incorrectResult','31167360UXmGUD','table','quizSidebar','HLSnX','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','ZJwAa','JOClP','yEJPt','xAznT','qXTRt','wsRnB','ozyFi','</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-','avgTimeResult','ZPhvn','Syqoa','questionMedia','hdcTe','not_attempted','Which\x20of\x20the\x20following\x20mood\x20stabilisers\x20causes\x20hepatotoxicity\x20and\x20hyperammonemia?','selected','BhYMS','EABxh','strokeDasharray','Candida\x20Glabrata\x20-\x20Amphotericin\x20B','ENqlG','20poqCWD','getAttribute','FMzGT','mEcBK','LUTCO','Fostamatinib','<p>Management\x20of\x20hyperkalemia\x20involves\x20an\x20immediate\x20reversal\x20of\x20cardiac\x20effects\x20by\x20administration\x20of\x20<strong>10mL\x20of\x2010%\x20calcium\x20gluconate\x20intravenously</strong>.\x20This\x20leads\x20to\x20the\x20reversal\x20of\x20the\x20depolarization\x20blockade\x20due\x20to\x20hyperkalemia.\x20Redistributing\x20the\x20excess\x20potassium\x20by\x20administering\x20<strong>10U\x20of\x20intravenous\x20insulin\x20</strong>followed\x20by\x20<strong>50mL\x20of\x2050%\x20dextrose</strong>\x20can\x20also\x20be\x20given,\x20as\x20insulin\x20facilitates\x20the\x20intracellular\x20shift\x20of\x20potassium.\x20<strong>Beta-2-agonists</strong>\x20can\x20also\x20be\x20used\x20in\x20the\x20management\x20of\x20hyperkalemia.\x20But\x20patients\x20with\x20end-stage\x20renal\x20disease\x20are\x20resistant\x20to\x20beta-2-agonists\x20and\x20hence\x20must\x20be\x20used\x20with\x20caution.\u00a0Removal\x20of\x20potassium\x20can\x20be\x20done\x20using\x20<strong>cation\x20exchange\x20resins</strong>\x20like\x20<strong>patiromer\x20</strong>and<strong>\x20sodium\x20polystyrene\x20sulfonate</strong>,<strong>\x20diuretics</strong>,<strong>\u00a0</strong>and\x20<strong>dialysis.</strong></p>','vlcFU','anAxj','explanation_audio_eng','ROzwb','aAdpt','Methionine','iubaJ','questionNav','gcLRx','Which\x20is\x20a\x20rare\x20but\x20very\x20severe\x20side\x20effect\x20of\x20clozapine\x20that\x20requires\x20regular\x20monitoring?','ZbFLt','test','<p><strong>Thalidomide</strong>\x20does\x20<strong>not\x20cause</strong>\x20teratogenicity\x20by\x20<strong>inhibition\x20of\x20IL2,\x20IL4,\x20and\x20IL5.</strong></p>\x0a<p>The\x20mechanism\x20of\x20thalidomide\x20teratogenicity\x20include\u00a0<strong>oxidative\x20stress,\x20anti-angiogenesis,</strong>\x20and\x20thalidomide-binding\x20protein,\x20<strong>cereblon\x20</strong>which\x20has\x20a\x20role\x20in\x20the\x20development\x20of\x20cerebral\x20tissues\x20and\x20because\x20its\x20expression\x20in\x20the\x20hippocampus\x20among\x20other\x20areas\x20is\x20associated\x20with\x20<strong>memory\x20and\x20learning\x20processes\x20(CRBN).\u00a0</strong>Fetal\x20thalidomide\x20exposure\x20causes\x20phocomelia.\x20This\x20disorder\x20is\x20associated\x20with\x20<strong>underdeveloped\x20limbs</strong>\x20and\x20<strong>absent\x20pelvic\x20bones.</strong>\x20Both\x20<strong>upper</strong>\x20and\x20<strong>lower</strong>\x20limbs\x20are\x20<strong>affected</strong>,\x20and\x20a\x20part\x20of\x20the\x20limbs\x20may\x20be\x20missing.\x20Fused\x20fingers\x20and\x20missing\x20thumbs\x20are\x20also\x20seen.\x20Thalidomide\x20was\x20originally\x20used\x20for\x20the\x20treatment\x20of\x20<strong>pregnancy-associated\x20morning\x20sickness</strong>\x20but\x20was\x20<strong>withdrawn</strong>\x20due\x20to\x20this\x20adverse\x20effect.\u00a0It\x20is\x20now\x20used\x20for\x20the\x20treatment\x20of\x20erythema\x20nodosum\x20leprosum.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x201423\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Thalidomide\x20is\x20an\x20immunomodulator.\x20Thalidomide\x20absorption\x20from\x20the\x20GI\x20tract\x20is\x20slow\x20and\x20highly\x20variable.\x20It\x20distributes\x20throughout\x20most\x20tissues\x20and\x20organs,\x20without\x20significant\x20binding\x20to\x20plasma\x20proteins.\x20Thalidomide\x20and\x20its\x20metabolites\x20are\x20excreted\x20in\x20the\x20urine,\x20while\x20the\x20<strong>nonabsorbed</strong>\x20portion\x20of\x20the\x20drug\x20is\x20<strong>excreted\x20unchanged\x20in\x20feces</strong>.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a<p>\u00a0Common\x20adverse\x20effects\x20of\x20thalidomide\x20include\x20sedation\x20and\x20constipation.\x20However,\x20one\x20of\x20the\x20most\x20serious\x20adverse\x20effects\x20is\x20<strong>peripheral\x20sensory\x20neuropathy</strong>,\x20characterized\x20by\x20<strong>asymmetrical,\x20painful,\x20peripheral\x20paresthesia\x20with\x20sensory\x20loss</strong>.\x20Symptoms\x20often\x20present\x20as\x20numbness\x20of\x20the\x20toes\x20and\x20feet,\x20muscle\x20cramps,\x20weakness,\x20signs\x20of\x20pyramidal\x20tract\x20involvement,\x20and\x20carpal\x20tunnel\x20syndrome.</p>','Sporothrix\x20-\x20Itraconazole','kcISs','custom_quiz.html','All\x20of\x20the\x20following\x20side\x20effects\x20are\x20more\x20commonly\x20seen\x20with\x20carbamazepine\x20than\x20oxcarbazepine\x20except','<p><strong>Empaglifozin</strong>,\x20which\x20is\x20a\x20<strong>sodium-glucose\x20transporter-2\x20(SGLT-2)\x20inhibitor</strong>\x20has\x20been\x20recently\x20approved\x20for\x20use\x20in\x20patients\x20with\x20<strong>Heart\x20Failure\x20with\x20Reduced\x20Ejection\x20Fraction</strong>,\x20and\x20can\x20be\x20initiated\x20in\x20patients\x20with\x20<strong>impaired\x20renal\x20function</strong>\x20with\x20<strong>estimated\x20glomerular\x20filtration\x20rate\x20&gt;\x2020\x20mL/min/1.73</strong>\x20<strong>m2</strong>.</p>\x0a<p>Empagliflozin\x20works\x20by\x20inhibiting\x20the\x20sodium-glucose\x20co-transporter-2\x20<strong>(SGLT-2)</strong>\x20in\x20the\x20<strong>proximal\x20renal\x20tubules</strong>\x20resulting\x20in\x20<strong>reduced\x20reabsorption</strong>\x20and\x20<strong>increased\x20urinary\x20excretion\x20of\x20glucose</strong>.\x20The<strong>\x20glucose-lowering</strong>\x20effect\x20is\x20<strong>independent\x20of\x20insulin</strong>.\x20Empagliflozin\x20acts\x20as\x20a\x20<strong>diuretic</strong>\x20and\x20<strong>natriuretic</strong>\x20by\x20reducing\x20sodium\x20and\x20volume\x20load,\x20causing\x20intravascular\x20contraction.\x20Empagliflozin\x20is\x20also\x20associated\x20with\x20<strong>weight\x20loss</strong>,\x20with\x20<strong>reductions\x20in\x20blood\x20pressure</strong>\x20without\x20increasing\x20heart\x20rate.\x20Empagliflozin\x20has\x20been\x20found\x20to\x20<strong>decrease\x20the\x20risk\x20of\x20mortality</strong>\x20from\x20<strong>cardiovascular\x20causes\x20in\x20diabetic\x20patients</strong>.\u00a0<br\x20/><br\x20/>SGLT-2\x20inhibitors\x20have\x20a\x20<strong>cardioprotective\x20effect</strong>\x20resulting\x20from<strong>\x20improved\x20cardiac\x20cell\x20metabolism</strong>,<strong>\x20improvement\x20of\x20ventricular\x20loading\x20mechanism</strong>,\x20<strong>reduction\x20of\x20cardiac\x20cell\x20necrosis</strong>\x20and\x20<strong>fibrosis</strong>.\x20It\x20also\x20has\x20a\x20<strong>renoprotective</strong>\x20property.</p>\x0a<p><strong>Except\x20for\x20empaglifozin</strong>\x20which\x20<strong>can\x20be\x20used\x20in\x20chronic\x20kidney\x20disease</strong>,\x20use\x20of\x20<strong>other\x20SGLT-2\x20inhibitors\x20might\x20lead\x20to\x20acute\x20kidney\x20injury</strong>\x20and\x20should\x20be\x20avoided\x20in\x20patients\x20with\x20renal\x20failure.\x20<strong>Side\x20effects\x20</strong>of\u00a0<strong>empaglifozin\u00a0</strong>includes\u00a0<strong>dehydration,\x20euglycemic\x20diabetic\x20ketoacidosis,\x20urinary\x20tract\x20infections,\x20genital\x20mycotic\x20infections,\x20hypoglycemia\x20and\x20necrotizing\x20fasciitis.</strong><br\x20/><br\x20/><strong>Side</strong>\x20<strong>effects</strong>\x20of\x20<strong>SGLT-2\x20inhibitors</strong>\x20include\x20<strong>dehydration</strong>,\x20<strong>hyperkalemia</strong>,\x20<strong>worsening\x20of\x20diabetic\x20ketoacidosis</strong>,\x20increased\x20risk\x20of\x20<strong>fractures</strong>,\x20<strong>leg\x20and\x20foot\x20amputation</strong>\x20with\x20<strong>canagliflozin</strong>,\x20and\x20a\x20possible\x20increased\x20risk\x20of\x20<strong>bladder\x20cancer\x20with\x20dapagliflozin</strong>.\x20<strong>Dapagliflozin</strong>\x20has\x20also\x20been\x20recently\x20approved\x20by\x20the\x20FDA\x20for\x20treatment\x20of\x20<strong>Heart\x20failure\x20with\x20Reduced\x20Ejection\x20Fraction</strong>\x20in\x20both\x20<strong>diabetic\x20and\x20non-diabetic</strong>\x20patients,\x20it\x20has\x20been\x20associated\x20with\x20<strong>increased\x20risk</strong>\x20of\x20<strong>bladder\x20cancer</strong>\x20and<strong>\x20breast\x20cancer</strong>.\u00a0<br\x20/><br\x20/><strong>Other\x20options\x20:\u00a0<br\x20/><br\x20/></strong>Option\x20B\x20:\x20<strong>Degludec</strong>\x20is\x20a\x20form\x20of\x20<strong>long\x20acting\x20insulin</strong>,\x20and\x20is\x20not\x20indicated\x20for\x20the\x20treatment\x20of\x20heart\x20failure.<br\x20/><br\x20/>Option\x20C\x20:\x20<strong>Linagliptin</strong>\x20is\x20a\u00a0<strong>dipeptidyl\x20peptidase-4\x20(DPP-4)\x20inhibitor</strong>,\x20which\x20<strong>enhances\x20the\x20action\x20of\x20incretins</strong>\x20that\x20<strong>promote\x20the\x20release\x20of\x20insulin</strong>\x20into\x20circulation.\x20Dipeptidyl\x20peptidase-4\x20inhibitors\x20enhance\x20the\x20release\x20of\x20insulin\x20postprandially,<strong>\x20decrease\x20glucagon</strong>,\x20and\x20thereby<strong>\x20lower\x20mealtime\x20as\x20well\x20as\x20fasting\x20glucose</strong>.\x20Linagliptin\x20is<strong>\x20safe\x20to\x20use\x20in\x20chronic\x20kidney\x20disease</strong>\x20as\x20it\x20is\x20cleared\x20primarily\x20by\x20hepatobiliary\x20system,\x20but\x20is\x20<strong>not\x20approved\x20for\x20heart\x20failure</strong>.\u00a0<br\x20/><br\x20/>Option\x20D\x20:\x20<strong>Rosiglitazone</strong>\x20is\x20a\x20<strong>thiazolidinedione</strong>,\x20which\x20<strong>activates\x20PPAR-γ\x20receptors\x20</strong>in\x20adipose\x20tissue\x20and\x20skeletal\x20muscles.\x20These\x20are\x20<strong>insulin\x20sensitizers</strong>\x20and<strong>\x20increase\x20insulin-mediated\x20glucose\x20uptake</strong>\x20in\x20patients\x20with\x20type\x202\x20diabetes.\x20Rosiglitazone\x20is\x20<strong>currently\x20banned\x20in\x20India</strong>\x20as\x20it\x20has\x20shown\x20an\x20increased\x20risk\x20of\x20developing\x20<strong>myocardial\x20infarction,\x20stroke,\x20congestive\x20heart\x20failure,\x20and\x20death</strong>.\u00a0</p>','EyDkY','status','question_images','Denotes\x20safety\x20and\x20efficacy\x20in\x20the\x20population','notAttemptedResult','gHcuz','iLUnA','rhNFW','ArrowRight','Linagliptin','CQynj','Tqlmq','kZpYy','keydown','Amitriptyline','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20','cjfoE','DLrPW','Pramlinitide','Arrhythmias','Propoxyphene','userHistory','aesNR','LzLnd','NfpnT','Ethionamide','tqPfv','bind','SFQGu','289390oWcqub','iJbmL','kSusq','fRFxO','BLEqW','Candida\x20krusei\x20-\x20Fluconazole','Valproate'];_0x37ce=function(){return _0x3ac59c;};return _0x37ce();}function clearProgress(){const _0x599de6=_0x3f4b85,_0xe16106={'qXTRt':_0x599de6(0x359),'jDEnU':_0x599de6(0x2dc)},_0x49c8d3=JSON['parse'](localStorage[_0x599de6(0x25a)](_0x599de6(0x359)))||{};_0x49c8d3[quizFilename]&&(delete _0x49c8d3[quizFilename],localStorage[_0x599de6(0x23a)](_0xe16106[_0x599de6(0x31a)],JSON[_0x599de6(0x3f1)](_0x49c8d3)),console[_0x599de6(0x3f3)](_0xe16106[_0x599de6(0x40d)]));}function markQuizAsCompleted(){const _0x495f7c=_0x3f4b85,_0x1f2b5d={'beIsz':_0x495f7c(0x359),'hyBCI':'completed'},_0x12dfd4=JSON['parse'](localStorage[_0x495f7c(0x25a)](_0x1f2b5d[_0x495f7c(0x415)]))||{},_0x2757b3=questionsData[_0x495f7c(0x491)],_0x4ccf37=stats[_0x495f7c(0x43e)]||0x0;_0x12dfd4[quizFilename]={'score':_0x4ccf37,'total':_0x2757b3,'status':_0x1f2b5d[_0x495f7c(0x2cf)],'completedOn':new Date()[_0x495f7c(0x4ba)]()},localStorage['setItem'](_0x1f2b5d[_0x495f7c(0x415)],JSON[_0x495f7c(0x3f1)](_0x12dfd4));}const urlParams=new URLSearchParams(window[_0x3f4b85(0x496)][_0x3f4b85(0x382)]),startAt=parseInt(urlParams['get'](_0x3f4b85(0x3a4))),resume=urlParams[_0x3f4b85(0x4b9)](_0x3f4b85(0x455))==='true';function goBack(){const _0x3fbff4=_0x3f4b85,_0x52e55c={'fjyHB':function(_0x2108b2){return _0x2108b2();}};if(!isQuizCompleted)_0x52e55c['fjyHB'](saveProgress);window[_0x3fbff4(0x496)][_0x3fbff4(0x3ab)]=document[_0x3fbff4(0x42d)]||_0x3fbff4(0x259);}function selectMode(_0x3d9671){const _0x2d7788=_0x3f4b85,_0x10aa9c={'RucHQ':'none','SSUsD':function(_0x501b39){return _0x501b39();}};currentMode=_0x3d9671,document[_0x2d7788(0x3ce)]('modeModal')[_0x2d7788(0x263)]['display']=_0x10aa9c[_0x2d7788(0x1f5)],_0x10aa9c[_0x2d7788(0x2fe)](initializeQuiz);}function initializeQuiz(){const _0x2453a6=_0x3f4b85,_0x5a57e8={'ghWYY':_0x2453a6(0x219),'zLIpG':_0x2453a6(0x36b),'dIIxX':function(_0x4a83f7,_0x16c333){return _0x4a83f7===_0x16c333;},'AwCBi':_0x2453a6(0x33d),'JOClP':function(_0x3c7e0f,_0x3b3bde){return _0x3c7e0f===_0x3b3bde;},'gzbXi':_0x2453a6(0x275),'ASqrF':_0x2453a6(0x237),'fRFxO':_0x2453a6(0x412),'ShzZY':'none','kGPxV':_0x2453a6(0x261),'MxhWn':'submitSection','LSthS':_0x2453a6(0x2f8),'IBEJG':_0x2453a6(0x3e5),'eLHyB':_0x2453a6(0x2a4),'CKySY':function(_0x4e7bc4,_0x2da992){return _0x4e7bc4(_0x2da992);},'YxHnM':function(_0x3186c3,_0x4022c2){return _0x3186c3>=_0x4022c2;},'ZsUSJ':function(_0x5450fe,_0x32d30d){return _0x5450fe<_0x32d30d;},'aesNR':function(_0x15be81){return _0x15be81();},'SDTNc':function(_0x4fa958){return _0x4fa958();}};quizStartTime=Date[_0x2453a6(0x274)]();const _0x28c478=document['getElementById'](_0x5a57e8[_0x2453a6(0x38a)]),_0xe78aa3=document['getElementById'](_0x2453a6(0x2d5)),_0x1c1734=document[_0x2453a6(0x3ce)](_0x5a57e8[_0x2453a6(0x1ec)]),_0x24401c=_0x5a57e8[_0x2453a6(0x1e6)](currentMode,_0x5a57e8['AwCBi'])||_0x5a57e8[_0x2453a6(0x317)](currentMode,_0x5a57e8[_0x2453a6(0x1fe)]);document['getElementById'](_0x5a57e8[_0x2453a6(0x2e0)])[_0x2453a6(0x263)][_0x2453a6(0x1ed)]=_0x24401c?'none':_0x2453a6(0x261),document[_0x2453a6(0x3ce)](_0x5a57e8[_0x2453a6(0x364)])[_0x2453a6(0x263)]['display']=_0x24401c?_0x5a57e8[_0x2453a6(0x236)]:_0x5a57e8[_0x2453a6(0x214)],document[_0x2453a6(0x3ce)](_0x2453a6(0x39c))[_0x2453a6(0x263)]['display']=_0x24401c?_0x5a57e8[_0x2453a6(0x214)]:_0x5a57e8['ShzZY'],document[_0x2453a6(0x3ce)](_0x5a57e8['MxhWn'])[_0x2453a6(0x263)][_0x2453a6(0x1ed)]=_0x24401c?_0x5a57e8[_0x2453a6(0x214)]:_0x2453a6(0x49a),_0x28c478['style'][_0x2453a6(0x1ed)]=_0x24401c?_0x5a57e8[_0x2453a6(0x236)]:'flex',_0xe78aa3['style']['display']=_0x24401c?_0x5a57e8[_0x2453a6(0x1f0)]:_0x2453a6(0x49a),_0x1c1734['style'][_0x2453a6(0x1ed)]=_0x24401c?_0x5a57e8[_0x2453a6(0x1f0)]:_0x5a57e8[_0x2453a6(0x236)],(_0x5a57e8[_0x2453a6(0x1e6)](currentMode,_0x5a57e8['IBEJG'])||_0x5a57e8['JOClP'](currentMode,_0x5a57e8[_0x2453a6(0x1fe)]))&&(_0x5a57e8[_0x2453a6(0x317)](_0x2453a6(0x3a6),_0x2453a6(0x34b))?_0x29beeb=_0x210f8e[_0x2453a6(0x399)](_0x43c469=>!(_0x43c469[_0x2453a6(0x498)][_0x2453a6(0x2a6)](_0x40480d['toLowerCase']()[_0x2453a6(0x461)](/ /g,'-'))&&_0x43c469[_0x2453a6(0x1ee)]===_0x18da43)):document[_0x2453a6(0x3ce)](_0x5a57e8[_0x2453a6(0x38c)])[_0x2453a6(0x485)]['remove'](_0x2453a6(0x462))),!_0x5a57e8[_0x2453a6(0x3aa)](isNaN,startAt)&&_0x5a57e8[_0x2453a6(0x26a)](startAt,0x0)&&_0x5a57e8[_0x2453a6(0x3b1)](startAt,questionsData['length'])&&(currentQuestionIndex=startAt),_0x5a57e8[_0x2453a6(0x35a)](loadBookmarkedQuestions),_0x5a57e8[_0x2453a6(0x35a)](generateQuestionNav),updateStats(),_0x5a57e8[_0x2453a6(0x423)](displayQuestion);}function generateQuestionNav(){const _0x212921=_0x3f4b85,_0x4194cb={'FMzGT':_0x212921(0x339),'zszXK':function(_0x231471,_0x54c3a8){return _0x231471<_0x54c3a8;},'EZoFf':_0x212921(0x473),'ynURX':_0x212921(0x234),'Qbvkz':function(_0x34d934){return _0x34d934();}},_0xea8d37=document[_0x212921(0x3ce)](_0x4194cb[_0x212921(0x32d)]);_0xea8d37[_0x212921(0x271)]='';for(let _0x261d2f=0x0;_0x4194cb['zszXK'](_0x261d2f,questionsData[_0x212921(0x491)]);_0x261d2f++){const _0x43bd25=document['createElement'](_0x4194cb['EZoFf']);_0x43bd25['textContent']=_0x261d2f+0x1,_0x43bd25['className']=_0x4194cb[_0x212921(0x4b3)],_0x43bd25[_0x212921(0x2ea)]=()=>jumpToQuestion(_0x261d2f),_0x43bd25['id']=_0x212921(0x3b8)+_0x261d2f,_0xea8d37[_0x212921(0x474)](_0x43bd25);}_0x4194cb[_0x212921(0x445)](updateQuestionNav);}function updateQuestionNav(){const _0x23128e=_0x3f4b85,_0x5e3741={'ZWTgR':'userHistory','LGCFZ':_0x23128e(0x2dc),'xDbhP':function(_0x425dab){return _0x425dab();},'FGJdX':_0x23128e(0x22b),'IBOBj':function(_0x3430ea,_0x14f71c){return _0x3430ea<_0x14f71c;},'AseYs':function(_0x3ed430,_0x39a061){return _0x3ed430===_0x39a061;},'NiRDi':function(_0x336ab1,_0x33ed54){return _0x336ab1===_0x33ed54;},'qLJMz':_0x23128e(0x43d),'QSdIm':'nav-btn-current','RYCyS':_0x23128e(0x299),'EyJTH':function(_0x11ec8b,_0x2286d7){return _0x11ec8b!==_0x2286d7;},'NNZyd':_0x23128e(0x3bb),'cOvHR':_0x23128e(0x3da),'nwNLT':_0x23128e(0x419),'eUrXz':function(_0x33db0e,_0x2a4a18){return _0x33db0e===_0x2a4a18;},'kcISs':_0x23128e(0x439),'BhYMS':_0x23128e(0x3e5),'FjttR':_0x23128e(0x41b),'yfRfc':_0x23128e(0x45b),'MKORB':_0x23128e(0x3cc),'xftcE':_0x23128e(0x238),'UYrJY':function(_0xefe357,_0xfcfe5f){return _0xefe357===_0xfcfe5f;},'PbddP':_0x23128e(0x41d),'Rnryk':function(_0x532411,_0x5d1dd3){return _0x532411!==_0x5d1dd3;},'LiXNM':'nav-btn-answered'};for(let _0x2ea753=0x0;_0x5e3741[_0x23128e(0x3fa)](_0x2ea753,questionsData[_0x23128e(0x491)]);_0x2ea753++){const _0x30c802=document[_0x23128e(0x3ce)](_0x23128e(0x3b8)+_0x2ea753),_0x74a1f6=questionStates[_0x2ea753];let _0x31c361='';if(_0x5e3741['AseYs'](_0x2ea753,currentQuestionIndex))_0x5e3741[_0x23128e(0x46f)](_0x23128e(0x2c2),_0x5e3741[_0x23128e(0x2b5)])?(delete _0x1da12e[_0x262a4e],_0x5cd478[_0x23128e(0x23a)](_0x5e3741['ZWTgR'],_0x44798b[_0x23128e(0x3f1)](_0x1314a1)),_0x172ef2['log'](_0x5e3741[_0x23128e(0x47f)])):_0x31c361=_0x5e3741['QSdIm'];else{if(_0x74a1f6['bookmarked'])_0x31c361=_0x5e3741[_0x23128e(0x304)];else{if(_0x74a1f6[_0x23128e(0x2a2)])_0x5e3741[_0x23128e(0x36e)](_0x5e3741[_0x23128e(0x1fa)],_0x5e3741['cOvHR'])?_0x31c361=_0x5e3741[_0x23128e(0x3b3)]:_0x5e3741[_0x23128e(0x37e)](_0x50abe5);else{if(_0x5e3741[_0x23128e(0x3b9)](currentMode,_0x5e3741[_0x23128e(0x340)])||currentMode===_0x5e3741[_0x23128e(0x326)]){if(_0x5e3741[_0x23128e(0x46f)](_0x74a1f6[_0x23128e(0x345)],_0x23128e(0x3d7)))_0x31c361=_0x5e3741[_0x23128e(0x242)];else{if(_0x5e3741[_0x23128e(0x37d)](_0x74a1f6['status'],_0x5e3741['yfRfc']))_0x31c361=_0x5e3741[_0x23128e(0x44b)];else _0x31c361=_0x5e3741[_0x23128e(0x369)];}}else{if(_0x5e3741['UYrJY'](_0x23128e(0x41d),_0x5e3741[_0x23128e(0x478)])){if(_0x5e3741['Rnryk'](_0x74a1f6['selectedAnswer'],null))_0x31c361=_0x5e3741[_0x23128e(0x2d6)];else _0x31c361=_0x23128e(0x238);}else{if(_0x32437b[_0x23128e(0x4ae)]()){const _0x2663de=new _0x396f2f();_0x2663de['loadSource'](_0x1bb4a7),_0x2663de[_0x23128e(0x404)](_0x450749);}else _0xdcf471[_0x23128e(0x2a9)](_0x5e3741['FGJdX'])&&(_0x4aca41[_0x23128e(0x390)]=_0x5574a6);}}}}}_0x30c802[_0x23128e(0x441)]=_0x23128e(0x353)+_0x31c361;}}function jumpToQuestion(_0x4b7c5e){const _0x150a57=_0x3f4b85,_0x4334f0={'okibf':'button','GFOKJ':function(_0x15e6c9,_0x545c14){return _0x15e6c9+_0x545c14;},'cjfoE':_0x150a57(0x234),'qvelb':function(_0x40e1db,_0x1c7a76){return _0x40e1db>=_0x1c7a76;},'gcLRx':function(_0x6a3452,_0x33f29f){return _0x6a3452<_0x33f29f;},'pAbJw':function(_0x27d993,_0x383d0d){return _0x27d993===_0x383d0d;},'cCfSM':_0x150a57(0x32e),'mUhkH':function(_0x492350,_0x198b2a){return _0x492350-_0x198b2a;},'YLiRv':function(_0x50f039){return _0x50f039();}};if(_0x4334f0[_0x150a57(0x4bd)](_0x4b7c5e,0x0)&&_0x4334f0[_0x150a57(0x33a)](_0x4b7c5e,questionsData[_0x150a57(0x491)])){if(questionStartTime){if(_0x4334f0[_0x150a57(0x497)](_0x150a57(0x344),_0x4334f0[_0x150a57(0x46a)])){const _0x59db0d=_0x3e253d['createElement'](_0x4334f0['okibf']);_0x59db0d['textContent']=_0x4334f0['GFOKJ'](_0xda41cb,0x1),_0x59db0d[_0x150a57(0x441)]=_0x4334f0[_0x150a57(0x354)],_0x59db0d[_0x150a57(0x2ea)]=()=>_0x1e65dd(_0x3e5b4d),_0x59db0d['id']=_0x150a57(0x3b8)+_0x33933e,_0x55c3c1[_0x150a57(0x474)](_0x59db0d);}else questionStates[currentQuestionIndex]['timeSpent']+=_0x4334f0['mUhkH'](Date[_0x150a57(0x274)](),questionStartTime);}currentQuestionIndex=_0x4b7c5e,_0x4334f0[_0x150a57(0x3f4)](displayQuestion),_0x4334f0[_0x150a57(0x3f4)](saveProgress);}}function updateStats(){const _0x5331a0=_0x3f4b85,_0x2438fd={'YnElJ':'nav-btn-marked-review','yxZou':function(_0xf276ef,_0x45be5e){return _0xf276ef===_0x45be5e;},'Cssez':_0x5331a0(0x439),'aKFEa':function(_0x4030e2,_0x10433c){return _0x4030e2===_0x10433c;},'KnjWp':function(_0x449c2b,_0x12c264){return _0x449c2b!==_0x12c264;},'MyqBc':_0x5331a0(0x4b5),'QZjVu':_0x5331a0(0x3d1),'DcuFn':_0x5331a0(0x484),'ZPhvn':_0x5331a0(0x487),'jSHqR':_0x5331a0(0x409),'RqnjM':function(_0x38a406,_0x50d864){return _0x38a406*_0x50d864;},'WNDWa':function(_0x57eda0,_0x32a56d){return _0x57eda0/_0x32a56d;},'HEKld':'accuracy','YPOyL':function(_0x4cef8f,_0x1fcf3c){return _0x4cef8f+_0x1fcf3c;},'NBxWF':function(_0x59c557,_0x5afe7c){return _0x59c557/_0x5afe7c;},'aFuPt':function(_0xd48a2e,_0x4935d7){return _0xd48a2e%_0x4935d7;},'sVBXn':_0x5331a0(0x40e),'aOrmR':function(_0x16c191,_0xb8922b){return _0x16c191+_0xb8922b;}};if(_0x2438fd[_0x5331a0(0x2bf)](currentMode,_0x2438fd[_0x5331a0(0x1f6)])||_0x2438fd[_0x5331a0(0x447)](currentMode,_0x5331a0(0x3e5))){if(_0x2438fd[_0x5331a0(0x2dd)](_0x2438fd[_0x5331a0(0x2db)],_0x2438fd[_0x5331a0(0x475)])){document[_0x5331a0(0x3ce)](_0x2438fd['DcuFn'])[_0x5331a0(0x463)]=stats[_0x5331a0(0x43e)],document[_0x5331a0(0x3ce)](_0x2438fd[_0x5331a0(0x31f)])[_0x5331a0(0x463)]=stats[_0x5331a0(0x426)],document[_0x5331a0(0x3ce)](_0x2438fd[_0x5331a0(0x3d3)])[_0x5331a0(0x463)]=stats[_0x5331a0(0x409)];const _0x4558d0=stats[_0x5331a0(0x409)]>0x0?Math[_0x5331a0(0x272)](_0x2438fd[_0x5331a0(0x48d)](_0x2438fd[_0x5331a0(0x37c)](stats[_0x5331a0(0x43e)],stats[_0x5331a0(0x409)]),0x64)):0x0;document[_0x5331a0(0x3ce)](_0x2438fd['HEKld'])[_0x5331a0(0x463)]=_0x2438fd['YPOyL'](_0x4558d0,'%'),stats['totalTime']=questionStates[_0x5331a0(0x205)]((_0x1d4c55,_0x508ec2)=>_0x1d4c55+_0x508ec2[_0x5331a0(0x40e)],0x0);const _0x24a9f0=Math[_0x5331a0(0x3a3)](_0x2438fd['NBxWF'](stats['totalTime'],0x3e8)),_0x5a0622=Math[_0x5331a0(0x3a3)](_0x2438fd[_0x5331a0(0x37c)](_0x24a9f0,0x3c)),_0xdbe085=_0x2438fd[_0x5331a0(0x440)](_0x24a9f0,0x3c);document[_0x5331a0(0x3ce)](_0x2438fd[_0x5331a0(0x3ba)])['textContent']=_0x2438fd[_0x5331a0(0x30d)](_0x2438fd[_0x5331a0(0x30d)](_0x5a0622,':'),_0xdbe085[_0x5331a0(0x23f)]()[_0x5331a0(0x3c2)](0x2,'0'));}else _0x9b95b6=_0x2438fd[_0x5331a0(0x285)];}}function setupVideo(_0x12c5c7,_0x38824c){const _0xbdfe5f=_0x3f4b85,_0x9bb192={'LptAR':function(_0x7d8cf5,_0x445e17){return _0x7d8cf5===_0x445e17;},'gTxvu':function(_0x3046f2,_0x2977cd){return _0x3046f2===_0x2977cd;},'DOcmc':'border-gray-600','hdcTe':_0xbdfe5f(0x4a3),'dzrhX':function(_0x379002,_0x58285c){return _0x379002+_0x58285c;},'Npqnd':_0xbdfe5f(0x2c1),'aurmL':_0xbdfe5f(0x22b),'nrWTx':function(_0x58e239,_0x21a042){return _0x58e239!==_0x21a042;},'DUhnr':'iuscH'};if(Hls[_0xbdfe5f(0x4ae)]()){if(_0x9bb192[_0xbdfe5f(0x4bb)](_0x9bb192[_0xbdfe5f(0x39e)],_0x9bb192[_0xbdfe5f(0x39e)])){const _0x4dc2d2=new Hls();_0x4dc2d2['loadSource'](_0x38824c),_0x4dc2d2['attachMedia'](_0x12c5c7);}else _0x3f49e7[_0x5c3fb1]['timeSpent']+=_0x273c1e['now']()-_0x5d2d9b,_0x344ecb=_0xf5f0ed[_0xbdfe5f(0x274)]();}else{if(_0x12c5c7[_0xbdfe5f(0x2a9)](_0x9bb192[_0xbdfe5f(0x2c0)])){if(_0x9bb192[_0xbdfe5f(0x3ed)](_0xbdfe5f(0x2e5),_0x9bb192[_0xbdfe5f(0x26d)]))_0x12c5c7['src']=_0x38824c;else{const _0x140a7b=_0x9bb192[_0xbdfe5f(0x2bc)](_0x3310d0[_0xbdfe5f(0x482)],_0x1fd68d),_0x216635=_0x9bb192['gTxvu'](_0x5e346b['id'],_0x54d94f);let _0x397a20=_0x9bb192['DOcmc'];if(_0x216635)_0x397a20='border-green-500';else{if(_0x140a7b)_0x397a20=_0x9bb192[_0xbdfe5f(0x322)];}return _0xbdfe5f(0x47a)+_0x397a20+'\x22><span\x20class=\x22font-bold\x20mr-3\x22>'+_0xe46ec4[_0xbdfe5f(0x2ca)](_0x9bb192[_0xbdfe5f(0x22f)](0x41,_0x27de6a))+_0xbdfe5f(0x3de)+_0x4a5eed[_0xbdfe5f(0x288)]+_0xbdfe5f(0x1ef);}}}}function displayQuestion(){const _0x4c706f=_0x3f4b85,_0xc19408={'kkYEc':'userHistory','Nsobf':_0x4c706f(0x2f9),'mFDbC':_0x4c706f(0x305),'KblcZ':function(_0x248f97,_0x4f2e04){return _0x248f97===_0x4f2e04;},'crifC':_0x4c706f(0x3a7),'fPEZx':function(_0x592ec2,_0x2f102f){return _0x592ec2+_0x2f102f;},'ZzbdF':_0x4c706f(0x428),'cImuC':_0x4c706f(0x325),'VUMcs':_0x4c706f(0x43a),'jePRd':_0x4c706f(0x430),'HkaKo':function(_0xebc58,_0x5f10bb){return _0xebc58(_0x5f10bb);},'yuWoH':'data-option-index','DdGVS':function(_0x1aa62b,_0x5ab248){return _0x1aa62b(_0x5ab248);},'JZEJm':_0x4c706f(0x45b),'Oiren':_0x4c706f(0x425),'rwahU':_0x4c706f(0x2a8),'UmYeZ':_0x4c706f(0x456),'vlcFU':function(_0x17bbed,_0x2dd026){return _0x17bbed*_0x2dd026;},'EABxh':function(_0x501467,_0x4ae2a8){return _0x501467/_0x4ae2a8;},'NiwBt':'progressBar','BLEqW':'currentQuestion','MtTxr':function(_0x5e5e2a,_0x3bf36c){return _0x5e5e2a===_0x3bf36c;},'vXlSi':_0x4c706f(0x44f),'XvdSf':_0x4c706f(0x462),'kqfeb':_0x4c706f(0x4a7),'vWZSg':_0x4c706f(0x321),'TjjIK':_0x4c706f(0x22a),'anAxj':_0x4c706f(0x480),'QunjU':function(_0x1c75c3){return _0x1c75c3();},'Bvvve':_0x4c706f(0x3e5),'GVqhu':_0x4c706f(0x275),'PxqYT':_0x4c706f(0x212)};if(!questionsData||_0xc19408['KblcZ'](questionsData[_0x4c706f(0x491)],0x0)){document['getElementById'](_0xc19408[_0x4c706f(0x278)])[_0x4c706f(0x271)]=_0xc19408[_0x4c706f(0x3ff)];return;};const _0x311692=questionsData[currentQuestionIndex];questionStartTime=Date[_0x4c706f(0x274)](),selectedOption=questionStates[currentQuestionIndex][_0x4c706f(0x482)];const _0x234773=_0xc19408[_0x4c706f(0x332)](_0xc19408[_0x4c706f(0x327)](_0xc19408['fPEZx'](currentQuestionIndex,0x1),questionsData[_0x4c706f(0x491)]),0x64);document[_0x4c706f(0x3ce)](_0xc19408[_0x4c706f(0x3ea)])[_0x4c706f(0x263)]['width']=_0x234773+'%',document[_0x4c706f(0x3ce)](_0xc19408[_0x4c706f(0x365)])[_0x4c706f(0x463)]=_0xc19408[_0x4c706f(0x4ab)](currentQuestionIndex,0x1),updateQuestionNav(),document[_0x4c706f(0x3ce)](_0x4c706f(0x4b6))['disabled']=_0xc19408[_0x4c706f(0x2cd)](currentQuestionIndex,0x0),document['getElementById'](_0xc19408[_0x4c706f(0x2ee)])['classList']['add'](_0xc19408['XvdSf']),document[_0x4c706f(0x3ce)](_0xc19408[_0x4c706f(0x278)])[_0x4c706f(0x271)]=_0x311692[_0x4c706f(0x288)]||_0xc19408['kqfeb'];let _0x28bc4e='';if(_0x311692['question_audio'])_0x28bc4e+=_0x4c706f(0x2ec)+_0x311692[_0x4c706f(0x225)]+_0x4c706f(0x4a8);if(_0x311692[_0x4c706f(0x48a)])_0x28bc4e+=_0x4c706f(0x3e2)+_0x311692[_0x4c706f(0x48a)]+_0x4c706f(0x23b);_0x311692[_0x4c706f(0x346)]&&_0x311692['question_images'][_0x4c706f(0x2da)](_0x127682=>{const _0x23064d=_0x4c706f;if(_0xc19408['KblcZ'](_0xc19408['crifC'],_0xc19408[_0x23064d(0x374)])){if(_0x127682)_0x28bc4e+='<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22'+_0x127682+'\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>';}else{const _0x571b7e=_0x2fba94[_0x23064d(0x249)](_0x57e882[_0x23064d(0x25a)](_0xc19408[_0x23064d(0x229)]))||{},_0x48ab28=_0x571b7e[_0x4af3ab];if(_0x48ab28){const _0x4d7eae=_0xc19408['Nsobf'][_0x23064d(0x3dd)]('|');let _0x390a74=0x0;while(!![]){switch(_0x4d7eae[_0x390a74++]){case'0':_0x23d046['log'](_0xc19408[_0x23064d(0x421)]);continue;case'1':_0x147b72=_0x48ab28[_0x23064d(0x268)];continue;case'2':_0xe014b3=_0x48ab28['currentMode'];continue;case'3':_0x31e6aa=_0x48ab28['currentQuestionIndex'];continue;case'4':_0x42a186=_0x48ab28[_0x23064d(0x1f9)];continue;case'5':return!![];}break;}}return![];}});document[_0x4c706f(0x3ce)](_0xc19408[_0x4c706f(0x4af)])[_0x4c706f(0x271)]=_0x28bc4e;const _0x2c4041=document['getElementById'](_0xc19408['TjjIK']);_0x2c4041[_0x4c706f(0x271)]='',_0x2c4041[_0x4c706f(0x485)][_0x4c706f(0x2e9)](_0xc19408[_0x4c706f(0x333)]),_0x311692['choices']&&Array[_0x4c706f(0x469)](_0x311692['choices'])&&(_0x311692[_0x4c706f(0x2f1)]['forEach']((_0x277230,_0x34a4d4)=>{const _0x741c13=_0x4c706f,_0x2a301b=String[_0x741c13(0x2ca)](_0xc19408[_0x741c13(0x4ab)](0x41,_0x34a4d4)),_0x5f5070=_0xc19408[_0x741c13(0x44e)](selectedOption,_0x34a4d4),_0x31ca68=document['createElement'](_0xc19408['ZzbdF']);_0x31ca68[_0x741c13(0x271)]=_0x741c13(0x2a5)+(_0x5f5070?_0xc19408[_0x741c13(0x221)]:'')+_0x741c13(0x407)+_0x34a4d4+'\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>'+_0x2a301b+_0x741c13(0x3bf)+(_0x277230['text']||_0xc19408[_0x741c13(0x3f9)]+(_0x34a4d4+0x1))+_0x741c13(0x291),_0x2c4041['appendChild'](_0x31ca68);}),_0x2c4041[_0x4c706f(0x377)](_0x4c706f(0x468),function(_0x3f18fc){const _0x2a32ff=_0x4c706f,_0x34fbfc=_0x3f18fc[_0x2a32ff(0x467)][_0x2a32ff(0x477)](_0xc19408['jePRd']);if(_0x34fbfc){const _0x49df7b=_0xc19408['HkaKo'](parseInt,_0x34fbfc[_0x2a32ff(0x32c)](_0xc19408['yuWoH']));_0xc19408[_0x2a32ff(0x273)](selectOption,_0x49df7b);}})),updateBookmarkButton(),_0xc19408[_0x4c706f(0x232)](updateMarkReviewButton),(currentMode===_0xc19408[_0x4c706f(0x395)]||_0xc19408[_0x4c706f(0x2cd)](currentMode,_0xc19408[_0x4c706f(0x30b)]))&&!isQuizCompleted&&(_0xc19408['MtTxr'](_0xc19408[_0x4c706f(0x42c)],'snvQQ')?_0xc19408[_0x4c706f(0x232)](startTimer):(_0x1ccc6d=_0xc19408['JZEJm'],_0x51e2eb=_0xc19408[_0x4c706f(0x226)]));}function selectOption(_0x5675fc){const _0x9e8e8c=_0x3f4b85,_0x5376ac={'LxmIT':'selected','diYcU':function(_0x44f603,_0x59e058){return _0x44f603===_0x59e058;},'EfbNI':_0x9e8e8c(0x22a),'LbpLC':_0x9e8e8c(0x480),'NZxhy':'timed_study','EYHcj':function(_0x37c690){return _0x37c690();},'osKpP':_0x9e8e8c(0x323)},_0xe3811d=document[_0x9e8e8c(0x3ce)](_0x5376ac['EfbNI']);if(_0xe3811d[_0x9e8e8c(0x485)][_0x9e8e8c(0x386)](_0x5376ac['LbpLC']))return;questionStartTime&&(questionStates[currentQuestionIndex][_0x9e8e8c(0x40e)]+=Date[_0x9e8e8c(0x274)]()-questionStartTime,questionStartTime=Date[_0x9e8e8c(0x274)]()),selectedOption=_0x5675fc,questionStates[currentQuestionIndex][_0x9e8e8c(0x482)]=_0x5675fc,document[_0x9e8e8c(0x2b8)](_0x9e8e8c(0x430))['forEach']((_0x24a092,_0x146e4b)=>{const _0x4759f9=_0x9e8e8c;_0x24a092[_0x4759f9(0x485)][_0x4759f9(0x41a)](_0x5376ac[_0x4759f9(0x2b2)],_0x5376ac[_0x4759f9(0x28d)](_0x146e4b,_0x5675fc));}),_0x5376ac['diYcU'](currentMode,_0x9e8e8c(0x439))||currentMode===_0x5376ac[_0x9e8e8c(0x411)]?_0x5376ac[_0x9e8e8c(0x30f)](processAnswer):(_0x5376ac[_0x9e8e8c(0x28d)](questionStates[currentQuestionIndex]['status'],_0x5376ac['osKpP'])&&(questionStates[currentQuestionIndex][_0x9e8e8c(0x345)]=_0x5376ac['LbpLC'],stats[_0x9e8e8c(0x409)]++,stats[_0x9e8e8c(0x3be)]--),_0x5376ac['EYHcj'](updateQuestionNav)),_0x5376ac[_0x9e8e8c(0x30f)](saveProgress);}function processAnswer(){const _0x7b8998=_0x3f4b85,_0x4deb83={'fHUKP':function(_0x24b556,_0x1b0009){return _0x24b556===_0x1b0009;},'piGla':_0x7b8998(0x323),'GlUgb':_0x7b8998(0x3d7),'TJQNs':function(_0x3a37d0){return _0x3a37d0();},'UtBGn':function(_0x27926e,_0x2284e0){return _0x27926e(_0x2284e0);},'JlgcA':function(_0x5d95e0){return _0x5d95e0();}},_0x19cab4=questionsData[currentQuestionIndex],_0x266821=_0x19cab4['correct_choice_id'];if(_0x4deb83[_0x7b8998(0x2ac)](selectedOption,null))return;const _0x7caecf=_0x19cab4[_0x7b8998(0x2f1)][selectedOption],_0x37eb25=_0x7caecf['id']===_0x266821;if(_0x4deb83[_0x7b8998(0x2ac)](questionStates[currentQuestionIndex]['status'],_0x4deb83[_0x7b8998(0x277)])){stats['totalAttempted']++,stats[_0x7b8998(0x3be)]--;if(_0x37eb25)stats[_0x7b8998(0x43e)]++;else stats[_0x7b8998(0x426)]++;}questionStates[currentQuestionIndex][_0x7b8998(0x345)]=_0x37eb25?_0x4deb83[_0x7b8998(0x20f)]:'incorrect',_0x4deb83['TJQNs'](updateStats),_0x4deb83[_0x7b8998(0x48c)](showInlineFeedback,_0x37eb25),_0x4deb83[_0x7b8998(0x397)](updateQuestionNav);}function showInlineFeedback(_0x169d66){const _0x44f738=_0x3f4b85,_0x131039={'SKDAA':'npQpk','DCEvO':_0x44f738(0x2de),'wOWfe':_0x44f738(0x325),'foUXU':function(_0x578e89,_0xa8ba7a){return _0x578e89===_0xa8ba7a;},'aIXfS':_0x44f738(0x3d7),'ftqKs':function(_0x1b8250,_0x33647a){return _0x1b8250!==_0x33647a;},'oFpCD':'study','dMpJL':_0x44f738(0x3e5),'ghAmo':_0x44f738(0x430),'FRAJl':'answered'};if(_0x131039['ftqKs'](currentMode,_0x131039[_0x44f738(0x245)])&&_0x131039[_0x44f738(0x27f)](currentMode,_0x131039[_0x44f738(0x2b6)]))return;const _0x428883=document[_0x44f738(0x3ce)](_0x44f738(0x22a)),_0x4fb275=_0x428883[_0x44f738(0x2b8)](_0x131039['ghAmo']),_0x1951d7=questionsData[currentQuestionIndex],_0x3b19ef=_0x1951d7[_0x44f738(0x3d5)];let _0x52914d=_0x1951d7['choices']['findIndex'](_0x39a57d=>_0x39a57d['id']===_0x3b19ef);_0x428883[_0x44f738(0x485)][_0x44f738(0x2bb)](_0x131039[_0x44f738(0x3d6)]),_0x4fb275['forEach']((_0x21fb94,_0x119157)=>{const _0x2f6bc3=_0x44f738;if(_0x131039[_0x2f6bc3(0x24e)]===_0x131039[_0x2f6bc3(0x4aa)])_0x48a697[_0x2f6bc3(0x346)][_0x2f6bc3(0x2da)](_0x46dec7=>{if(_0x46dec7)_0x4649b1+='<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22'+_0x46dec7+'\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>';});else{_0x21fb94['classList']['remove'](_0x131039['wOWfe']);if(_0x131039[_0x2f6bc3(0x422)](_0x119157,_0x52914d))_0x21fb94[_0x2f6bc3(0x485)]['add'](_0x131039[_0x2f6bc3(0x1f8)]);else{if(_0x131039[_0x2f6bc3(0x422)](_0x119157,selectedOption)&&!_0x169d66)_0x21fb94[_0x2f6bc3(0x485)][_0x2f6bc3(0x2bb)](_0x2f6bc3(0x45b));}}}),showSolution();}function showSolution(){const _0x161568=_0x3f4b85,_0x3231bd={'ZBxzQ':_0x161568(0x3d7),'HTXol':_0x161568(0x46e),'LbsqM':_0x161568(0x45b),'cprfP':'Incorrect','MykuD':function(_0x1fb8ff){return _0x1fb8ff();},'zKKZU':_0x161568(0x2e7),'Wtclx':function(_0x2a30ae,_0x51b92e){return _0x2a30ae!==_0x51b92e;},'gLbCP':_0x161568(0x3e5),'ShoZW':_0x161568(0x2ef),'bPvCs':_0x161568(0x20c),'bxsnw':_0x161568(0x231),'aRKaJ':'explanationVideoPlayer','NUYTe':function(_0x482c61,_0x540422){return _0x482c61===_0x540422;},'akaXv':_0x161568(0x21d),'lkqjp':_0x161568(0x222),'bFUNr':_0x161568(0x462),'JVxOx':function(_0x115a3d,_0x264fc8,_0x2b88e0){return _0x115a3d(_0x264fc8,_0x2b88e0);},'EtPSO':_0x161568(0x479),'Jyqvb':function(_0x16d4c0,_0x367d2a){return _0x16d4c0!==_0x367d2a;},'ZbFLt':_0x161568(0x336),'Eujgr':_0x161568(0x44f)};if(_0x3231bd[_0x161568(0x1ff)](currentMode,_0x161568(0x439))&&_0x3231bd[_0x161568(0x1ff)](currentMode,_0x3231bd[_0x161568(0x300)]))return;const _0x3768d5=questionsData[currentQuestionIndex];document[_0x161568(0x3ce)](_0x3231bd[_0x161568(0x207)])[_0x161568(0x271)]=_0x3768d5[_0x161568(0x47d)]||_0x3231bd[_0x161568(0x230)];const _0x1122c9=document[_0x161568(0x3ce)](_0x3231bd[_0x161568(0x307)]),_0x1fc02d=document[_0x161568(0x3ce)](_0x3231bd[_0x161568(0x246)]),_0x53c07f=_0x3768d5['explanation_video'];if(_0x53c07f){if(_0x3231bd[_0x161568(0x282)](_0x3231bd[_0x161568(0x2b0)],_0x3231bd['lkqjp'])){const _0x522606=_0x4fde02['choices'][_0x580a8a[_0x161568(0x482)]];_0x522606['id']===_0x2dd9d9?(_0x37fd97=_0x3231bd['ZBxzQ'],_0x56ffa6=_0x3231bd[_0x161568(0x293)]):(_0x1e45c5=_0x3231bd[_0x161568(0x2b1)],_0x5d7e7d=_0x3231bd[_0x161568(0x45c)]);}else{_0x1122c9[_0x161568(0x485)][_0x161568(0x2e9)](_0x3231bd[_0x161568(0x380)]);if(_0x53c07f[_0x161568(0x2a6)](_0x161568(0x383)))_0x3231bd[_0x161568(0x42e)](setupVideo,_0x1fc02d,_0x53c07f);else _0x1fc02d[_0x161568(0x390)]=_0x53c07f;}}else _0x1122c9['classList']['add']('hidden');const _0x282256=document[_0x161568(0x3ce)](_0x3231bd[_0x161568(0x218)]);_0x282256['innerHTML']='';_0x3768d5[_0x161568(0x334)]&&(_0x282256['innerHTML']+=_0x161568(0x29d)+_0x3768d5['explanation_audio_eng']+_0x161568(0x4a8));_0x3768d5[_0x161568(0x3b2)]&&(_0x282256[_0x161568(0x271)]+=_0x161568(0x46c)+_0x3768d5['explanation_audio_hin']+_0x161568(0x4a8));const _0x3a3c11=document[_0x161568(0x3ce)]('solutionImages');_0x3a3c11['innerHTML']='',_0x3768d5[_0x161568(0x3d8)]&&(_0x3231bd[_0x161568(0x393)](_0x3231bd[_0x161568(0x33c)],_0x161568(0x336))?_0x3231bd[_0x161568(0x492)](_0x48da9a):_0x3768d5[_0x161568(0x3d8)][_0x161568(0x2da)](_0x29b31e=>{const _0x17106c=_0x161568;if(_0x3231bd['zKKZU']!==_0x17106c(0x45f)){if(_0x29b31e)_0x3a3c11[_0x17106c(0x271)]+=_0x17106c(0x2f3)+_0x29b31e+_0x17106c(0x3b5);}else _0x153f8c['preventDefault'](),_0x21c7a9();})),document[_0x161568(0x3ce)](_0x3231bd['Eujgr'])[_0x161568(0x485)][_0x161568(0x2e9)](_0x3231bd['bFUNr']);}function submitQuiz(){const _0x41849c=_0x3f4b85,_0xb6d2c={'oPGiQ':function(_0x33d737,_0x23d204){return _0x33d737===_0x23d204;},'hvZWj':_0x41849c(0x3d7),'PMbqN':function(_0x45dfec,_0x3b9506){return _0x45dfec===_0x3b9506;},'ZTppK':_0x41849c(0x45b),'fhFce':function(_0x12a61f,_0x543696){return _0x12a61f/_0x543696;},'NJKdb':_0x41849c(0x3bd),'urupu':function(_0x32a86c,_0x49c646){return _0x32a86c+_0x49c646;},'AoGkX':'answered','qjjwi':function(_0x318f7f,_0x3239f4){return _0x318f7f!==_0x3239f4;},'kyWrU':_0x41849c(0x240),'JTrSZ':'zcQob','qHLUp':function(_0x26051d,_0x4f1334){return _0x26051d===_0x4f1334;},'FImFs':_0x41849c(0x32f),'ybgQR':_0x41849c(0x316),'AgHlZ':function(_0x147a67,_0x3591f1){return _0x147a67===_0x3591f1;},'jenMJ':function(_0x2aefb0,_0x2cf319){return _0x2aefb0===_0x2cf319;},'SFQGu':_0x41849c(0x2fd),'WogLv':function(_0x3646c3,_0x4e12bd){return _0x3646c3(_0x4e12bd);},'rpRnq':function(_0xa39667,_0x225aea){return _0xa39667(_0x225aea);},'CFRyk':_0x41849c(0x387),'DLrPW':function(_0x20eb42,_0x13d521){return _0x20eb42-_0x13d521;},'njxlM':_0x41849c(0x2d4),'bBNYo':function(_0x4976ee,_0x3e30e7){return _0x4976ee-_0x3e30e7;}};if(timer)_0xb6d2c[_0x41849c(0x44c)](clearInterval,timer);if(!_0xb6d2c['rpRnq'](confirm,_0xb6d2c[_0x41849c(0x227)]))return;isQuizCompleted=!![];let _0x12e51=0x0,_0x3abe72=0x0;const _0x485f9d=_0xb6d2c[_0x41849c(0x355)](Date['now'](),quizStartTime);questionsData[_0x41849c(0x2da)]((_0x4c5984,_0x37453e)=>{const _0x4b94a1=_0x41849c,_0x11ce46={'fLFVT':function(_0x4303ec,_0x50fdc3){const _0x192d16=_0x2dfa;return _0xb6d2c[_0x192d16(0x40c)](_0x4303ec,_0x50fdc3);},'iubaJ':_0xb6d2c[_0x4b94a1(0x3f6)],'frgvE':function(_0x372d90,_0x1ab434){const _0x6c11ae=_0x4b94a1;return _0xb6d2c[_0x6c11ae(0x25d)](_0x372d90,_0x1ab434);},'zAXIb':function(_0x447a30,_0x7c86d1){return _0x447a30+_0x7c86d1;},'kitHv':_0xb6d2c['AoGkX']};if(_0xb6d2c['qjjwi'](_0xb6d2c[_0x4b94a1(0x223)],_0xb6d2c[_0x4b94a1(0x2c9)])){const _0x37190e=questionStates[_0x37453e];if(_0x37190e['selectedAnswer']!==null){if(_0xb6d2c[_0x4b94a1(0x25e)](_0xb6d2c['FImFs'],_0xb6d2c[_0x4b94a1(0x453)])){if(_0xb6d2c[_0x4b94a1(0x2f5)](_0x104550['status'],_0xb6d2c[_0x4b94a1(0x370)]))_0x57cf14='nav-btn-correct';else{if(_0xb6d2c['PMbqN'](_0x5a5faa[_0x4b94a1(0x345)],_0xb6d2c[_0x4b94a1(0x29a)]))_0x51ad9f=_0x4b94a1(0x3cc);else _0x59b1f3=_0x4b94a1(0x238);}}else{if(_0xb6d2c[_0x4b94a1(0x4bc)](_0x4c5984[_0x4b94a1(0x2f1)][_0x37190e[_0x4b94a1(0x482)]]['id'],_0x4c5984[_0x4b94a1(0x3d5)])){if(_0xb6d2c['jenMJ'](_0xb6d2c['SFQGu'],_0xb6d2c[_0x4b94a1(0x360)]))_0x12e51++,_0x37190e[_0x4b94a1(0x345)]=_0xb6d2c['hvZWj'];else{const _0x661590=_0x5ece7b['floor'](_0x11ce46[_0x4b94a1(0x471)](_0x7bfad1,0x3c)),_0x5ad706=_0x31240a%0x3c;_0xf26b88[_0x4b94a1(0x3ce)](_0x11ce46[_0x4b94a1(0x338)])[_0x4b94a1(0x463)]=_0x11ce46[_0x4b94a1(0x400)](_0x11ce46['zAXIb'](_0x661590,':'),_0x5ad706[_0x4b94a1(0x23f)]()[_0x4b94a1(0x3c2)](0x2,'0'));}}else _0x3abe72++,_0x37190e[_0x4b94a1(0x345)]=_0xb6d2c[_0x4b94a1(0x29a)];}}}else _0x4f7fea[_0x5d09b3][_0x4b94a1(0x345)]=_0x11ce46['kitHv'],_0x4d9414[_0x4b94a1(0x409)]++,_0x36e1d4['notAttempted']--;});const _0xe53cb5=JSON[_0x41849c(0x249)](localStorage[_0x41849c(0x25a)](_0xb6d2c['njxlM']))||[];_0xe53cb5[_0x41849c(0x4a0)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0x41849c(0x274)](),'totalTime':_0x485f9d,'stats':{'correct':_0x12e51,'incorrect':_0x3abe72,'notAttempted':_0xb6d2c[_0x41849c(0x414)](questionsData[_0x41849c(0x491)],_0xb6d2c[_0x41849c(0x25d)](_0x12e51,_0x3abe72))}}),localStorage[_0x41849c(0x23a)](_0x41849c(0x2d4),JSON[_0x41849c(0x3f1)](_0xe53cb5)),stats[_0x41849c(0x43e)]=_0x12e51,stats['incorrectAnswers']=_0x3abe72,markQuizAsCompleted(),showPerformanceAnalysis(_0x12e51,_0x3abe72,_0xb6d2c[_0x41849c(0x414)](questionsData['length'],_0x12e51+_0x3abe72),_0x485f9d);}function showPerformanceAnalysis(_0x28fdaa,_0x2865d0,_0x162d73,_0xa81e87){const _0x4b31bd=_0x3f4b85,_0x3f51dc={'hAfrX':'performanceModal','yEJPt':function(_0x2891fb,_0x32148f){return _0x2891fb+_0x32148f;},'iSdJK':function(_0x1d2ccd,_0x14e215){return _0x1d2ccd/_0x14e215;},'urtyO':function(_0x1ee4b9,_0x55c328){return _0x1ee4b9+_0x55c328;},'Fzige':_0x4b31bd(0x394),'hxQSh':function(_0xab60b3,_0x22c246){return _0xab60b3-_0x22c246;},'gkbGB':_0x4b31bd(0x420),'snnbk':'totalQuestionsResult','NfpnT':_0x4b31bd(0x310),'ZHyQU':_0x4b31bd(0x348),'AiqDl':function(_0x58d3d1,_0x2a8ccf){return _0x58d3d1/_0x2a8ccf;},'gdmjB':function(_0x4915a0,_0x42f5ca){return _0x4915a0%_0x42f5ca;},'zJseE':_0x4b31bd(0x457),'mYBHl':function(_0x2048f5,_0x12627a){return _0x2048f5/_0x12627a;},'PGEtE':_0x4b31bd(0x31e),'zcnuM':_0x4b31bd(0x462)},_0x2a7817=document['getElementById'](_0x3f51dc[_0x4b31bd(0x4b7)]),_0x2d514e=_0x3f51dc[_0x4b31bd(0x318)](_0x28fdaa,_0x2865d0)>0x0?Math[_0x4b31bd(0x272)](_0x3f51dc[_0x4b31bd(0x454)](_0x28fdaa,_0x3f51dc[_0x4b31bd(0x3ef)](_0x28fdaa,_0x2865d0))*0x64):0x0,_0x21cf36=0x2*Math['PI']*0x41,_0x342872=document['getElementById'](_0x3f51dc['Fzige']);_0x342872[_0x4b31bd(0x263)][_0x4b31bd(0x328)]=_0x21cf36+'\x20'+_0x21cf36,_0x342872['style'][_0x4b31bd(0x2d0)]=_0x3f51dc[_0x4b31bd(0x3e1)](_0x21cf36,_0x3f51dc['iSdJK'](_0x2d514e,0x64)*_0x21cf36),document[_0x4b31bd(0x3ce)](_0x3f51dc[_0x4b31bd(0x2a1)])[_0x4b31bd(0x463)]=_0x2d514e+'%',document[_0x4b31bd(0x3ce)](_0x3f51dc['snnbk'])[_0x4b31bd(0x463)]=questionsData[_0x4b31bd(0x491)],document['getElementById'](_0x4b31bd(0x24d))[_0x4b31bd(0x463)]=_0x28fdaa,document['getElementById'](_0x3f51dc[_0x4b31bd(0x35c)])[_0x4b31bd(0x463)]=_0x2865d0,document[_0x4b31bd(0x3ce)](_0x3f51dc[_0x4b31bd(0x458)])['textContent']=_0x162d73;const _0x5739da=Math['floor'](_0x3f51dc[_0x4b31bd(0x454)](_0xa81e87,0xea60)),_0x27ddf2=Math[_0x4b31bd(0x3a3)](_0x3f51dc[_0x4b31bd(0x3d9)](_0x3f51dc[_0x4b31bd(0x262)](_0xa81e87,0xea60),0x3e8));document[_0x4b31bd(0x3ce)](_0x3f51dc[_0x4b31bd(0x21f)])['textContent']=_0x5739da+':'+_0x27ddf2[_0x4b31bd(0x23f)]()[_0x4b31bd(0x3c2)](0x2,'0');const _0x127c2a=_0xa81e87/questionsData[_0x4b31bd(0x491)],_0xa54d85=Math['floor'](_0x3f51dc[_0x4b31bd(0x454)](_0x127c2a,0xea60)),_0x40cee8=Math[_0x4b31bd(0x3a3)](_0x3f51dc[_0x4b31bd(0x391)](_0x3f51dc[_0x4b31bd(0x262)](_0x127c2a,0xea60),0x3e8));document['getElementById'](_0x3f51dc[_0x4b31bd(0x3c5)])[_0x4b31bd(0x463)]=_0xa54d85+':'+_0x40cee8[_0x4b31bd(0x23f)]()[_0x4b31bd(0x3c2)](0x2,'0'),_0x2a7817[_0x4b31bd(0x485)][_0x4b31bd(0x2e9)](_0x3f51dc[_0x4b31bd(0x378)]);}function closePerformanceModal(){const _0x142a73=_0x3f4b85;document[_0x142a73(0x3ce)](_0x142a73(0x47e))[_0x142a73(0x485)][_0x142a73(0x2bb)](_0x142a73(0x462));}function reviewQuestions(){const _0x561b5c=_0x3f4b85,_0x32d399={'YutKE':function(_0x2cf70d,_0x11189c){return _0x2cf70d===_0x11189c;},'bjwJf':function(_0x34a963,_0x562887){return _0x34a963===_0x562887;},'qKXcx':_0x561b5c(0x49b),'AQMZY':'border-red-500','GkTJd':function(_0x14e682,_0xb0efc4){return _0x14e682-_0xb0efc4;},'zcFtm':function(_0x4f8726,_0x5f30b7){return _0x4f8726<_0x5f30b7;},'XfHRH':'not-attempted','TNTBc':function(_0x3426e2,_0x163e05){return _0x3426e2!==_0x163e05;},'xAznT':'OExrs','Yhoju':_0x561b5c(0x3d7),'DYvqz':_0x561b5c(0x46e),'GtQnp':_0x561b5c(0x2cb),'EmFUp':_0x561b5c(0x45b),'SdSQI':_0x561b5c(0x425),'tqPfv':'div','LcCPU':function(_0x1f8092,_0x294495){return _0x1f8092+_0x294495;},'CToOp':_0x561b5c(0x3a8),'qWTjw':function(_0xf94605,_0x2124b8){return _0xf94605===_0x2124b8;},'QvVOf':'red','sMhDd':_0x561b5c(0x3bc),'gcyXU':_0x561b5c(0x2c4),'HYwcV':_0x561b5c(0x2e4),'lrNeL':_0x561b5c(0x462),'EMGhD':_0x561b5c(0x403),'wdJZA':function(_0x5a0609){return _0x5a0609();}};document['getElementById'](_0x32d399[_0x561b5c(0x39d)])[_0x561b5c(0x485)][_0x561b5c(0x2e9)](_0x32d399[_0x561b5c(0x26e)]);const _0x55e8b1=document[_0x561b5c(0x3ce)](_0x32d399[_0x561b5c(0x3f0)]);_0x55e8b1[_0x561b5c(0x271)]='',questionsData[_0x561b5c(0x2da)]((_0x159c66,_0x3c9faf)=>{const _0x176aa0=_0x561b5c,_0x572b46={'Syqoa':function(_0x4bc286,_0x33681b){const _0x329ad5=_0x2dfa;return _0x32d399[_0x329ad5(0x2e1)](_0x4bc286,_0x33681b);},'Cyiko':function(_0x23980c,_0x54d731){return _0x23980c(_0x54d731);},'bDlZa':_0x176aa0(0x430),'HJCqK':function(_0x4b562e,_0x4fa011){const _0x4fb1fa=_0x176aa0;return _0x32d399[_0x4fb1fa(0x3fd)](_0x4b562e,_0x4fa011);},'PeIBN':function(_0x284a66,_0x4ac20c){return _0x284a66(_0x4ac20c);}},_0x24bd86=questionStates[_0x3c9faf],_0x481b15=_0x159c66['correct_choice_id'];let _0xcb13d1=_0x32d399[_0x176aa0(0x220)],_0x9f222a='Not\x20Attempted';if(_0x32d399[_0x176aa0(0x3e9)](_0x24bd86[_0x176aa0(0x482)],null)){const _0x49560d=_0x159c66['choices'][_0x24bd86[_0x176aa0(0x482)]];if(_0x32d399[_0x176aa0(0x3e3)](_0x49560d['id'],_0x481b15)){if(_0x32d399[_0x176aa0(0x3e9)](_0x32d399[_0x176aa0(0x319)],_0x32d399['xAznT'])){const _0xc9c9ba=_0x572b46[_0x176aa0(0x320)](_0x572b46[_0x176aa0(0x2b4)](_0x5e9b0f,_0x127f47['key']),0x1),_0x4faa15=_0x54feec[_0x176aa0(0x2b8)](_0x572b46[_0x176aa0(0x267)]);if(_0x572b46['HJCqK'](_0xc9c9ba,_0x4faa15['length']))_0x572b46[_0x176aa0(0x1e5)](_0x40c217,_0xc9c9ba);}else _0xcb13d1=_0x32d399[_0x176aa0(0x42a)],_0x9f222a=_0x32d399[_0x176aa0(0x2df)];}else'BcqKm'!==_0x32d399[_0x176aa0(0x43f)]?(_0xcb13d1=_0x32d399['EmFUp'],_0x9f222a=_0x32d399[_0x176aa0(0x2b3)]):_0x422316[_0x5270f7[_0x176aa0(0x1ee)]]['bookmarked']=!![];}const _0x39bd1a=document[_0x176aa0(0x436)](_0x32d399[_0x176aa0(0x35e)]);_0x39bd1a[_0x176aa0(0x441)]='review-question\x20'+_0xcb13d1;let _0x45151e=(_0x159c66[_0x176aa0(0x2f1)]||[])['map']((_0x1ca975,_0x12eb57)=>{const _0x4fc9a9=_0x176aa0,_0x2723e5=_0x32d399[_0x4fc9a9(0x3e3)](_0x24bd86[_0x4fc9a9(0x482)],_0x12eb57),_0x3fc709=_0x32d399[_0x4fc9a9(0x495)](_0x1ca975['id'],_0x481b15);let _0x39fcde=_0x4fc9a9(0x38f);if(_0x3fc709)_0x39fcde=_0x32d399[_0x4fc9a9(0x302)];else{if(_0x2723e5)_0x39fcde=_0x32d399[_0x4fc9a9(0x3fc)];}return'<div\x20class=\x22p-3\x20rounded-lg\x20border\x20'+_0x39fcde+'\x22><span\x20class=\x22font-bold\x20mr-3\x22>'+String[_0x4fc9a9(0x2ca)](0x41+_0x12eb57)+_0x4fc9a9(0x3de)+_0x1ca975['text']+_0x4fc9a9(0x1ef);})[_0x176aa0(0x3ad)]('');const _0x39cd9f=_0x159c66[_0x176aa0(0x211)]?_0x176aa0(0x298)+_0x3c9faf+_0x176aa0(0x3cf)+_0x159c66[_0x176aa0(0x211)]+_0x176aa0(0x375):'';let _0x4cd3d7='';if(_0x159c66[_0x176aa0(0x334)])_0x4cd3d7+=_0x176aa0(0x20a)+_0x159c66[_0x176aa0(0x334)]+_0x176aa0(0x4a8);if(_0x159c66[_0x176aa0(0x3b2)])_0x4cd3d7+=_0x176aa0(0x2c8)+_0x159c66[_0x176aa0(0x3b2)]+_0x176aa0(0x4a8);let _0x1c73f3=(_0x159c66[_0x176aa0(0x3d8)]||[])['map'](_0x4ad995=>_0x4ad995?_0x176aa0(0x2f3)+_0x4ad995+_0x176aa0(0x3b5):'')[_0x176aa0(0x3ad)]('');_0x39bd1a[_0x176aa0(0x271)]=_0x176aa0(0x2a0)+_0x32d399[_0x176aa0(0x4a1)](_0x3c9faf,0x1)+_0x176aa0(0x31d)+(_0x32d399[_0x176aa0(0x3e3)](_0xcb13d1,'correct')?_0x32d399[_0x176aa0(0x2e2)]:_0x32d399[_0x176aa0(0x27d)](_0xcb13d1,_0x32d399[_0x176aa0(0x2e3)])?_0x32d399[_0x176aa0(0x47b)]:_0x32d399[_0x176aa0(0x2eb)])+'-600\x20text-white\x22>'+_0x9f222a+_0x176aa0(0x37f)+_0x159c66[_0x176aa0(0x288)]+_0x176aa0(0x3b0)+_0x45151e+_0x176aa0(0x42f)+(_0x159c66['solution']||_0x32d399[_0x176aa0(0x3e7)])+_0x176aa0(0x315)+_0x39cd9f+_0x176aa0(0x489)+_0x4cd3d7+_0x176aa0(0x489)+_0x1c73f3+_0x176aa0(0x253),_0x55e8b1[_0x176aa0(0x474)](_0x39bd1a);}),_0x32d399[_0x561b5c(0x29e)](initializeReviewVideos);}function initializeReviewVideos(){const _0x36979c=_0x3f4b85,_0x13b6a1={'cUgNB':_0x36979c(0x21e),'HLSnX':function(_0x5d5b80,_0xfa4ff6){return _0x5d5b80!==_0xfa4ff6;},'NxnbN':_0x36979c(0x465),'GwpgS':_0x36979c(0x3d2)};document[_0x36979c(0x2b8)](_0x13b6a1[_0x36979c(0x29c)])[_0x36979c(0x2da)](_0x5a4aa4=>{const _0x13dfbd=_0x36979c;if(_0x13b6a1[_0x13dfbd(0x314)](_0x13b6a1[_0x13dfbd(0x28f)],_0x13b6a1['NxnbN']))_0x3dd927(),_0xeddd5e[_0x13dfbd(0x3ce)](_0x13b6a1[_0x13dfbd(0x3ec)])[_0x13dfbd(0x263)][_0x13dfbd(0x1ed)]=_0x13dfbd(0x2f8);else{const _0x33733e=_0x5a4aa4[_0x13dfbd(0x266)][_0x13dfbd(0x390)];if(_0x33733e&&_0x33733e[_0x13dfbd(0x2a6)](_0x13dfbd(0x383)))setupVideo(_0x5a4aa4,_0x33733e);else _0x33733e&&(_0x5a4aa4['src']=_0x33733e);}});}function retakeQuiz(){const _0x3ff8a7=_0x3f4b85,_0x314e4d={'RAoCd':function(_0x57ddf0,_0x277e09){return _0x57ddf0+_0x277e09;},'YVhqU':function(_0x2dc00f,_0x2925f5){return _0x2dc00f===_0x2925f5;},'tJUNh':_0x3ff8a7(0x428),'JhXkH':_0x3ff8a7(0x325),'rtxTz':function(_0x38b137,_0x3f9cf8){return _0x38b137+_0x3f9cf8;},'ZPkOV':'bookmarkBtn','mgXFm':'bookmarkText','sawLT':_0x3ff8a7(0x1e9),'MIWdw':_0x3ff8a7(0x4a6),'ENqlG':'Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','SYqsz':function(_0x5c833f,_0x19971e){return _0x5c833f!==_0x19971e;},'CDzvT':_0x3ff8a7(0x46b),'zimKY':_0x3ff8a7(0x459),'ZtvLP':_0x3ff8a7(0x406),'iSqBV':_0x3ff8a7(0x3d0),'aDmUM':function(_0x5a26d4){return _0x5a26d4();}};if(confirm(_0x314e4d[_0x3ff8a7(0x32a)])){if(_0x314e4d[_0x3ff8a7(0x398)](_0x314e4d[_0x3ff8a7(0x43b)],_0x314e4d['zimKY'])){if(window['location']['pathname']['endsWith'](_0x3ff8a7(0x341))){if(_0x314e4d[_0x3ff8a7(0x2bd)]===_0x314e4d[_0x3ff8a7(0x2bd)])localStorage['removeItem'](_0x314e4d[_0x3ff8a7(0x49d)]);else{const _0x4a1102=_0x1eb7d9['fromCharCode'](_0x314e4d[_0x3ff8a7(0x21c)](0x41,_0x3a8997)),_0x44c18e=_0x314e4d['YVhqU'](_0x372504,_0x4695bf),_0x1c2d88=_0x315168[_0x3ff8a7(0x436)](_0x314e4d[_0x3ff8a7(0x25c)]);_0x1c2d88[_0x3ff8a7(0x271)]=_0x3ff8a7(0x2a5)+(_0x44c18e?_0x314e4d[_0x3ff8a7(0x43c)]:'')+_0x3ff8a7(0x407)+_0x21bc15+_0x3ff8a7(0x201)+_0x4a1102+_0x3ff8a7(0x3bf)+(_0x1195c1[_0x3ff8a7(0x288)]||_0x314e4d['rtxTz'](_0x3ff8a7(0x43a),_0xdf039c+0x1))+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20',_0x417e7e[_0x3ff8a7(0x474)](_0x1c2d88);}}_0x314e4d['aDmUM'](clearProgress),location['reload']();}else{const _0x4360dd=_0x28cc2e['getElementById'](_0x314e4d[_0x3ff8a7(0x449)]),_0x5a6e45=_0x41f02a['getElementById'](_0x314e4d[_0x3ff8a7(0x27c)]),_0x4b0fb=_0xdebe4b[_0x102b54][_0x3ff8a7(0x2ff)];_0x4360dd[_0x3ff8a7(0x441)]=_0x4b0fb?_0x314e4d[_0x3ff8a7(0x3f7)]:_0x3ff8a7(0x368),_0x5a6e45[_0x3ff8a7(0x463)]=_0x4b0fb?_0x3ff8a7(0x38e):_0x314e4d[_0x3ff8a7(0x213)];}}}function loadBookmarkedQuestions(){const _0x22d492=_0x3f4b85,_0x58b9b9={'hQMLj':function(_0x384700,_0x43bc95){return _0x384700===_0x43bc95;},'yLyJm':_0x22d492(0x3d7),'yfOWn':_0x22d492(0x45b),'osWjt':function(_0xf669df,_0x303818){return _0xf669df<_0x303818;},'ysIrD':function(_0x220bc0,_0x5b5127){return _0x220bc0!==_0x5b5127;},'nJPdF':_0x22d492(0x435),'JfKUO':'aoehK','iXZrQ':function(_0x33c9a4,_0x2de8bc){return _0x33c9a4<_0x2de8bc;},'BocXt':_0x22d492(0x3fe),'nbFfJ':_0x22d492(0x472)},_0x2a8e7c=JSON[_0x22d492(0x249)](localStorage[_0x22d492(0x25a)](_0x58b9b9[_0x22d492(0x308)]))||[];_0x2a8e7c[_0x22d492(0x2da)](_0x45ceab=>{const _0xd1e608=_0x22d492,_0x5a6316={'lhTED':function(_0x58bc5e,_0x520ae1){return _0x58bc5e===_0x520ae1;},'OseBe':function(_0x50dc25,_0x98f58c){return _0x58b9b9['hQMLj'](_0x50dc25,_0x98f58c);},'YJAuP':_0xd1e608(0x323),'IHiyH':_0x58b9b9[_0xd1e608(0x371)],'kpBzo':_0x58b9b9[_0xd1e608(0x40b)],'iLUnA':function(_0x2cf832){return _0x2cf832();},'lBNRu':function(_0x569b93,_0x3634d8){return _0x58b9b9['osWjt'](_0x569b93,_0x3634d8);}};if(_0x58b9b9[_0xd1e608(0x2f0)](_0x58b9b9['nJPdF'],_0x58b9b9[_0xd1e608(0x376)])){if(_0x45ceab[_0xd1e608(0x498)][_0xd1e608(0x2a6)](quizName[_0xd1e608(0x2be)]()[_0xd1e608(0x461)](/ /g,'-'))){if(_0x58b9b9[_0xd1e608(0x446)](_0x45ceab['questionIndex'],questionsData[_0xd1e608(0x491)])){if(_0x58b9b9['hQMLj'](_0x58b9b9[_0xd1e608(0x29f)],_0x58b9b9[_0xd1e608(0x29f)]))questionStates[_0x45ceab[_0xd1e608(0x1ee)]]['bookmarked']=!![];else{const _0x5d830a=_0x16db16[_0x23396d],_0x5705a2=_0x5d830a[_0xd1e608(0x3d5)];if(_0x5a6316[_0xd1e608(0x21a)](_0x4fd772,null))return;const _0x309c64=_0x5d830a[_0xd1e608(0x2f1)][_0x3164a3],_0x5cce63=_0x5a6316[_0xd1e608(0x40a)](_0x309c64['id'],_0x5705a2);if(_0x5a6316[_0xd1e608(0x21a)](_0x5ba2d5[_0x5642a5][_0xd1e608(0x345)],_0x5a6316[_0xd1e608(0x3c9)])){_0x29483f[_0xd1e608(0x409)]++,_0x386ea2[_0xd1e608(0x3be)]--;if(_0x5cce63)_0x36f802[_0xd1e608(0x43e)]++;else _0xd6100d[_0xd1e608(0x426)]++;}_0x3b6144[_0x4cd8c7][_0xd1e608(0x345)]=_0x5cce63?_0x5a6316[_0xd1e608(0x30a)]:_0x5a6316['kpBzo'],_0xd8ccdc(),_0x223100(_0x5cce63),_0x5a6316[_0xd1e608(0x34a)](_0x373d3c);}}}}else _0x2a5551['quizFile'][_0xd1e608(0x2a6)](_0x26ac3b[_0xd1e608(0x2be)]()[_0xd1e608(0x461)](/ /g,'-'))&&(_0x5a6316['lBNRu'](_0x21a839[_0xd1e608(0x1ee)],_0x1c53c3[_0xd1e608(0x491)])&&(_0x459af1[_0x1aa557['questionIndex']][_0xd1e608(0x2ff)]=!![]));});}function toggleBookmark(){const _0x1993d9=_0x3f4b85,_0x315c56={'GVCgI':'bookmarkedQuestions','Lipmy':function(_0x2ac380,_0x201792){return _0x2ac380===_0x201792;},'FAXjM':_0x1993d9(0x295),'NVeqB':function(_0x1e56d2){return _0x1e56d2();}},_0x526685=!questionStates[currentQuestionIndex][_0x1993d9(0x2ff)];questionStates[currentQuestionIndex][_0x1993d9(0x2ff)]=_0x526685;let _0x5d251e=JSON[_0x1993d9(0x249)](localStorage[_0x1993d9(0x25a)](_0x315c56['GVCgI']))||[];if(_0x526685){const _0x1587c9={'quizName':quizName,'quizFile':window[_0x1993d9(0x496)][_0x1993d9(0x2c7)][_0x1993d9(0x3dd)]('/')['pop'](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x1993d9(0x274)]()};_0x5d251e[_0x1993d9(0x4a0)](_0x1587c9);}else _0x315c56[_0x1993d9(0x4b4)](_0x1993d9(0x295),_0x315c56[_0x1993d9(0x21b)])?_0x5d251e=_0x5d251e[_0x1993d9(0x399)](_0x3a7983=>!(_0x3a7983['quizFile'][_0x1993d9(0x2a6)](quizName[_0x1993d9(0x2be)]()['replace'](/ /g,'-'))&&_0x3a7983[_0x1993d9(0x1ee)]===currentQuestionIndex)):_0x9d4398();localStorage[_0x1993d9(0x23a)](_0x315c56[_0x1993d9(0x22e)],JSON[_0x1993d9(0x3f1)](_0x5d251e)),updateBookmarkButton(),_0x315c56[_0x1993d9(0x381)](updateQuestionNav);}function updateBookmarkButton(){const _0x2091df=_0x3f4b85,_0xf73ce1={'duSMB':'bookmarkBtn','fZpqL':_0x2091df(0x2f2),'CbCWQ':'gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','KBelv':_0x2091df(0x368),'NRhSA':'Bookmark'},_0x4c1169=document[_0x2091df(0x3ce)](_0xf73ce1['duSMB']),_0x40b571=document[_0x2091df(0x3ce)](_0xf73ce1['fZpqL']),_0x421c0d=questionStates[currentQuestionIndex][_0x2091df(0x2ff)];_0x4c1169[_0x2091df(0x441)]=_0x421c0d?_0xf73ce1['CbCWQ']:_0xf73ce1[_0x2091df(0x216)],_0x40b571[_0x2091df(0x463)]=_0x421c0d?_0x2091df(0x38e):_0xf73ce1[_0x2091df(0x4b0)];}function toggleMarkForReview(){const _0x334079=_0x3f4b85,_0xa43d5={'LmfgH':function(_0x4c4bed){return _0x4c4bed();}};questionStates[currentQuestionIndex][_0x334079(0x2a2)]=!questionStates[currentQuestionIndex][_0x334079(0x2a2)],_0xa43d5[_0x334079(0x431)](updateMarkReviewButton),updateQuestionNav();}function updateMarkReviewButton(){const _0x30a165=_0x3f4b85,_0x3df197={'gHcuz':'markReviewBtn','cWgpD':_0x30a165(0x1f7),'DchZL':_0x30a165(0x28a),'TgPiZ':_0x30a165(0x3ae)},_0x54d38f=document[_0x30a165(0x3ce)](_0x3df197[_0x30a165(0x349)]),_0x3a0d10=document[_0x30a165(0x3ce)](_0x3df197['cWgpD']),_0x3899f4=questionStates[currentQuestionIndex][_0x30a165(0x2a2)];_0x54d38f['className']=_0x3899f4?_0x30a165(0x448):_0x3df197[_0x30a165(0x36f)],_0x3a0d10[_0x30a165(0x463)]=_0x3899f4?_0x30a165(0x3c0):_0x3df197['TgPiZ'];}function previousQuestion(){const _0x3e0b10=_0x3f4b85,_0x518a78={'vOpmN':function(_0x535f27){return _0x535f27();},'PcmEY':function(_0x511e33,_0x72d814){return _0x511e33>_0x72d814;},'ubfOL':'EmRKr','GhuDN':function(_0x180318,_0x226764){return _0x180318-_0x226764;}};_0x518a78['PcmEY'](currentQuestionIndex,0x0)&&(questionStartTime&&('ynMkP'===_0x518a78[_0x3e0b10(0x203)]?_0x518a78[_0x3e0b10(0x2a7)](_0x57ebf2):questionStates[currentQuestionIndex][_0x3e0b10(0x40e)]+=_0x518a78[_0x3e0b10(0x44a)](Date[_0x3e0b10(0x274)](),questionStartTime)),currentQuestionIndex--,_0x518a78[_0x3e0b10(0x2a7)](displayQuestion),_0x518a78['vOpmN'](saveProgress));}function nextQuestion(){const _0x4b627d=_0x3f4b85,_0x269391={'Tqlmq':function(_0x78e95,_0x1ac3d8){return _0x78e95-_0x1ac3d8;},'jdXzY':function(_0x41734,_0x12ee13){return _0x41734<_0x12ee13;},'phYNF':function(_0x200248){return _0x200248();},'owJBK':function(_0x865424,_0x3e0786){return _0x865424===_0x3e0786;},'AFKMO':_0x4b627d(0x33d),'ZBftM':_0x4b627d(0x275),'yqFFD':function(_0x1a07ae,_0x14999c){return _0x1a07ae(_0x14999c);},'UgmhG':_0x4b627d(0x2c5),'aEtYX':function(_0x164e04,_0x260cd9){return _0x164e04(_0x260cd9);},'ywIZI':_0x4b627d(0x3e4)};questionStartTime&&(questionStates[currentQuestionIndex][_0x4b627d(0x40e)]+=_0x269391[_0x4b627d(0x34f)](Date[_0x4b627d(0x274)](),questionStartTime)),_0x269391[_0x4b627d(0x244)](currentQuestionIndex,_0x269391[_0x4b627d(0x34f)](questionsData[_0x4b627d(0x491)],0x1))?(currentQuestionIndex++,_0x269391[_0x4b627d(0x3a1)](displayQuestion),_0x269391[_0x4b627d(0x3a1)](saveProgress)):_0x269391[_0x4b627d(0x284)](currentMode,_0x269391[_0x4b627d(0x37b)])||_0x269391[_0x4b627d(0x284)](currentMode,_0x269391['ZBftM'])?_0x269391[_0x4b627d(0x286)](confirm,_0x269391[_0x4b627d(0x1f4)])&&submitQuiz():_0x269391[_0x4b627d(0x24c)](confirm,_0x269391[_0x4b627d(0x217)])&&(currentQuestionIndex=0x0,_0x269391[_0x4b627d(0x3a1)](displayQuestion),_0x269391[_0x4b627d(0x3a1)](saveProgress));}function startTimer(){const _0x14e959=_0x3f4b85,_0x31a8a8={'oyArL':_0x14e959(0x2d5),'UyWNc':function(_0x518a20,_0xde4f16){return _0x518a20<=_0xde4f16;},'ROzwb':_0x14e959(0x3d4),'iJbmL':function(_0x45c256,_0x5c5b58){return _0x45c256===_0x5c5b58;},'bFLXZ':'timed_exam','QusRV':function(_0x3c2b12,_0xaca54){return _0x3c2b12===_0xaca54;},'lPGXf':_0x14e959(0x228),'WnCwJ':function(_0x59fd48,_0x491467){return _0x59fd48(_0x491467);},'FJQgw':function(_0x56e175){return _0x56e175();},'bWhrc':function(_0x5900b5,_0xc63cd8,_0x57bcd4){return _0x5900b5(_0xc63cd8,_0x57bcd4);}};if(timer)_0x31a8a8[_0x14e959(0x429)](clearInterval,timer);timeRemaining=0x78,_0x31a8a8['FJQgw'](updateTimerDisplay),timer=_0x31a8a8[_0x14e959(0x40f)](setInterval,()=>{const _0x1b12d0=_0x14e959,_0x1ae598={'hCLHx':_0x1b12d0(0x299),'zDwkV':_0x31a8a8[_0x1b12d0(0x289)],'AJsWE':'markReviewText','pcFMD':_0x1b12d0(0x28a),'qOyTL':'Marked'};timeRemaining--,updateTimerDisplay();if(_0x31a8a8[_0x1b12d0(0x264)](timeRemaining,0x0)){if(_0x31a8a8['ROzwb']!==_0x31a8a8[_0x1b12d0(0x335)])_0x70212=_0x1ae598[_0x1b12d0(0x209)];else{clearInterval(timer);if(_0x31a8a8[_0x1b12d0(0x362)](currentMode,_0x31a8a8[_0x1b12d0(0x233)])){if(_0x31a8a8['QusRV'](_0x31a8a8[_0x1b12d0(0x2aa)],_0x31a8a8[_0x1b12d0(0x2aa)]))submitQuiz();else{const _0x245a0f=_0x19bfc3[_0x1b12d0(0x3ce)](_0x1ae598['zDwkV']),_0x5b498e=_0x13a00b[_0x1b12d0(0x3ce)](_0x1ae598[_0x1b12d0(0x3e6)]),_0x296d6b=_0x30a242[_0x1ca2f9]['markedForReview'];_0x245a0f[_0x1b12d0(0x441)]=_0x296d6b?'gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center':_0x1ae598[_0x1b12d0(0x2f7)],_0x5b498e[_0x1b12d0(0x463)]=_0x296d6b?_0x1ae598[_0x1b12d0(0x248)]:_0x1b12d0(0x3ae);}}else nextQuestion();}}},0x3e8);}function updateTimerDisplay(){const _0x5d0028=_0x3f4b85,_0x71c493={'tLYhr':function(_0x452149,_0x555f93){return _0x452149/_0x555f93;},'DyXYA':function(_0x3b1f58,_0xfc67c0){return _0x3b1f58%_0xfc67c0;},'WuHax':function(_0x19443d,_0x2b0a46){return _0x19443d+_0x2b0a46;}},_0x32cdbb=Math[_0x5d0028(0x3a3)](_0x71c493[_0x5d0028(0x280)](timeRemaining,0x3c)),_0x1ca4bc=_0x71c493[_0x5d0028(0x27e)](timeRemaining,0x3c);document[_0x5d0028(0x3ce)](_0x5d0028(0x3bd))[_0x5d0028(0x463)]=_0x71c493[_0x5d0028(0x23d)](_0x32cdbb+':',_0x1ca4bc['toString']()[_0x5d0028(0x3c2)](0x2,'0'));}function toggleSidebar(){const _0x56efeb=_0x3f4b85,_0x4cca30={'uBUFF':_0x56efeb(0x313)};document[_0x56efeb(0x3ce)](_0x4cca30['uBUFF'])[_0x56efeb(0x485)][_0x56efeb(0x41a)](_0x56efeb(0x39b));}document[_0x3f4b85(0x377)](_0x3f4b85(0x309),()=>{const _0x8d3578=_0x3f4b85,_0x157cd5={'UhSLu':_0x8d3578(0x472),'FUQhd':function(_0x34d769){return _0x34d769();},'LTrAa':_0x8d3578(0x359),'gFVef':function(_0x5abd4c,_0x51799d){return _0x5abd4c===_0x51799d;},'PDioO':'PJmGN','syORs':function(_0x2f4820){return _0x2f4820();},'LMrRd':_0x8d3578(0x21e),'XNvUz':_0x8d3578(0x2f8),'bawgE':_0x8d3578(0x341),'dihKk':function(_0x2520f3){return _0x2520f3();}};if(resume){if(_0x157cd5[_0x8d3578(0x452)](_0x8d3578(0x45a),_0x157cd5[_0x8d3578(0x290)])){const _0xdc4c4c=!_0x63e594[_0x379c8f]['bookmarked'];_0x119028[_0x12aee2][_0x8d3578(0x2ff)]=_0xdc4c4c;let _0x56a895=_0x266639[_0x8d3578(0x249)](_0x20fffc[_0x8d3578(0x25a)](_0x8d3578(0x472)))||[];if(_0xdc4c4c){const _0x529178={'quizName':_0x4f5382,'quizFile':_0x397b2e['location'][_0x8d3578(0x2c7)]['split']('/')[_0x8d3578(0x208)](),'questionIndex':_0x239eac,'question':_0x4b27d3[_0x2c3e1d],'hierarchy':_0xe1130a,'timestamp':_0x3b5db6[_0x8d3578(0x274)]()};_0x56a895[_0x8d3578(0x4a0)](_0x529178);}else _0x56a895=_0x56a895[_0x8d3578(0x399)](_0x25ce3b=>!(_0x25ce3b[_0x8d3578(0x498)]['includes'](_0x406869[_0x8d3578(0x2be)]()['replace'](/ /g,'-'))&&_0x25ce3b[_0x8d3578(0x1ee)]===_0x35d72c));_0x3f66df[_0x8d3578(0x23a)](_0x157cd5['UhSLu'],_0x3b246d[_0x8d3578(0x3f1)](_0x56a895)),_0x17eb00(),_0x157cd5['FUQhd'](_0x1bd458);}else{if(_0x157cd5[_0x8d3578(0x3a2)](loadProgress)){if(_0x8d3578(0x2fc)===_0x8d3578(0x2fc))document[_0x8d3578(0x3ce)](_0x157cd5[_0x8d3578(0x2cc)])['style'][_0x8d3578(0x1ed)]=_0x8d3578(0x49a),_0x157cd5[_0x8d3578(0x3a2)](initializeQuiz);else{const _0x94d100=_0x69897a['parse'](_0x3c723a['getItem'](_0x8d3578(0x359)))||{},_0x269cab=_0x5d82e0[_0x8d3578(0x491)],_0x3098bc=_0x1c2d6f[_0x8d3578(0x43e)]||0x0;_0x94d100[_0xa52fa2]={'score':_0x3098bc,'total':_0x269cab,'status':'completed','completedOn':new _0x58918f()['toISOString']()},_0x38cff0[_0x8d3578(0x23a)](_0x157cd5['LTrAa'],_0x1790fb[_0x8d3578(0x3f1)](_0x94d100));}}else _0x157cd5['FUQhd'](clearProgress),document[_0x8d3578(0x3ce)](_0x8d3578(0x21e))[_0x8d3578(0x263)][_0x8d3578(0x1ed)]=_0x157cd5[_0x8d3578(0x265)];}}else!window[_0x8d3578(0x496)][_0x8d3578(0x2c7)][_0x8d3578(0x385)](_0x157cd5[_0x8d3578(0x384)])?(_0x157cd5['FUQhd'](clearProgress),document[_0x8d3578(0x3ce)](_0x157cd5['LMrRd'])[_0x8d3578(0x263)][_0x8d3578(0x1ed)]=_0x157cd5[_0x8d3578(0x265)]):_0x157cd5[_0x8d3578(0x460)](initializeQuiz);}),document[_0x3f4b85(0x377)](_0x3f4b85(0x351),function(_0x9e6672){const _0x1340af=_0x3f4b85,_0x1ff936={'UWnMk':function(_0x332b5f,_0x13d421){return _0x332b5f!==_0x13d421;},'SnDVv':_0x1340af(0x49a),'Thjdy':function(_0x3ed1ca,_0x3e634e){return _0x3ed1ca===_0x3e634e;},'ULFuJ':function(_0x1edbcd,_0x5d72b4){return _0x1edbcd-_0x5d72b4;},'REgdg':function(_0x5d7dfb,_0x12b371){return _0x5d7dfb(_0x12b371);},'nagoN':function(_0x5843f9,_0x54ab6d){return _0x5843f9<_0x54ab6d;},'fViWW':function(_0x3d4320,_0x255163){return _0x3d4320(_0x255163);},'bTSMA':function(_0x5eccd7){return _0x5eccd7();},'kSusq':function(_0x1ba514,_0x3f4792){return _0x1ba514===_0x3f4792;},'ddZkn':'SbZbu','AwLbI':_0x1340af(0x439),'wsRnB':_0x1340af(0x33d),'ZDSgV':_0x1340af(0x275),'GxFDB':function(_0x28e874,_0x21cb63){return _0x28e874===_0x21cb63;},'kCypX':_0x1340af(0x38d)};if(_0x1ff936[_0x1340af(0x241)](document[_0x1340af(0x3ce)]('modeModal')[_0x1340af(0x263)][_0x1340af(0x1ed)],_0x1ff936[_0x1340af(0x442)]))return;if(_0x1ff936[_0x1340af(0x2d1)](document['getElementById']('performanceModal')[_0x1340af(0x485)][_0x1340af(0x386)](_0x1340af(0x462)),![]))return;if(_0x9e6672[_0x1340af(0x36a)]>='1'&&_0x9e6672['key']<='4'){const _0x1cb021=_0x1ff936['ULFuJ'](_0x1ff936[_0x1340af(0x2c6)](parseInt,_0x9e6672['key']),0x1),_0x5dc15b=document[_0x1340af(0x2b8)]('.option-button');if(_0x1ff936[_0x1340af(0x2e6)](_0x1cb021,_0x5dc15b[_0x1340af(0x491)]))_0x1ff936['fViWW'](selectOption,_0x1cb021);}else{if(_0x9e6672[_0x1340af(0x36a)]===_0x1340af(0x49e))_0x1ff936[_0x1340af(0x4ad)](previousQuestion);else{if(_0x1ff936[_0x1340af(0x2d1)](_0x9e6672[_0x1340af(0x36a)],_0x1340af(0x34c))||_0x1ff936['kSusq'](_0x9e6672[_0x1340af(0x36a)],'\x20')){if(_0x1ff936['ddZkn']!=='aftjB')_0x9e6672[_0x1340af(0x1f1)](),_0x1ff936[_0x1340af(0x4ad)](nextQuestion);else{const _0x549ab9={'quizName':_0x225d60,'quizFile':_0x515442[_0x1340af(0x496)][_0x1340af(0x2c7)][_0x1340af(0x3dd)]('/')[_0x1340af(0x208)](),'questionIndex':_0x1421b7,'question':_0xec8124[_0x4aebc5],'hierarchy':_0x5d12ab,'timestamp':_0x5d4d36[_0x1340af(0x274)]()};_0x2de1c2['push'](_0x549ab9);}}else{if(_0x1ff936[_0x1340af(0x2d1)](_0x9e6672['key']['toLowerCase'](),'b')&&(_0x1ff936['kSusq'](currentMode,_0x1ff936[_0x1340af(0x4b1)])||_0x1ff936[_0x1340af(0x363)](currentMode,_0x1340af(0x3e5))))_0x1ff936[_0x1340af(0x4ad)](toggleBookmark);else{if(_0x1ff936[_0x1340af(0x363)](_0x9e6672[_0x1340af(0x36a)][_0x1340af(0x2be)](),'m')&&(currentMode===_0x1ff936['wsRnB']||currentMode===_0x1ff936['ZDSgV']))toggleMarkForReview();else{if(_0x9e6672[_0x1340af(0x36a)][_0x1340af(0x2be)]()==='s'&&(_0x1ff936[_0x1340af(0x25f)](currentMode,_0x1ff936[_0x1340af(0x31b)])||currentMode===_0x1340af(0x275))){if(_0x1ff936['kCypX']!=='hxpGj')_0x1ff936[_0x1340af(0x4ad)](submitQuiz);else{if(_0x492ab0){const _0x475131=_0x229ac0[_0x1340af(0x418)](_0x1bc8ee,arguments);return _0x29d4e2=null,_0x475131;}}}}}}}}});</script>

</body></html>